Osteoporosis in inflammatory Bowel disease : epidemiological, pathophysiological and clinical studies

Citation for published version (APA):

Schoon, E. J. (2001). *Osteoporosis in inflammatory Bowel disease : epidemiological, pathophysiological and clinical studies*. [Doctoral Thesis, Maastricht University]. Universitaire Pers Maastricht. <https://doi.org/10.26481/dis.20011116es>

Document status and date:

Published: 01/01/2001

DOI:

[10.26481/dis.20011116es](https://doi.org/10.26481/dis.20011116es)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Osteoporosis in Inflammatory Bowel Disease

Epidemiological, Pathophysiological
and Clinical Studies

© Erik Jan Schoon, Maastricht 2001

ISBN 90 5278 327 6

cover: "Marlstone from Limburg" photography: EJ Schoon design: Datawyse

Scientific studies in this thesis were supported by an educational grant from AstraZeneca, the Netherlands.

Printing of this thesis was financially supported by AstraZeneca, the Netherlands. Additional financial support by Astra Zeneca Sweden, Byk, MSD, Tramedico, Ferring, Eli Lilly, Procter & Gamble, Aventis, Janssen-Cilag and Schering-Plough was gratefully acknowledged.

Osteoporosis in Inflammatory Bowel Disease

Epidemiological, Pathophysiological
and Clinical Studies

PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Universiteit Maastricht,
op gezag van de Rector Magnificus,
Prof. dr. A.C. Nieuwenhuijzen Kruseman,
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen
op vrijdag 16 november 2001 om 12.00 uur

door

Erik Jan Schoon

Promotor

Prof. dr. R.W. Stockbrügger

Co-promotores

Dr. R.-J.M. Brummer

Dr. M.G.V.M. Russel

Beoordelingscommissie

Prof. dr. E.F.M. Wouters (voorzitter)

Prof. dr. G. Bianchi Porro (University of Milan, Italy)

Prof. dr. S.B. Hanauer (University of Chicago, USA)

Prof. dr. J.M.J.P. van der Linden

Prof. dr. P.B. Soeters

Let us not forget
how fragile we are

Sting

Aan mijn ouders
Gabrielle,
Folkert, Veerle en Karlijn

Contents

	Abbreviations	8
Chapter 1	Introduction	9
Chapter 2	Osteoporosis in IBD: a review	15
Chapter 3	The prevalence of osteoporosis in Crohn's disease: a population-based study in the Netherlands	33
Chapter 4	Clinical determinants of bone mineral density in Crohn's disease	45
Chapter 5	Bone mineral density in patients with recently diagnosed IBD	59
Chapter 6	Low serum and bone vitamin K status in patients with long-standing Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease ?	73
Chapter 7	Abnormal bone turnover in longstanding Crohn's disease in remission	87
Chapter 8	Osteoporosis and spontaneous vertebral fractures in Crohn's disease: size of the problem and risk factor analysis in a large European study population	103
Chapter 9	General discussion	119
Chapter 10	Summary	129
Chapter 11	Samenvatting	133
Chapter 12	Metabole botziekten bij chronische inflammatoire darmziekten (ziekte van Crohn en colitis ulcerosa)	139
	Dankwoord	153
	Curriculum Vitae	157

Abbreviations

5-ASA	= 5-amino-salicylic acid
BAP	= bone specific alkaline phosphatase
BMD	= bone mineral density
BMI	= body mass index
CD	= Crohn's disease
CDAI	= Crohn's disease activity index
CI	= confidence interval
CTX	= collagen type I C-terminal crosslinks
DXA	= dual energy X-ray absorptiometry
DPD	= deoxypyridinoline
FN	= femoral neck
Gla	= gamma-carboxyglutamate
Glu	= glutamic acid
HBC	= hydroxyapatite binding capacity
IBD	= inflammatory bowel disease
IGF-I	= insulin like growth factor I
LS	= lumbar spine
MGP	= matrix Gla proteins
PTH	= parathyroid hormone
OC	= osteocalcin
OC _{BOUND}	= bound osteocalcin (carboxylated)
OC _{FREE}	= free osteocalcin (undercarboxylated)
OC _{TOTAL}	= total osteocalcin
QCT	= quantitative computer tomography
SD	= standard deviation
SPA	= single photon absorptiometry
TB	= <i>total body</i>
UC	= ulcerative colitis
WHO	= World Health Organization

CHAPTER 1

Introduction

Introduction

Inflammatory bowel disease was first described 300 years ago, but it was 32 years after the first report by Burril Bernard Crohn, in 1932, recognizing terminal ileitis as a clinical entity, that bone problems were described as a potential complication^{1,2}. In 1964, Edwards and Truelove³ described radiologically assessed osteoporosis in 9 of 624 (1.4%) patients with Ulcerative colitis and they stated that: "...this must be regarded as an underestimate of its true frequency, which would only be determined by systematic studies".

In 1976 Genant et al. reported impaired skeletal growth and mineralization in 54 adolescent and adult patients with inflammatory bowel disease by qualitative and quantitative radiological techniques which consisted of conventional röntgenography, photon absorptiometry, and radiographic morphometry⁴.

In 1987 Compston et al. published a cross-sectional study on 75 patients with inflammatory bowel disease (IBD) using single photon absorptiometry of the forearm and computer tomography scanning (CT) of the vertebrae⁵.

In the 1990's dual energy X-ray absorptiometry (DXA) became available, as a safe and easy method to assess bone mineral density (BMD), and the number and size of the studies increased subsequently. Pigot et al. described the first cross-sectional study using DXA in a group of patients with both ulcerative colitis (UC) and Crohn's disease (CD)⁶. After this several studies were published, which will be discussed in more detail in the next chapter.

In the last decades an increasing number of treatment options for IBD became available and were implemented in daily practice. Nowadays, the life expectancy of IBD patients is comparable to that of the background population^{7,8}. This might be the reason that patients and clinicians are compelled to focus on the long-term complications and the quality of life in IBD.

In a recent study performed in the Netherlands (1991-1994), an incidence rate for CD was found of 6.9 per 100.000 inhabitants per year and 10.0 for UC, respectively⁹. That study was the start of the South-Limburg IBD registration, which was also the base of a number of the investigations which are described in the present thesis.

Early attention to the problem of bone disease could mean a long-term benefit for the patient as the age profile in CD shows a peak incidence between 15 and 30 years, with a female preponderance.

In 1998, the Dutch Health Council advised against a general population screening for osteoporosis but recommended a case-finding strategy¹⁰. For prevention of the late complications of osteoporosis, particularly bone fractures, IBD patients seem an excellent example of a group in which screening would be useful.

Many questions regarding the clinical management of metabolic bone disease in IBD remain unanswered: "Who is at risk? Why? And: What shall we do about it?"¹¹. There is a lack of evidence-based knowledge in this field of metabolic bone disease. Hopefully, the studies described in this thesis will contribute to an increasing basal knowledge of this complication for clinicians and will offer benefit to the patients by preventing debilitating fractures.

References

1. Inflammatory bowel disease. In: Kirsner JB and Shorter RG, eds. 4 ed. 1995:3-27.
2. Crohn BB, Ginzberg L, Oppenheimer GD. Regional ileitis: A pathologic and clinical entity. *J A M A* 1932;99:1323-1329.
3. Edwards F, Truelove SC. The course and prognosis of ulcerative colitis. *Gut* 1964;5:1-22.
4. Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. *Invest Radiol* 1976;11:541-549.
5. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987;28:410-415.
6. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy MT, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992;37:1396-1403.
7. Farrokhyar F, Swarbrick ET, Grace RH, Hellier MD, Gent AE, Irvine EJ. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. *Am J Gastroenterol* 2001;96:501-507.
8. Witte J, Shivananda S, Lennard-Jones JE, Beltrami M, Politi P, Bonanomi A, Tsianos EV, Mouzas I, Schulz TB, Monteiro E, Clofent J, Odes S, Limonard CB, Stockbrugger RW, Russel MG. Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Scand J Gastroenterol* 2000;35:1272-1277.
9. Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, Bos LP, Limonard CB, Stockbrugger RW. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. *Dis Colon Rectum* 1998;41:33-40.
10. Prevention of osteoporosis related fractures. Health Counsel: osteoporosis commission. 1998. Health Counsel of the Netherlands.
11. Sachar D, Personal communication.

Outline of the thesis

Chapter 2 reviews the current knowledge on the relation between IBD and metabolic bone disease.

In **chapter 3** the results are presented regarding the prevalence of osteoporosis and osteopenia in Crohn's disease of a well-defined population-based cohort from the IBD South-Limburg study area.

In **chapter 4** clinical determinants of bone mineral density are discussed in a population-based cohort of patients with Crohn's disease. Many potential risk factors for low bone mineral density have been taken into consideration and analysed by linear regression.

A study investigating whether bone mineral density in patients with IBD is already low at diagnosis is described in **chapter 5**. Bone mineral density measurement of recently diagnosed patients with Crohn's disease and ulcerative colitis is measured and compared to age and gender matched population controls. Bone mineral density of patients with Crohn's disease and ulcerative colitis are compared, in this respect. Determinants for bone mineral density at diagnosis are assessed.

In **chapter 6** vitamin K status in serum and bone of patients with long-standing Crohn's disease in remission is assessed. The level of circulating uncarboxylated osteocalcin, as a marker for vitamin K status of bone, is correlated with bone mineral density and is presented as a novel risk factor for osteopenia in Crohn's disease.

In **chapter 7** the pathophysiologic process of bone turnover is described in a homogeneous group of patients with long-standing Crohn's disease in clinical remission by using biochemical markers.

In **chapter 8** describes the baseline data of an European multi-centre intervention study in which the prevalence and risk factors of osteoporosis in Crohn's disease are considered. This is the first study in which results are described on systematical radiographic assessment of vertebral fractures in patients with Crohn's disease.

In **chapter 9** the results of above mentioned studies are discussed in the context of current literature. An opinion is given on future developments.

In **chapter 10** a summary is given of the studies in this thesis.

Chapter 11 is a summary in Dutch.

Chapter 12 is a review in Dutch.

CHAPTER 2

Osteoporosis in IBD: a review

EJ Schoon, BHR Wolffenbuttel,
RW Stockbrügger

Published in part in:

Drugs of Today 1999;35(Suppl.A):17-28

And in:

*Maladies inflammatoires chroniques de
l'intestin/Inflammatory Bowel Disease.*

R Modigliani ed. John Libbey Eurotext, Paris 2000

Abstract

The association between inflammatory bowel disease (IBD) and metabolic bone disease has been known for some decades. When dual-energy X-ray absorptiometry (DXA) became available, the number and the size of studies on this subject increased. The reported prevalence of decreased bone mass varies from 2.7% to 77%, depending on patient selection, method of bone density measurement and definitions used. Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with an increase in bone fragility and fracture risk. Osteopenia is the preclinical condition of osteoporosis. The pathogenesis of bone loss in IBD is probably multifactorial and involves maldigestion and malabsorption with vitamin D-deficiency and calcium deficiency, sex hormone deficiency, smoking, disease activity, and corticosteroid use. In several studies, bone mineral density in patients with Crohn's disease is similar to bone mineral density in patients with ulcerative colitis, but others have indicated that low bone mineral density is preferentially a feature of Crohn's disease. In Crohn's disease more risk factors for the pathogenesis of bone loss are present than in ulcerative colitis. The use of corticosteroids and the disease process in IBD are supposed to have a central role in the negative effects on bone metabolism. Many studies support the negative effect of corticosteroids on bone mineral density, but there are also controversial data. Corticosteroids are effective in the treatment of IBD. However, they cause a negative calcium balance, reduce bone formation, they increase bone resorption, and suppress the gonadal steroid production. Furthermore, it has been demonstrated that pro-inflammatory cytokines directly influence osteoblast and osteoclast function. Osteoblast and osteoclast function can be measured by biochemical markers of bone turnover, such as bone-specific alkaline phosphatase, osteocalcin, deoxypyridinoline and collagen type 1 degradation products. With these methods some studies find no significant changes, while others find a disturbed remodelling due to impaired bone formation, increased bone resorption, or both. Clinical risk factors are inadequate predictors of actual bone mass in the individual patient, and there seems to be an individual susceptibility for steroids. Therefore, the threshold for measuring bone mineral density should be low and such a measurement should be performed in every patient in whom long-term corticosteroid therapy can be expected. Recently, the first series of children with Crohn's disease who developed vertebral fractures were reported. Presently, only a few studies on the prevention and treatment of osteopenia and osteoporosis in IBD are available. Supplementation of calcium and vitamin D in corticosteroid-treated patients should become a basic therapy. Recently, a study has been published on treatment with bisphosphonates in Crohn's disease and the results are positive. Locally-applied corticosteroids like budesonide may have a less negative effect on bone metabolism than prednisolone; however, this has yet to be proven.

Prevalence of osteoporosis in IBD

The association between bone loss and inflammatory bowel disease (IBD) was first reported in 1964¹. The reported prevalence was low, as it was based on relatively insensitive criteria, such as fractures and radiological signs of osteoporosis in patients with ulcerative colitis (UC). There was another early report on skeletal abnormalities in IBD by Genant et al.². The results indicated that osteopenia and retardation of growth were common in IBD, particularly in adolescents.

Osteoporosis is a systemic skeletal disease characterized by microarchitectural reduction of bone tissue leading to low bone mass, increased bone fragility and, thereby, increased fracture risk³. The preclinical state of osteoporosis is called osteopenia. Osteoporosis is commonly found as senile or post-menopausal osteoporosis, or as a consequence of chronic disease or medical treatment. Osteomalacia is a defect in mineralization of an essentially normal bone matrix and is called rickets in children. Osteomalacia is mainly a consequence of vitamin D- and calcium-deficiency seen in children or elderly with malnutrition or malabsorption, or in rare cases of vitamin D resistance.

Different methods of bone density measurements can be used such as quantitative computed tomography (QCT), single-photon absorptiometry (SPA), double-photon absorptiometry (DPA) and dual energy X-ray absorptiometry (DXA). DXA is accurate, reproducible and involves very low doses of radiation.

Bone mineral density (BMD) is expressed in standard deviations of means, T- and Z-scores, which are compared to reference populations (Table 2.1). One standard deviation decrease in BMD increases the fracture risk 1.5 to 3-fold^{3,4}.

Table 2.1 Definitions of T- and Z-score

T-score =	A standard deviation compared to a young adult gender matched control population
Z-score =	A standard deviation compared to a age and gender matched control population

The WHO-definition for osteoporosis and osteopenia (Table 2.2) was initially designed for post-menopausal bone mineral density but is presently also used for secondary osteoporosis and in males. As there is no commonly accepted definition of osteoporosis expressed in Z-score, the comparison of the present data on the prevalence of osteoporosis can be confusing.

Table 2.2 World Health Organization definitions of osteopenia and osteoporosis

osteopenia	=	T-score -1 to -2.5
osteoporosis	=	T-score $\leq$ -2.5
severe osteoporosis	=	T-score $\leq$ -2.5 and one or more fractures

Since 1987, several cross-sectional studies have been published on the prevalence of osteopenia and osteoporosis in IBD^{3,5-12}. The reported prevalence of decreased bone mass varies widely from 2.7% to 77%, and is higher in Crohn's disease (CD) than in UC. These studies, as summarized in Table 2.3, are, in general, studies from referral centers and involve mostly mixed groups of CD as well as UC patients. Several different definitions of osteoporosis and osteopenia, expressed as T-score and/or Z-score, have been used. Apart from the lack of uniformity in these studies, it is obvious that there is a high prevalence of osteopenia and osteoporosis in IBD. Strikingly, no gender-dependent risk for bone loss is found, and in larger studies the hip seems to be more frequently involved in the bone-losing process than the spine. Also, in IBD, the risk for osteoporosis significantly increases after menopause, as expected from the normal population.

The prevalence of symptomatic fractures was established in six studies. In a study by Compston, 6 of 23 patients (26%) with osteoporosis (in this case defined as Z-score < -2) had radiological evidence of one or more vertebral crush fractures⁷. In two other studies^{8,9} vertebral crush fractures were found in 5% and 7%, respectively, of the IBD patients. Jahnsen et al. found 3.3% fractures in CD and 1.6% in UC¹³. Vestergaard et al. reported an increased fracture risk in Crohn's disease but not in UC; in female patients especially, the relative risk was 2.5¹⁴. No increased risk for male patients was found in this study. In a large epidemiological study, the overall relative risk of fracture was 40% higher in patients with IBD than in population controls¹⁵. However, both studies were retrospective, BMD was not measured, and X-rays of the spine were not performed systematically. Vertebral crush fractures have even been reported in children with CD using corticosteroids¹⁶ and, anecdotally, as presenting symptom¹⁷.

Pathophysiology of osteoporosis in IBD

Bone is a living tissue in which there is a constant cycle of degradation (resorption) performed by osteoclasts and bone formation by osteoblasts replacing old bone with new bone. This bone turnover should be in balance; otherwise, decreased formation, increased resorption or both lead to bone loss. Osteoblasts and osteoclasts originate from stem cells in the bone marrow and proliferate under a complex influence of growth factors, cytokines, and hormones. Remodelling imbalance can result in osteopenia and osteoporosis. To diagnose osteomalacia, histologic examination of bone acquired by biopsy and the presence of unmineralized "osteoid" is necessary.

Histomorphometry

A study on the histomorphometric changes in bone of 19 osteoporotic patients with IBD showed reduced bone formation at the cellular and tissue level¹⁸. The proportionately greater change in wall width than in resorption cavity was consistent with a negative remodelling balance. None of the patients had osteomalacia as defined by the criteria of increased osteoid border width and mineralization lag time, but there was an indication for a mild mineralization defect.

In an earlier study of patients with small bowel resections, mostly with IBD, 9 of 25 patients had bone changes indicative of osteomalacia¹⁹. In another study of nine patients selected to be at "high risk" for metabolic bone disease, histologic examination of bone biopsies showed osteomalacia in six patients and concomitant osteopenia in four²⁰. In a study on bone biopsies of 36 unselected CD patients with small-bowel resections, a mean reduced trabecular bone mass was found, but frank signs of osteomalacia were found in only two biopsies²¹.

Table 2.3 Cross-sectional and population based studies on prevalence of osteopenia and osteoporosis in inflammatory bowel disease.

author	CD/UC(n)	method	definition	prevalence (%)
Compston ⁷	52/17	SPA CT	osteoporosis $Z \leq -2$	lumbar spine + forearm CD: 41 UC: 14
Tromm ¹²	52/23	CT	osteopenia $Z \leq -1$ osteoporosis $Z \leq -2$	lumbar spine (CD): 30 lumbar spine (UC): 9 lumbar spine (CD): 7.5 lumbar spine (UC): 4.4
Abitbol ⁹	34/50	DXA	osteopenia $Z \leq -1$	lumbar spine: 43
Silvennoinen ¹¹	78/60	DXA	osteopenia $Z \leq -1$	lumbar spine: 5.3 femoral neck: 5.9
Bjarnasson ⁶	44/35	DXA	osteopenia $T \leq -1$ osteoporosis $T \leq -2.5$	lumbar spine: 54 femoral neck: 77 lumbar spine: 18 femoral neck: 29
Schoon ¹⁰	114/0	DXA	osteopenia $T \leq -1$ osteoporosis $T \leq -2.5$	lumbar spine: 22 femoral neck: 41 total body: 27 lumbar spine: 7 femoral neck: 11 total body: 6

CD = Crohn's disease; UC = ulcerative colitis; DXA = dual energy X-ray absorptiometry; SPA = single photon absorptiometry; CT = quantitative computed tomography.

Biochemical markers

Osteoblast and osteoclast function can be measured by using biochemical markers of bone turnover²² (Table 2.4). While these biochemical markers are inadequate predictors of actual bone mass, they do provide information on the bone turnover in the entire skeleton²³. Some studies have found no significant changes using these markers, while others have found a disturbed remodelling due to impaired bone formation, increased bone resorption, or both. The different outcomes of these studies can partially be explained by differences in patient selection, disease activity, and corticosteroid use^{5,6,24-27}.

Table 2.4 Biochemical parameters of bone turnover.

bone formation	bone resorption
osteocalcin	hydroxyproline
bone-specific alkaline phosphatase	hydroxylusine glycoside
C- and N-propeptides of type I collagen	pyridinium crosslinks of collagen
	telopeptides
	tartrate resistant acid phosphatase

In a study on bone turnover in patients with CD, osteoblast activity, reflected in serum osteocalcin levels, was impaired in patients treated with prednisolone, whereas budesonide in controlled ileal release formulation did not have such an effect. Urinary markers of bone degradation, i.e. pyridinolines and deoxypyridinolines, did not differ between the groups²⁸.

Risk factors for osteoporosis in IBD

Risk factors contributing to the development of osteoporosis in IBD are in mostly similar to those in other conditions leading to secondary loss of bone mass. However, some are disease-specific or a consequence of treatment and, therefore, need the special attention of the physician (gastroenterologist).

Corticosteroids

Corticosteroid therapy is, in general, the most important cause of secondary osteoporosis. Although corticosteroids are effective in the treatment of patients with IBD, they cause a negative calcium balance by reducing calcium absorption and increasing urinary calcium excretion. They also reduce bone formation, increase bone resorption, and suppress gonadal steroid production^{29,30}. Several studies have reported a negative effect of steroids on BMD in patients with IBD^{5,7,9,12,13}. This finding has also been described in other chronic diseases treated with corticosteroids, such as rheumatoid arthritis and obstructive pulmonary disease³¹. Although many studies support the hypothesis of the negative effect of corticosteroids, there are controversial data too. In a study by Bjarnasson et al., no correlation was found between the BMD of patients who were never treated with corticosteroids and those who had received a maximum lifetime dose of 10 g⁶. One explanation could be the exclusion of high-risk groups of patients using more than 10 mg/day prednisolone for 6 weeks before DXA, patients with a lifetime dose exceeding 25 g, and post-menopausal patients. Although Silvennoinen et al. reported a relatively low prevalence of osteopenia in IBD, a weak but significant negative correlation between BMD and total lifetime steroid dose was found¹¹. Andreassen et al. observed that CD patients who had

been using steroids had a significantly lower BMD than healthy controls, but that cumulative corticosteroid dose did not correlate with BMD³².

Jahnsen et al. completed a study on BMD involving 60 patients with CD, 60 patients with UC, and 60 controls¹³. The total steroid dose for CD was significantly higher than for those with UC. BMD was significantly lower in CD patients than in UC patients and in controls. Disease localization, duration of disease, and resection did not significantly influence BMD. In this study, treatment with corticosteroids had a significant negative influence on BMD in CD patients but not in UC patients. An equivalent result was found for the lifetime prednisolone dosage. In a covariate analysis, corticosteroid use and low body mass index were the most important predictive factors of BMD in the patients with CD.

In a longitudinal study in children with CD, no difference was found in BMD/body mass ratio between patients with alternate day corticosteroids and without corticosteroids, over a 2-year follow up³³.

Disease activity

Disease activity is supposed to play a significant role in the development of metabolic bone disease in IBD, especially in CD. A significantly lower BMD was already found at diagnosis in CD compared to UC, indicating that factors other than corticosteroids may be involved⁸. However, in a case-control study on 64 recently diagnosed IBD patients, BMD did not differ from that of age and gender-matched healthy controls³⁴. A period of untreated disease of more than 6 months before diagnosis was identified as a risk factor for low BMD in the IBD patient group.

It has been demonstrated that cytokines directly affect bone formation and resorption as they influence the osteoblast and osteoclast function. Particularly proinflammatory cytokines like TNF, IL-1, and IL-6 are supposed to have a pivotal role in this process^{35,36}. These cytokines are also important in the inflammatory process in IBD³⁷. In a recent study serum of pediatric patients with active CD was injected into rats³⁸. Compared to controls, this serum significantly decreased bone dry weight and calcium content, while serum from UC patients had no such effect. These data suggest that proinflammatory cytokines influence bone formation and bone resorption, resulting in bone loss. The exact factors causing bone loss have to be defined by further research³⁹. In one study, genetic factors, i.e. the presence of IL-6 allele and the absence of the interleukin 1 receptor antagonist (IL-1ra) allele correlated with bone loss in a mixed group of 86 UC and CD patients⁴⁰.

Smoking

Only one study has to date, addressed smoking habits as a risk factor for osteoporosis in IBD⁴¹. The authors found a significant negative effect of smoking on BMD in female IBD patients. No effect on BMD in male IBD patients was found, which was not surprising because almost all male patients in this study smoked.

Hypogonadism

Although corticosteroids are supposed to suppress the production of sex hormones, low testosterone levels in male IBD patients have also been described as an independent risk factor for osteoporosis⁴². Total testosterone levels were significantly associated with serum osteocalcin levels as a marker for increased bone formation. This association was independent of age and current steroid use. Female patients receiving high doses of corticosteroids can become amenorrhoeic, due to lower estrogen levels. When estrogen protection of bone stops after menopause, bone resorption increases and the rate of bone loss increases, especially in the first years thereafter^{43,44}.

Body composition

Low body mass is a risk factor for osteoporosis in the general population. Several studies show that low body weight is one of the most important risk factors for osteopenia^{32,43,45}.

Vitamin D deficiency

There is a high prevalence of vitamin D deficiency in patients with CD^{20,46}. This is caused by small intestinal disease, diarrhea, dietary effects, use of cholestyramin and, possibly, decreased sun exposure. These processes lead to a decrease in calcium absorption and cause a negative calcium balance. Vitamin D status can be measured by 25-hydroxyvitamin D, which best reflects the total body vitamin D stores. Although 25-hydroxyvitamin D levels were low in 56% of CD patients in a controlled study, those of 1,25-hydroxyvitamin D, the active metabolite, did not significantly differ from the levels in controls⁴⁷. In this study vitamin D status was independent of nutritional status, disease location, and previous intestinal resections.

Osteomalacia, as a consequence of vitamin D deficiency, is clinically associated with bone pain, bone deformations in children, fractures, muscle weakness, and tetany caused by hypocalcemia in severe cases. Typical radiographic changes are described. These clinical symptoms, elevated parathyroid hormone (PTH), elevated bone-specific alkaline phosphatase, and very low levels of 25-hydroxyvitamin D (< 10 nmol/l) could indicate the presence of osteomalacia, and a bone biopsy for confirmation should be considered. DXA does not differentiate between osteomalacia and osteoporosis. However, clinical signs of osteomalacia are rare in IBD²⁰.

In a study on the relationship between vitamin D, PTH, and BMD in IBD, patients had lower serum levels of 25-hydroxyvitamin D than healthy controls, but similar PTH concentrations and vitamin D intake⁴⁸. Vitamin D intake, serum levels of 25-hydroxy-vitamin D and PTH were not associated with BMD. In another study, BMD of all measured areas was significantly lower in patients with increased PTH than in those with normal PTH, except for the lumbar spine⁴⁹.

Disease duration

A small number of studies address the issue of time-dependent bone loss and risk factors in IBD. In seven longitudinal studies of IBD patients, different rates of annual bone loss were found. The studies are summarized in Table 2.5. Both studies by Motley et al. describe the same patient population^{41,50}. Study populations were generally small, and mixed groups of UC and CD patients were involved. The rate of spinal trabecular bone loss measured by QCT was studied for one year in 70 IBD patients. A mean loss of 3% was found. BMD of the radius was measured by SPA in 39 IBD patients, with a mean follow-up of almost 8 years⁵². The mean rate of annual bone loss was less than 1% in both sexes. In a smaller study by Ryde et al., in 13 IBD patients, a rapid decrease in total body calcium of 7.8% per year over a period of 2 years was found (by prompt γ -neutron activation analysis)⁵³. BMD of the lumbar spine decreased 2.5%, and of the radius 2.1% annually, measured by quantitative computed tomography and single photon absorptiometry, respectively. In a study by Ghosh et al., no bone loss was found over a one-year follow-up period by DXA measurements in 23 IBD patients, 20 of whom received corticosteroids⁵⁴. Roux et al. prospectively studied 35 patients with IBD by DXA for a mean follow-up period of 19 months. Mean annual BMD changes were -6.2% and -0.9% in patients with and without steroids, respectively, which was significantly different. Interestingly, bone loss was not observed in UC patients after colectomy⁵⁵.

In another longitudinal study involving 108 CD patients with bowel resections and a mean follow-up of 5.5 years, bone loss was only demonstrated in the femoral neck and was not related to steroid use or length of the resected small-bowel segment⁵⁶. Schulte et al. found low mean BMD changes over an 18-month follow-up period, and no difference with regard to CD or UC was observed⁵⁷. However, a subgroup of patients lost a significant amount of bone, whereas other patients even gained bone mass. Twenty-five percent of the patients were on vitamin D and calcium supplements, but no difference in bone loss was found compared to the group not taking prophylactic drugs.

In conclusion, bone loss was found in five out of seven studies, and in some the rate of bone loss was higher than the expected age-related bone loss, which is about 1% for pre-menopausal females and 0.5% for males, after peak bone mass has been achieved. There is a great variation in BMD changes, and evidence for bone gain in a subgroup of patients.

Table 2.5 Longitudinal studies on bone mineral density changes in IBD

author	number (male/female)	mean age (years)	CD / UC	mean follow-up period (months)	instrument	bone loss during follow-up	correlation between BMD loss and steroid use	mean dose of steroids (mg)	mean daily dose of steroids (mg)	number of steroid treated patients (%)
Motley ⁵⁰	54(21/33)	47	34/19	12	CT	Yes	No	275	?	29 (54%)
Ryde ⁵³	13(8/5)	?	12/1	23	CT, SPA	Yes (radius)	No	?	?	118 (85%)
Clements ⁵²	50(25/25)	45	33/17	95	SPA	Yes	No	?	?	19 (38%)
Motley ⁵¹	70(26/44)	41	51/22	48	CT, SPA	Yes	Yes, only in females	males: 600 females: 200	?	?
Ghosh ⁵⁴	23	26	11/12	12	DXA	No	No	282	?	23 (100%)
Roux ⁵⁵	35(18/17)	36	14/21	19	DXA	Yes (LS, sign in 34%)	No	4930	24	14 (40%)
Staun ⁵⁶	108(31/77)	38	108/0	66	DPA	Yes (FN, sign)	No	?	?	?
Schulte ⁵⁷	80(45/35)	39	61/19	18	DXA	No	Yes (FN)	?	9.3	28 (35%)

CD = Crohn's disease; UC = ulcerative colitis; DPA = dual-photon absorptiometry; DXA dual energy X-ray absorptiometry;
SPA = single photon absorptiometry; CT = quantitative computed tomography; ? = unknown; LS = lumbar spine;
FN = femoral neck; sign = significant.

Young age

Juvenile patients with CD are at a higher risk of developing osteoporosis⁵⁸. Children with CD have a higher risk of developing osteopenia than children with UC. Steroid therapy and nutritional status are important determinants of BMD in these patients⁵⁹. Treatment of the underlying CD can result in marked improvement in bone mineralization⁶⁰. However, many adolescent IBD patients will reach a lower peak bone mass than healthy persons¹⁰. In the general population, peak bone mass is reached at about the age of thirty. IBD patients, who have a disease onset early in life and achieve lower peak bone mass, may reach the fracture threshold earlier in life. Recently, the first series of five pediatric patients with CD in whom vertebral compression fractures developed as a complication of active disease, steroid treatment, and low BMD was described¹⁶.

Extra-intestinal disease

Female patients with CD located in the terminal ileum with concomitant sacroiliac joint inflammation had significantly lower BMD than patients with ileitis terminalis Crohn without sacroiliac joint involvement, despite longer disease duration in the control group⁶¹. Therefore, a concomitant clinical condition predisposing to osteoporosis may considerably increase the risk for low BMD. This has not been evaluated in male CD patients, and in UC patients yet.

Prevention and treatment of osteoporosis in IBD

Since therapies that completely restore bone mass lost over years are not available, preventive measures should be taken if possible. In general, one is advised to have an adequate dietary intake of vitamin D and calcium, to stop smoking and excessive use of alcohol, and to exercise. The daily needs of elementary calcium are about 1200 mg for adolescent and adults and 1500 mg for postmenopausal females. Calcium intake below these recommendations are seen more often in IBD patients than in healthy controls, but calcium intake was not associated with BMD in a cross-sectional study⁶². A low-lactose diet is common among IBD patients.

Several therapies for primary and secondary osteoporosis are available: calcium, vitamin D and derivatives, sex hormones, anabolic steroids, calcitonin, fluorides, and bisphosphonates.

Six studies regarding the prevention and treatment of osteoporosis in IBD have been published. These studies are summarized in Table 2.6. Vogelsang et al. reported that vitamin D and calcium substitution over a period of one year prevented bone loss in a group of 75 CD patients⁶³. Placebo-treated patients had a significant bone loss (median 7%). In an uncontrolled study, estrogen replacement therapy (HRT) was effective in the prevention of bone loss in post-menopausal IBD patients⁶⁴. A prospective study on oral calcium supplementation versus placebo in corticosteroid-using IBD patients failed to show a significant benefit after 1 year of treatment⁶⁵. In a small, randomized trial, one year of fluoride therapy significantly improved BMD⁶⁶.

Table 2.6. Intervention studies on BMD in IBD.

author	drug	number of patients	design	period (years)	results
Vogelsang ⁶¹	vitamin D 1000 IU	75 CD	open, randomized	1	+
Clements ⁶⁴	estrogens	25 UC, 22 CD	open	2	+
Bernstein ⁶⁵	calcium 1000 mg, vitamin D 250 IU	14 UC, 10 CD	randomized, placebo controlled	1	=
Tirptitz ⁶⁶	fluoride	33 CD	randomized	1	+
Haderslev ⁶⁹	alendronate	32 CD	randomized, placebo controlled	1	+
other					
Robinson ⁷¹	exercise	117 CD	randomized, placebo controlled	1	+

Results: + positive, and = unchanged

Given the current evidence, dietary advice concerning the intake of calcium and vitamin D should be given to every patient with IBD. Vitamin D and calcium should be supplemented in cases of vitamin D deficiency, steroid use, resection, or chronic use of cholestyramin. In a recent meta-analysis, it was concluded, that all patients started on corticosteroids should receive prophylactic therapy with calcium and vitamin D⁶⁷.

There are only a few studies on treating osteoporosis in IBD with bisphosphonates. Alendronate significantly improved BMD over a period of 48 weeks in corticosteroid-treated patients with several underlying diseases (only 5% were IBD patients)⁶⁸. The underlying disease did not affect the response to alendronate in subgroup analysis, although these data were not shown. Treatment with alendronate significantly improved lumbar spine BMD in patients with CD compared to placebo controls in a study with a one-year follow-up; however, these patients were in remission⁶⁹. Biochemical markers of bone turnover decreased significantly in the alendronate group compared to those taking placebo. In another study recently presented as abstract, addition of 30 mg of intravenous pamidronate to vitamin D and calcium, in a randomized controlled trial, was effective after one year of treatment⁷⁰. As bisphosphonates have been proven to be very effective in the treatment of post-menopausal osteoporosis and in the prevention of corticosteroid-induced osteoporosis in several other diseases, they could be considered for IBD patients receiving long-term corticosteroid therapy, particularly those with low bone density^{68,71,72}. Preventive therapy with anti-resorptive agents like bisphosphonates for every corticosteroid-using IBD patient, however, is a subject of debate as there seems to be an individual susceptibility for

steroids in every patient. Patients considered for preventive use of bisphosphonates could be selected on the basis of low BMD at the start of corticosteroid therapy, a history of non-traumatic fractures or having entered menopause. Another reason for considering treatment with bisphosphonates is the identification as rapid bone losers by serial BMD measurements or by biochemical markers. Osteoporosis (T-score ≤ -2.5), at any site of measurement or a non-traumatic fracture is an indication for active treatment. In osteopenia (T-score between -1 to -2.5) preventive measures should be taken. BMD and the results of treatment should be followed up at intervals of 2 - 3 years. It is important to treat the underlying disease optimally and, if necessary, to give corticosteroid therapy as briefly and as low-dosed as possible. "Steroid-saving" therapy like azathioprine should be considered in steroid-dependent patients. Low-impact physical exercise proved to be effective in maintaining BMD in a randomized, controlled trial⁷³.

Discussion

Although there are different methods for measuring BMD and different definitions of osteoporosis have been used, there is sufficient evidence of a high prevalence and high morbidity of metabolic bone disease, i.e., osteopenia and osteoporosis in IBD, especially in CD. Little has been published about the endpoint of symptomatic and asymptomatic fractures, and there is no long-term study on fracture risk in IBD. Since there is a very good correlation between BMD measurements with DXA and fracture risk in the general population, this can probably be extrapolated to IBD patients⁴. As a novel diagnostic method of low bone mass, the correlation between hand skin-fold thickness and BMD in patients with CD has recently been described. Mean hand skin-fold thickness was significantly lower in patients with osteoporosis than in patients with normal BMD⁷⁴. However, the association was not strong enough to recommend this method as a diagnostic test for osteoporosis in an individual patient. A study on ultrasound evaluation of the calcaneus in patients with Crohn's disease demonstrated that these patients had reduced broadband ultrasound attenuation compared with an age and gender matched control population⁷⁵. Calcaneal ultrasound was significantly associated with BMD at the hip and the spine, but the correlation was insufficient for use as a screening tool for DXA.

Different findings regarding the significance of corticosteroid effects on BMD in IBD patients can be explained by the multifactorial nature of bone loss, the difficulties of accurate, retrospective calculation of steroid doses used, the heterogeneity of the populations studied, the individual susceptibility of the patients to the damaging effect of steroids, and the confounding effects of disease activity. Patients with IBD are often treated with high initial doses of corticosteroids, tapered to lower levels with the aim of inducing remission. Most bone loss occurs in the first 3 months of corticosteroid use, and there may be a reversible component after stopping steroid therapy. Control of disease activity with appropriate therapy has the highest priority and may even improve bone mineralization. Studies in patients treated with corticosteroids may potentially be

confounded by the higher use of corticosteroids in patients with a higher disease burden. More knowledge is needed on the interrelationship between several risk factors. This could be obtained in large, preferably population-based, studies on BMD in IBD. In this context, it is interesting to assess, whether locally active steroids like budesonide have fewer negative effects on bone than prednisolone. This is presently being investigated in a large, randomized study.

Since patients with IBD are at an increased risk for osteoporosis, bone densitometry should be performed every 2 - 3 years to identify patients in need of treatment and to monitor the effects of interventions to prevent or treat bone loss⁷⁶. A past history of one or more fragility fractures is a strong risk factor for future fractures, independent of bone density, and should be regarded as an indication for treatment. If bone densitometry is not available, patients should be selected for treatment on the basis of strong risk factors, such as low body weight or malnutrition, post-menopausal status or hypogonadism, corticosteroid therapy, or persistent disease activity⁷⁷. Vitamin D deficiency should be corrected. Patients should have dietary advice on calcium and vitamin D intake or receive preventive supplementation of calcium and vitamin D. To reduce the risk of inadequate calcium intake, unnecessary dietary restrictions, e.g., milk products, should be avoided in these patients.

Since low BMD can already be found at diagnosis in long-term undiagnosed and untreated CD, the prevalence of low bone mineral density is higher and an abundance of circulating cytokines may be involved in the demineralization process. There are probably more mechanisms responsible for this condition in CD than in UC. For this reason, CD and UC should not be regarded as the same entity in the study of bone metabolism in IBD.

At present there is a need for more studies on the pathogenesis, prevention, and treatment of osteoporosis in CD as well as in UC.

References

1. Edwards F, Truelove SC. The course and prognosis of ulcerative colitis. *Gut* 1964; 5:1-22.
2. Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. *Invest Radiol* 1976; 11(6): 541-549.
3. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. *Am J Med* 1993; 94(6):646-650.
4. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996; 312(7041): 1254-1259.
5. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M et al. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995; 108(2):417-422.
6. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997; 40(2):228-233.
7. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA et al. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987; 28(4):410-415.
8. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994; 107(4): 1031-1039.
9. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy MT et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992; 37(9):1396-1403.
10. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl* 2000; 35(232):43-47.
11. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995; 37(1):71-76.
12. Tromm A, Rickels K, Huppe D, Wiebe V, May B. Osteopenia in chronic inflammatory bowel diseases. Results of a cross-sectional study using quantitative computerized tomography. *Leber Magen Darm* 1994; 24(1):23-30.
13. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997; 40(3):313-319.
14. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000; 46(2):176-181.
15. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med* 2000; 133(10):795-799.
16. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997; 112(5):1710-1713.
17. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. *J Clin Endocrinol Metab* 2000; 85(6):2122-2126.
18. Croucher PJ, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. *Osteoporos Int* 1993; 3(5):236-241.
19. Compston JE, Ayers AB, Horton LW, Tighe JR, Creamer B. Osteomalacia after small-intestinal resection. *Lancet* 1978; 1(8054):9-12.
20. Driscoll RH, Jr., Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* 1982; 83(6):1252-1258.
21. Hessel I, Mosekilde L, Melsen F, Fasth S, Hulten L, Lund B et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. *Scand J Gastroenterol* 1984; 19(5):691-696.

22. Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. *J Rheumatol* 1997; 24(6):1215-1217.
23. Marcus R. Biochemical assessment of bone resorption and formation. *Bone* 1996; 18(1 Suppl):155-165.
24. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. *Am J Gastroenterol* 1997; 92(7):1157-1163.
25. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M et al. Bone loss in patients with inflammatory bowel disease: a prospective study. *Osteoporos Int* 1995; 5(3):156-160.
26. Schoon EJ, Geerling BG, Van Dooren IM, Schurgers LJ, Vermeer C, Brummer RJ et al. Abnormal bone turnover in long-standing Crohn's disease in remission. *Aliment Pharmacol Ther* 2001; 15(6):783-792.
27. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. *Gut* 1996; 38(2):223-228.
28. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. *Aliment Pharmacol Ther* 1998; 12(5):419-424.
29. Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. *J Clin Endocrinol Metab* 1996; 81(10):3441-3447.
30. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. *J Intern Med* 1995; 237(5):439-447.
31. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. *N Engl J Med* 1983; 309(5):265-268.
32. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am J Gastroenterol* 1999; 94(3):824-828.
33. Issenman RM, Atkinson SA, Radoja C, Fraher L. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr* 1993; 17(4):401-406.
34. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. *Gastroenterology* 2000; 119(5):1203-1208.
35. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. *Lymphokine Cytokine Res* 1991; 10(1-2):15-21.
36. Wallach S, Avioli LV, Feinblatt JD, Carstens JH, Jr. Cytokines and bone metabolism. *Calcif Tissue Int* 1993; 53(5):293-296.
37. Hommes DW, van Dullemen H, Radema SA, Tytgat GN, van Deventer SJ. The role of cytokines in the pathogenesis of inflammatory intestinal diseases. *Ned Tijdschr Geneesk* 1994; 138(49):2427-2432.
38. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997; 24(3):289-295.
39. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997; 24(3):361-362.
40. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. *Gastroenterology* 2000; 119(4):909-920.
41. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. *Scand J Gastroenterol* 1996; 31(4): 367-371.
42. Robinson RJ, Iqbal SJ, al Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. *Aliment Pharmacol Ther* 1998; 12(1):21-25.
43. Delmas PD, Hardy P, Garnero P, Dain M. Monitoring individual response to hormone replacement therapy with bone markers. *Bone* 2000; 26(6):553-560.
44. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. *J Bone Miner Res* 2000; 15(7):1398-1404.

45. Robinson RJ, al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998; 43(11):2500-2506.
46. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S et al. Bone disease in vitamin D-deficient patients with Crohn's disease. *Dig Dis Sci* 1989; 34(7):1094-1099.
47. Vogelsang H, Ferenci P, Schilling R, Woloszczuk W, Haschke, W et al. Vitamin D-status in outpatients with Crohn's disease. *Eur J Gastroenterol Hepatol* 1994;6: 513-517.
48. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. *J Intern Med* 1996; 239(2):131-137.
49. Andreassen H, Rix M, Brot C, Eskildsen P. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. *Scand J Gastroenterol* 1998; 33(10):1087-1093.
50. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. *Gut* 1988; 29(10):1332-1336.
51. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. *Bone Miner* 1993; 23(2):95-104.
52. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. *Scand J Gastroenterol* 1992; 27(12):1055-1060.
53. Ryde SJ, Clements D, Evans WD, Motley R, Morgan WD, Evans C et al. Total body calcium in patients with inflammatory bowel disease: a longitudinal study. *Clin Sci (Colch)* 1991; 80(4):319-324.
54. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994; 107(4): 1031-1039.
55. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemand S, Dougados M et al. Bone loss in patients with inflammatory bowel disease: a prospective study. *Osteoporos Int* 1995; 5(3):156-160.
56. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. *Scand J Gastroenterol* 1997; 32(3):226-232.
57. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. *Scand J Gastroenterol* 1999; 34(7):696-702.
58. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. *Gut* 1998; 42(2):188-194.
59. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. *Gastroenterology* 1998; 114(5):902-911.
60. Cowan FJ, Gregory JW, Jenkins HR. Bone mineral density in Crohn's disease. *Gut* 1997; 41(4):578-579.
61. Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. *Rheumatol Int* 1997; 17(2):45-48.
62. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. *J Intern Med* 1996; 240(5):285-292.
63. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. *Eur J Gastroenterol Hepatol* 1995; 7(7):609-614.
64. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. *Gut* 1993; 34(11): 1543-1546.
65. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. *Aliment Pharmacol Ther* 1996; 10(5):777-786.
66. von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. *Eur J Gastroenterol Hepatol* 2000; 12(1):19-24.
67. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev* 2000;(2):CD000952.

68. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med* 1998; 339(5):292-299.
69. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. *Gastroenterology* 2000; 119(3):639-646.
70. Bartram SA, Francis RM, Thompson NP. A randomised trial of intravenous Pamidronate and calcium and vitamin D, in the treatment of osteoporosis associated with Crohn's disease. *Gastroenterology* 2001; Suppl.:A 3182.
71. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med* 1997; 337(6):382-387.
72. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R et al. Bisphosphonates for steroid induced osteoporosis. *Cochrane Database Syst Rev* 2000;(2): CD001347.
73. Robinson RJ, Krzywicki T, Almond L, al Azzawi F, Abrams K, Iqbal SJ et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. *Gastroenterology* 1998; 115(1):36-41.
74. Robinson RJ, al Azzawi F, Iqbal SJ, Abrams K, Mayberry JF. The relation of hand skin-fold thickness to bone mineral density in patients with Crohn's disease. *Eur J Gastroenterol Hepatol* 1997; 9(10):945-949.
75. Robinson RJ, Carr I, Iqbal SJ, al Azzawi F, Abrams K, Mayberry JF. Screening for osteoporosis in Crohn's disease. A detailed evaluation of calcaneal ultrasound. *Eur J Gastroenterol Hepatol* 1998; 10(2):137-140.
76. Gluer CC. Monitoring skeletal changes by radiological techniques. *J Bone Miner Res* 1999; 14(11):1952-1962.
77. Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1997; 9(10):931-933.

CHAPTER 3

The prevalence of osteoporosis in Crohn's disease: a population-based study in the Netherlands

EJ Schoon, AB van Nunen, RSME Wouters,
RW Stockbrügger, MGVM Russel

Scand J Gastroenterol 2000;35 Suppl 232:43-47

Abstract

Background

Reduced bone mineral density (BMD) has been reported in 3-77% of patients with inflammatory bowel disease (IBD). The majority of these studies are cross-sectional and from tertiary referral centres. The aim of our study was to estimate the prevalence of metabolic bone disease and of symptomatic fractures in a population of patients with Crohn's disease (CD) living in a well-defined geographic area.

Methods

Patients with CD living in three adjacent municipalities within the IBD South-Limburg study area were investigated. BMD was measured by dual-X-ray absorptiometry (DXA) of the femoral neck, lumbar spine and total body.

Results

The population comprised of 181 CD patients of which 23 were excluded. One-hundred-nineteen (75%) of the 158 eligible patients (37 males, 82 females with a mean age of 42 years (17-78)) were investigated. Osteopenia of lumbar spine and/or femoral neck was found in 45% of patients. Osteoporosis was found in another 13 % of patients. Mean BMD (T-score) of femoral neck was significantly lower than of lumbar spine ($p < 0.001$). Male CD patients and patients aged under 18 at diagnosis are more at risk of having a low bone mass at the lumbar spine ($p < 0.001$) and total body ($p = 0.018$). The prevalence of osteoporosis in postmenopausal CD patients (29%) was significantly higher than in premenopausal patients (3%) (Odds ratio: 12). Twenty-nine of 119 (24%) patients had a history of symptomatic fractures.

Conclusions

Osteopenia and osteoporosis are frequent in CD and should have the full attention of the treating physician.

Introduction

The association between inflammatory bowel disease (IBD) and low bone mineral density (BMD) was first reported in 1964¹. The reported prevalence was low as it was based on relatively insensitive criteria such as radiological signs of osteoporosis and fractures.

Since the introduction of novel methods of BMD measurement several studies have been published on the prevalence of osteopenia and osteoporosis in IBD. The reported prevalence of decreased bone mass varies widely (13-77%) and is dependent on patient selection, method of BMD measurement and definition of osteoporosis used²⁻⁹. The studies are usually cross-sectional from tertiary referral centres and mostly mixed groups of Crohn's disease (CD) and ulcerative colitis (UC) patients were reported. Several studies found a significant difference in BMD between CD and UC patients and in one study a significant difference in BMD was found even at diagnosis¹⁰. Only three studies have been published on BMD reporting CD patients alone¹¹⁻¹³.

Vertebral crush fractures, as a consequence of osteoporosis, are already reported in juvenile patients with CD¹⁴. The prevalence of fractures in IBD patients was established in four studies and varied from 5 to 26% regarding radiologically assessed fractures and from 3.3 to 7% concerning symptomatic fractures^{2,5,6,14}.

The aim of our study was to estimate the prevalence of metabolic bone disease and of symptomatic fractures in an unselected population of CD patients living in a well-defined geographic area.

Patients and methods

Patients with CD living in three adjacent municipalities of the IBD South-Limburg study area in the Netherlands¹⁶, with a total of 150,891 inhabitants (118,465 in Maastricht, 20,591 in Meerssen, 11,835 in Eijsden), were investigated during the period of January 1996 to July 1997. Crohn's disease was diagnosed on the basis of endoscopical and/or radiological evidence, supported by mucosal biopsies and/or examination of surgical specimen when available. For confirmation of the CD diagnosis the Lennard-Jones criteria were applied¹⁷. The University Hospital of Maastricht is the only hospital in the city of Maastricht and therefore also serves as the community hospital for the selected area.

The study population comprised of 181 CD patients, all of Caucasian ethnicity, of whom 14 patients were excluded because of pregnancy, renal insufficiency, ankylosing spondylitis (3x), rheumatoid arthritis, pulmonary cancer and change of diagnosis to ulcerative colitis (7x). Four patients from the IBD registry had died before inclusion, one patient due to a thrombo-embolic event (possibly related to an exacerbation of CD), three others died of causes unrelated to CD. Five patients had moved out of the study area.

The intention was to investigate each patient attending the outpatient clinic during the study period. One-hundred-nineteen (75%) of the 158 eligible patients, 37 males and 82 females with a mean age ($\pm$ SD) of 42 ($\pm$ 14) years (range 17-78)) were investigated. Mean duration of disease was 10.5 ($\pm$ 8.8) years. The disease was located in the small-bowel in 35 patients, in the colon in 10 patients, while 74 patients had both disease localisations. Seventy-three patients had one ($n = 42$) or more ($n = 31$) surgical resections. Patient characteristics are given in Table 3.1. Thirty-nine patients (14 males, 25 females) who did not attend the outpatient clinic during the study period could not be included. The mean age of this group of patients was 42 ($\pm$ 15) and mean duration of disease was 12 ($\pm$ 9) years.

Table 3.1 Patient characteristics

	all CD patients	male	female	difference male/female* p-value
number	119	37	82	
age	42 (14)	45 (17)	40 (14)	0.052
age at diagnosis	32 (14)	35 (18)	30 (13)	0.093
body mass index (kg/m ²)	23.5 (3.7)	23.9 (3.9)	23.3 (3.6)	0.403
disease duration	10.5 (8.9)	11.3 (11.4)	10.2 (7.3)	0.524
postmenopausal female (%)			21 (25.6)	
mean years after menopause			2.5 (5.5)	
bone fractures (%)	29 (24.3)			

All data are expressed as mean and standard deviation (SD), as numbers and percentage if indicated (%). * independent t-test.

Bone mineral Density

In all 119 patients, bone mineral density was measured using dual-energy X-ray absorptiometry (DXA) (Lunar DPX-L, Lunar software version DPX-L 1.3; Lunar Radiation Corp., Madison, WI)¹⁸ of lumbar spine (L₂-L₄) and the femoral neck of the non-dominant hip. DXA of the total body was performed in 61 patients. BMD was expressed in absolute values (g/cm²), T-score (one standard deviation compared to a young adult gender matched reference population), and Z-score (one standard deviation compared to an age and gender matched reference population), respectively. Reference data were based on populations from the United States, United Kingdom, and Northern Europe^{19,21}. The variation of mean BMD values among geographical areas contributing to normal data was 1.3%.

The number of patients with osteopenia and osteoporosis was assessed according to the WHO classification²² in which osteopenia is defined as a T-score between -1 and -2.5 and osteoporosis as T-score < -2.5. In addition the Z-score was applied to make the study comparable to previous prevalence studies. In this case an accepted biological concept of pathology was applied as Z-score < -1 to < -2 for osteopenia and Z-score $\leq$ -2 for more severe bone disease.

Fractures and other parameters

The number of wrist, vertebral, femoral and other spontaneous or traumatic fractures in the past history were assessed by questionnaire. The body mass index (kg/m^2) was calculated. Age of onset of CD, disease duration and disease localization were derived from the medical records.

Statistical analysis

Comparisons of risk factors between male and female patients were performed using a parametric test (independent t-test), otherwise a non-parametric (Mann-Whitney) was performed. In order to correct for the age difference between male and female CD patients the Z-score was applied in gender specific analysis of BMD. The Pearson's coefficient was used for expression of correlation.

The Statistical Package for the Social Sciences (SPSS 7.5, SPSS inc., Chicago, Ill) was used for the analysis. A P value of ≤ 0.05 was considered statistically significant.

Results

Prevalence of osteopenia and osteoporosis

Mean BMD (g/cm^2), T- and Z-score of lumbar spine, femoral neck and/or total body of all patients are given in Table 3.2. A highly significant correlation was found between BMD of total body and lumbar spine ($r = 0.715$, $p < 0.001$), total body and femoral neck ($r = 0.748$, $p < 0.001$) and lumbar spine and femoral neck ($r = 0.600$, $p < 0.001$). Highly significant correlations were also found for T- and Z-scores.

Table 3.2 Mean bone mineral density ($\pm$ SD)) at different sites expressed in absolute values (g/cm^2), T- and Z-score.

	BMD	T-score	Z-score
lumbar spine	1.164 (0.168)	-0.42 (1.31)	0.00 (1.24)
femoral neck	0.892 (0.167)	-0.96 (1.37)	-0.52 (1.19)
total body	1.116 (0.107)	-0.50 (1.32)	-0.27 (1.06)

Mean BMD of femoral neck expressed in T-score was significantly lower than BMD of lumbar spine and total body (Table 3.2, Figure 3.1). The prevalence of osteopenia and osteoporosis at different sites of measurement is given in Table 3.3.

Figure 3.1 T-score of lumbar spine versus femoral neck in 119 patients with Crohn's disease

Table 3.3 Prevalence (in percentage) of normal bone mass, osteopenia and osteoporosis in 119 patients with Crohn's disease defined as T-score (WHO-criteria) and as Z-score (biologic variability).

	T-score			Z-score		
	normal T > -1 %	osteopenia -2.5 < T ≤ -1 %	osteoporosis T ≤ -2.5 %	normal Z > -1 %	low -2 < Z ≤ -1 %	very low Z ≤ -2 %
lumbar spine	71	22	7	79	16	5
femoral neck	48	41	11	66	25	9
total body	67	27	6	74	21	4
femoral spine or femoral neck	42	45	13	59	28	13

* n=61

Gender

In the gender specific analysis, the gender difference in BMD of the total body (Z-score) was nearly significant ($p = 0.051$). No difference was found for lumbar spine ($p = 0.439$) or femoral neck ($p = 0.768$), respectively. Risk estimation for having osteoporosis revealed an odds ratio in females of 0.439 (95% CI: 0.170-1.138), but this was not statistically significant.

No significant difference in BMD (Z-score) at the lumbar spine, femoral neck or total body was found between pre-and postmenopausal females. The prevalence

of osteopenia did not differ significantly between postmenopausal and premenopausal women. However, in postmenopausal CD patients the prevalence of osteoporosis (6/21, 24%) was significantly higher than in premenopausal patients (2/61, 3%)(Odds ratio 12, 95% CI: 2.2-65.5).

Age of disease onset

Patients with a disease onset under 18 years ($n = 12$) had mean Z-scores, that were significantly lower than in patients with CD diagnosed above the age of 18 ($p < 0.01$), with exception of the femoral neck (Table 3.4).

Table 3.4 Mean bone mineral density (Z-score) of patients with age at diagnosis below or above 18 years.

Z-score	age at diagnosis ≤ 18 years $n = 12$	age at diagnosis > 18 years $n = 107$	p-value
lumbar spine	-1.07 (0.08)	0.12 (1.21)	0.000
femoral neck	1.13 (1.04)	-0.46 (1.18)	0.066
total body	-0.86 (0.70)*	-0.20 (1.08)**	0.018

Indepent t-test. * $n=10$; ** $n=81$

Figure 3.2 Mean bone mineral density (Z-score) of the lumbar spine of patients with age at diagnosis below or above 18 years ($p < 0.001$).

Fractures

Twenty-nine of the 119 (24%) of patients had a history of symptomatic fractures: 2 hip, 6 wrist and 16 other fractures (clavicle, ribs etc.). Symptomatic vertebral fractures were not reported. Although all mean BMD and T-scores were lower in this group, no significant differences in BMD (g/cm^3) or T-scores were found between patients with and without fractures. However, the two patients who had suffered from a hip fracture (both post-menopausal females aged 66 and 72 years), had low BMD of the femoral neck with T-scores of -2.30 and -2.93 , respectively.

Discussion

A high prevalence of osteopenia and osteoporosis was found in this population-based study on BMD in patients with CD. Fifty-eight percent of patients in this study had this type of metabolic bone disease. The risk of osteoporosis in CD significantly increased in female patients after menopause as expected from the normal population.

The WHO-definition for osteoporosis and osteopenia was initially designed for post-menopausal decrease of bone mineral density (primary osteoporosis), but is presently also used for secondary osteoporosis and in males. A T-score ≤ -2.5 indicates a definitively increased fracture risk. As there is no commonly accepted definition of osteoporosis expressed in Z-score, the comparison of the presently published studies on the prevalence of osteoporosis in IBD can be confusing. The results in Table 3.3 indicate that the use of Z-score gives a good indication of osteoporosis, but may underestimate the presence of osteopenia. It is the osteopenic patient that might benefit from preventive treatment to avoid further deterioration of bone mass.

In this study, which is different from a cross-sectional study performed in a referral centre, mild to severe cases of CD were involved. Twenty-five percent of patients in the pre-defined study area could not be investigated. However, there was no significant difference regarding mean age and duration of disease with the 75% included patients. The prevalence of osteopenia and osteoporosis could have been lower if all patients had been included considered that these patients had had less severe illness. Disease activity and concurrent use of corticosteroids are thought to be important factors influencing BMD in CD²³⁻²⁵.

Fracture history revealed two hip fractures. Considering the significantly lower BMD of the femoral neck in CD, this should possibly be an endpoint in further long-term studies on osteoporosis in CD. The relatively low hip fracture rate could be explained by the fact that osteoporosis is only one factor predisposing to fracture, and in this relatively young group of patients with good mobility and eyesight the tendency to fall is generally low. No X-ray examinations of lumbar and thoracic spine were performed, as only symptomatic vertebral fractures were considered.

In the overall population, mean BMD (T-score) of the femoral neck was lower than in the lumbar spine. This finding is comparable to the findings in other studies^{4,26}. The risk to develop metabolic bone disease did not differ between male and female IBD patients. Both these findings indicate that there is another

pathophysiologic mechanism responsible for the development of metabolic bone disease in IBD than in corticosteroid-induced or senile osteoporosis conditions in which trabecular bone is more affected than cortical bone²⁷. The predominant cortical bone loss could be explained by secondary parathyroidism caused by vitamin D or calcium malabsorption, both common in patients with small bowel resection²⁸.

This study demonstrates that disease onset before 18 years of age implicates a higher risk for development of metabolic bone disease. This phenomenon might be explained by the fact that growing and developing bones are more susceptible to the negative effects of disease activity and treatment of Crohn's disease, and that achievement of an adequate peak bone mass is more difficult²⁹⁻³¹.

In this large population based cohort on bone mineral density in Crohn's disease a high prevalence of osteopenia and osteoporosis was found. Mean bone mineral density of the femoral neck was significantly lower than in the lumbar spine. A physician taking care of patients with Crohn's disease has to be aware of this potential extra-intestinal complication of Crohn's disease, and probably preventive measures have to be applied.

References

1. Edwards F, Truelove S. The course and prognosis of ulcerative colitis. *Gut* 1964;5: 1-22.
2. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995;108:417-22.
3. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. *J Bone Miner Res* 1995; 10:250-6.
4. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997;40: 228-33.
5. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987; 28:410-5.
6. Pigot F, Roux C, Chaussade S, Hardein D, Pelleter O, Du-Puy MT, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. *Dig.Dis.Sci.* 1992;37:1396-403.
7. Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, Ziegler R. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). *Exp Clin Endocrinol* 1994; 102:44-9.
8. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995;37:71-6.
9. Tromm A, Rickels K, Huppe D, Wiebe V, May B. Osteopenia in chronic inflammatory bowel diseases. Results of a cross-sectional study using quantitative computerized tomography. *Leber.Magen.Darm.* 1994;24:23-30.
10. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994;107: 1031-9.
11. Robinson RJ, AlAzzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig.Dis.Sci.* 1998;43:2500-6.
12. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am.J.Gastroenterol.* 1999;94:824-8.
13. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A. Bone disease in vitamin D-deficient patients with Crohn's disease. *Dig.Dis.Sci.* 1989;34:1094-9.
14. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997; 112:1710-3.
15. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997; 40:313-9.
16. Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, Bos LP, Limonard CB, Stockbrugger RW. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. *Dis Colon Rectum* 1998;41(1):33-40.
17. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl.* 1989;170:2-6.
18. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. *Am J Clin Nutr* 1990;51(6):1106-12.
19. Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson HB, Baran D, Powell M, Notelovitz M. Spine and femur density using dual-photon absorptiometry in US white women. *Bone Miner* 1987;2:211-9.
20. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? *BMJ.* 1989;298:924-928.

21. Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. *Osteoporos Int* 1992;2(3):135-40.
22. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ.Tech.Rep.Ser.* 1994;843:1-129.
23. Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1997; 9:931-3.
24. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997; 24:289-95.
25. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997. 1997;24:361-2.
26. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am.J.Gastroenterol.* 1998;93:1483-90.
27. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. *Gut* 1993;34:1543-6.
28. Andreassen H, Rix M, Brot C, Eskildsen P. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. *Scand.J.Gastroenterol.* 1998;33:1087-93.
29. Boot AM, Bouquet J, Krenning EP, de MK. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. *Gut* 1998;42:188-94.
30. Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. *Inflammatory Bowel Diseases* 1998;4:261-7.
31. Issenman RM, Atkinson SA, Radoja C, Fraher L. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr* 1993;17:401-6.

CHAPTER 4

Clinical determinants of bone mineral density in Crohn's disease

EJ Schoon, AB van Nunen, P Geusens,
RW Stockbrügger, MGVM Russel

Submitted for publication

Abstract

Background

A high prevalence of osteopenia and osteoporosis has been reported in Crohn's disease (CD). The pathogenesis is probably multifactorial but not completely clarified.

Aim

The aim of our study was to establish determinants of osteoporosis in a large population-based group of patients with CD.

Methods

119 CD patients were investigated. Bone mineral density (BMD) was measured by dual-X-ray absorptiometry (DXA).

Results

Linear regression analysis indicated both body weight and female gender as significant positive determinants of BMD, and age as well as a combined use of prednisolone and azathioprine as negative determinants. In females positive determinants of BMD were: body weight and the use of azathioprine. Postmenopausal status, use of prednisolone, normal serum magnesium level, and the combined use of prednisolone and azathioprine, respectively, were negative determinants. In males, serum calcium level and body weight were significant positive determinants, whereas age was a negative determinant of BMD.

In the linear regression model, the contribution of all significant investigated risk factors for BMD of lumbar spine, femoral neck and total body accounted for 50% of the variation in BMD.

Conclusions

Patients with CD at risk for low BMD are: male and post-menopausal female patients, with low body weight and a history of combined use of prednisolone and azathioprine, normal serum magnesium level and a low serum calcium level. However, clinical risk factors are not strong enough predictors of BMD and do not replace DXA measurements in patients with CD.

Introduction

A high prevalence of osteopenia and osteoporosis has been reported in Crohn's disease¹⁻⁸. The pathogenesis is probably multifactorial, and several risk factors have been stated: corticosteroids^{4,6,9}, disease activity^{10,11}, malnutrition^{2,12}, malabsorption, vitamin D deficiency¹³, smoking¹⁴ and sex hormone deficiency¹⁵. Differences in the prevalence and in the risk factors of low bone mineral density (BMD), can be explained by the diversity of populations studied and by the varying methods used to measure BMD. In general, studies have indicated that low BMD is a feature of CD rather than of ulcerative colitis (UC)^{3,4}. Osteopenia of the femoral neck is more prevalent than that of the lumbar spine, distinguishing osteoporosis in CD from senile and corticosteroid-induced osteoporosis^{1,7,16-18}. We recently described that BMD in newly diagnosed IBD patients was not different from healthy controls, and concluded that low BMD must be a consequence of the disease process and/or the treatment modalities.¹⁹ With regard to fractures as a consequence of low BMD, an increased fracture risk was reported in Crohn's disease but not in UC.²⁰ In a large epidemiological study the relative risk of fracture was 40% higher in patients with IBD than in population controls²¹. Vertebral crush fractures have even been reported in children with CD using corticosteroids²², and anecdotally as presenting symptom¹⁷.

In two large cross-sectional studies, involving only CD patients, low body weight, male sex in addition to current use and cumulative dose of steroids were reported as independent determinants of low BMD in one⁶, and high age, male sex, and low body weight in the other study, respectively¹².

The aim of the present study was to identify determinants of low bone mineral density in a large Dutch population-based cohort of patients with Crohn's disease.

Methods

Patients

Patients with CD living in three adjacent municipalities of the IBD South-Limburg registry area in the Netherlands, with a total of 150,891 inhabitants (118,465 in Maastricht, 20,591 in Meerssen, and 11,835 in Eijsden), were investigated²³. Crohn's disease was diagnosed on clinical grounds using endoscopic and/or radiological evidence, supported by mucosal biopsies and/or examination of surgical specimens when available. For confirmation of the CD diagnosis, the Lennard-Jones criteria were applied²⁴.

The study population consisted of 181 CD patients, all of Caucasian ethnicity, of whom 14 patients were excluded because of: pregnancy, renal insufficiency, ankylosing spondylitis (3 patients)²⁵, rheumatoid arthritis, pulmonary cancer, and change of diagnosis to ulcerative colitis (7 patients). Four patients from the IBD registry had died before inclusion, one patient due to a thrombo-embolic event (possibly related to an exacerbation of CD), three others due to causes unrelated to CD. Five patients had moved out of the study area.

The intention was to investigate all patients attending the outpatient clinic during the study period. One-hundred-nineteen (75%) of the 158 eligible patients, 37 males and 82 females with a mean age ($\pm$ SD) of 42 ($\pm$ 14) years (range 17-78) were investigated. Mean duration of disease was 10.5 ($\pm$ 8.8) years. The disease was located in the small-bowel in 35 patients, in the colon in 10 patients, while 74 patients had ileo-colonic disease. Seventy-three patients had one ($n = 42$) or several ($n = 31$) surgical resections. Patient characteristics are given in Table 4.1. Thirty-nine patients (14 males, 25 females) who did not attend the outpatient clinic during the study period were not included. The mean age of these patients was 42 ($\pm$ 15) years and mean duration of disease was 12 ($\pm$ 9) years. The Ethics Committee of the University Hospital Maastricht approved the IBD epidemiological study protocol, and all subjects gave their written informed consent before the start of the study.

Table 4.1. Clinical characteristics of 119 patients with Crohn's disease.

	all CD patients	male	female	difference male/female p-value
number	119	37	82	
age	42 (14)	45 (17)	40 (14)	0.052
age at diagnosis	32 (14)	35 (18)	30 (13)	0.093
body mass index	23.5 (3.7)	23.9 (3.9)	23.3 (3.6)	0.403
disease duration	10.5 (8.8)	11.3 (11.4)	10.2 (7.3)	0.524
number of admissions	2.7 (3.1)	2.8 (3.7)	2.7 (2.8)	0.087
number of resections (%)				
one	43 (36)			
more than one	31 (26)			

Data are presented as mean (standard deviation), or in percentage when indicated (%)
Differences between male and female patients are calculated by independent t-test

Bone mineral Density

In all patients bone mineral density was measured using dual-energy X-ray absorptiometry (DXA) (Lunar DPX-L, Lunar software version DPX-L 1.3; Lunar Radiation Corp., Madison, WI) of lumbar spine (L₂-L₄) and femoral neck of the non-dominant hip. In 61 patients DXA of the total body was also performed. BMD was expressed in absolute values (g/cm²), T-score (one standard deviation compared to a young adult gender matched reference population), and Z-score (one standard deviation compared to an age and gender matched reference population). Reference data were based on populations from the US, United Kingdom, and Northern Europe²⁶⁻²⁸. There was a 1.3% standard deviation of mean BMD values of the populations in various geographical areas contributing to normal data. The proportion of patients with osteopenia and osteoporosis, respectively, was assessed according to the WHO classification in which osteopenia is defined as a T-score between -1 and -2.5 and osteoporosis as a T-score ≤ -2.5 ²⁹. The data on the prevalence of osteoporosis and on symptomatic fractures have been presented

earlier⁷. The Z-score was used to correct for age differences between groups if applicable.

Parameters

The cumulative lifetime amount of prednisolone or equivalent used and the previous (for more than three months) or current use of azathioprine, vitamin D, and calcium were collected from the medical records. From these records also the number of resections, number of hospital admissions, and the presence of lactose intolerance was noted. The current use of alcohol (g/day) and the cumulative amount of cigarettes smoked during lifetime was calculated in pack-years (one pack-year, being one package of cigarettes smoked daily during one year) were assessed from a patient questionnaire. Family history of osteoporosis was assessed by the same questionnaire and was considered positive if at least one of the first-degree family members had a clinical history of osteoporosis. Physical activity was assessed using a physical activity index score according to Baecke, which is an 18 points scale involving habitual physical activity (sports and daily physical activity) during childhood (< 12 years), young adulthood (12-18 years), and during the previous six months, respectively³⁰. The body weight and height were measured to calculate the body mass index (kg/m^2)³¹.

Laboratory parameters

Serum magnesium was measured in the routine laboratory and a reference value of 0.7-1.0 mmol Mg/l was applied. Serum calcium ($n = 2.1$ -2.6 mmol/l) was measured in the same laboratory and was corrected for the albumin level ($n = 32$ -42 mg/l). Serum 25-hydroxyvitamin D concentration was measured by using a ¹²⁵I radioactive immunoassay (RIA, Incstarr Corporation-Stillwater, Minnesota, US) with two different ranges of reference values (summer (June-December): 70-100 nmol/l, winter (January-May): 25-70 nmol/l)³². Serum parathyroid hormone was measured by immuno-radiometric assay (IMRA) for which the reference value (for normal calcium level) of 2-6 pmol/l was applied³³. Ninety-one patients agreed to do 72-hours faeces collection, while taking their habitual diet, to determine the faecal fat excretion (normal value ≤ 21 gr/72-hours).

Statistical analysis

Comparisons of risk factors were performed using a parametric test (independent t-test) if a normal distribution was present; otherwise an appropriate non-parametric test (Mann-Whitney U) was used. ANOVA was used for comparison of bone mineral density between groups. The Pearson's coefficient of correlation was used to calculate correlations.

Potential independent risk factors influencing BMD were selected by univariate analysis, these factors, including age and gender, were used in a linear regression analysis to identify independent determinants of BMD in CD. In the total group of the patients, and in male and female patient groups separately, R^2 -adjusted was calculated to estimate the contribution of all independent variables included in the linear regression model. Two-tailed tests for significance were used in all statistical

analyses. A p-value of <0.05 was considered to be statistically significant. The Statistical Package for the Social Sciences (SPSS 8.1, SPSS inc., Chicago, Ill, USA) was used for the analyses.

Results

The prevalence of osteopenia and osteoporosis is demonstrated in Table 4.2. Male CD patients had a significantly lower mean Z-score of the total body compared to females (-0.58 and -0.12, respectively (p = 0.05)), whereas no significant gender differences for femoral neck or lumbar spine BMD were found. As the mean age of the male population was almost significantly higher, the Z-score was applied to correct for age difference.

Table 4.2. Prevalence (in percentage) of normal bone mass, osteopenia and osteoporosis in 119 patients with Crohn's disease defined as T-score (WHO-criteria).			
	normal T > -1	osteopenia -2.5 < T ≤ -1	osteoporosis T ≤ -2.5
	%	%	%
L ₁ -L ₄	71	22	7
femoral neck	48	41	11
total body	67	27	6

Postmenopausal female patients had a lower BMD (g/cm³) than premenopausal patients, which was significant at the femoral neck (p = 0.037), using T-scores at the lumbar spine (p = 0.024). However, comparison of the Z-score demonstrated higher mean values except for the total body Z-score, which was not significantly different, meaning no significant difference compared to the normative DXA controls.

Possible risk factors influencing bone mineral density in CD patients that were studied are given in Table 4.3.

No correlation was found between severity of metabolic bone disease and disease duration, number of resections and number of hospital admissions. Disease localisation did not significantly influence BMD, T- or Z-scores (Table 4.4). No correlation was found between severity of metabolic bone disease and life-style factors (smoking and previous or current physical activity). Patients with a positive family history of osteoporosis did not have a significant lower bone mass than patient without such antecedents.

Patients with a serum magnesium level below the lowest limit of the applied reference value (19%) had a significantly higher Z-score at the lumbar spine than patients with a normal serum magnesium level (p = 0.008). Serum magnesium correlated significantly with serum calcium level (r = 0.315, p = 0.002).

Table 4.3. Possible factors influencing bone mineral density in 119 patients with Crohn's disease.

	CD patients
corticosteroids use ever (%)	69 (57.9%)
life prednisolone dose (mg)	4749 (9010)
azathioprine use ever (%)	35 (29.4%)
cholestyramin use ever (%)	22 (18%)
current calcium supplement	21 (18%)
current vitamin D supplement	15 (13%)
postmenopausal female (%)	20/82 (24.3%)
time from menopause (years)	2.5 (5.5)
females use of oral contraceptives	70/82 (85%)
periods of amenorrhoea	12/75 (16%)
lactose intolerance	15 (12.6%)
physical activity index	15.0 (2.7)
smoking: no smoker (%)	23%
current (%)	47%
previous (%)	30%
packet years of smoking	12.6 (12.8)
family history of osteoporosis	10 (8.4%)
alkaline phosphatase (IU/l)	89.4 (40.4)
serum calcium (mmol/l)	2.40 (0.12)
elevated PTH (> 6 pmol/l)	3/93 (3.2%)
serum PTH (pmol/l)	3.3 (1.4)
low serum magnesium (< 0.75 mmol/l)	19/102 (18.7%)
serum magnesium (mmol/l)	0.79 (0.08)
vitamin D deficiency *	40/111 (36%)
faecal fat excretion (gr/72 hours)	39.7 (51.7)
patients with steatorrhoea (> 21 gr/72 hours)	67/91 (74%)

Data are represented as mean (standard deviation) or as number and percentage if indicated (%).

*Two different ranges of reference values (summer (June-December): 70-100 nmol/l, winter (January-May): 25-70 nmol/l).

Table 4.4. Mean bone mineral density stratified according to disease localization in 119 patients with Crohn's disease.

	small bowel n = 35	colon n = 10	both n = 74	p-value
lumbar spine L ₂ -L ₄	-0.07 (1.33)	0.03 (1.36)	0.02 (1.21)	0.95
femoral neck	-0.50 (1.23)	-0.16 (1.11)	-0.57 (1.18)	0.60
total body	-0.27 (1.14)	-0.33 (0.44)	-0.27 (1.09)	0.99

Statistical analysis was determined by an analysis of variance (ANOVA). Bone mineral density is expressed as Z-scores (number of standard deviations from age- and sex-matched normal values). Mean Z-scores (standard deviation) are shown. No significant differences were found.

At the time of DXA measurement 21 patients were regular users of calcium supplements (median dose 500-1000 mg/day), and 15 were on vitamin D supplementation (median dose 400 IU/day). Patients who had vitamin D deficiency (36%) had a lower BMD at the femoral neck ($p = 0.044$), and a significantly lower T-score of the femoral neck ($p = 0.038$) than patients with normal vitamin D. Using the Z-score, to correct for age difference between the groups, this difference was absent ($p = 206$). No difference was found for the lumbar spine BMD, T- or Z-scores. Serum parathyroid hormone was elevated in 3%.

In the total group of patients linear regression analysis demonstrated both body weight and female gender as significant positive determinants of BMD and, age and a combined use of prednisolone and azathioprine as negative determinants (Table 4.5). In females significant positive determinants of BMD were body weight and the use of azathioprine. Postmenopausal status, use of prednisolone, normal serum magnesium level, and the combined use of prednisolone and azathioprine, respectively, were negative determinants (Table 4.6). In males significant positive determinants were corrected serum calcium level and body weight, whereas age was a negative determinant of BMD (Table 4.7).

Table 4.5. Determinants positively or negatively influencing bone mineral density in patients with Crohn's disease ($n = 119$) expressed in bone mineral density (g/cm^2) or Z-score.

	BMD-pos. p-value	BMD-neg. p-value	Z-score-pos. p-value	Z-score-neg. p-value
lumbar spine L_1-L_4	body weight 0.022	prednisolone & azathioprine 0.026		prednisolone & azathioprine 0.031
femoral neck	body weight 0.006	age 0.012		
total body	body weight 0.000		female gender 0.034	

Linear regression analysis. Prednisolone & azathioprine = previous or current combined use of prednisolone equivalent and azathioprin.

In the linear regression model, the contribution of all significant investigated risk factors for BMD of lumbar spine, femoral neck and total body accounted for 50% of the variation in BMD.

Table 4.6. Determinants positively or negatively influencing bone mineral density in female patients with Crohn's disease (n = 82) expressed in bone mineral density (g/cm³) and Z-score.

	BMD-pos. p-value	BMD-neg. p-value	Z-score-pos. p-value	Z-score-neg. p-value
lumbar spine L ₁ -L ₄	body weight 0.000	postmenopausal 0.000 magnesium 0.005	body weight 0.006	magnesium 0.005 prednisolone & azathioprin 0.022
femoral neck	body weight 0.000	postmenopausal 0.007		magnesium 0.037
total body	body weight 0.000 azathioprine 0.040	postmenopausal 0.001 prednisolone 0.046	body weight 0.004	

Linear regression analysis. Weight = body weight, postmenopausal = postmenopausal status, prednisolone & azathioprine = previous or current combined use of prednisolone equivalent and azathioprine, azathioprine = previous or current use of azathioprine against no use, magnesium = serum magnesium level (mmol/l)

Table 4.7. Determinants of positive and negative effects bone mineral density in male patients with Crohn's disease (n = 37) expressed in bone mineral density (g/cm³) and Z-score.

	BMD-pos. p-value	BMD-neg. p-value	Z-score-pos. p-value	Z-score-neg. p-value
lumbar spine L ₁ -L ₄	calcium 0.021		calcium 0.026	
femoral neck		age 0.012		
total body	body weight 0.003			

Linear regression analysis.

calcium = serum calcium level in mmol/l corrected for albumin level

Discussion

In this study we have confirmed the previously identified risk factors for low BMD, namely; age, low body weight, gender, postmenopausal status, and steroid use. In addition we have identified some novel risk factors: a history of combined use of azathioprine and corticosteroids was recognized as a significant independent risk factor at the level of the lumbar spine. The corrected serum calcium level was found to be a positive determinant of BMD especially in male patients at the level of the lumbar spine. The serum magnesium level was inversely correlated to the BMD (Z-score) of female CD patients.

The use of prednisolone or equivalent was only a weak negative determinant for BMD in the total body measurement of female patients. Controversies between studies on the effects of corticosteroids on BMD in patients with CD can be explained by: the multifactorial nature of bone loss, the difficulties of accurate retrospective calculations of steroid doses used, the heterogeneity and the size of the populations studied, the individual susceptibility of the patients to the damaging effects of corticosteroids, and the confounding effects of disease activity³⁴. During disease remissions there might be a reversible component, resulting in a recovery of BMD³⁵.

Regarding the combined use of azathioprine and corticosteroids, disease activity can be an important confounder, since patients using these agents could be considered to be more severely ill. Indications for the administration of azathioprine in this study were as specified in the literature: steroid dependency, recurrent activity of Crohn's disease, and peri-anal disease. The effect of azathioprine on bone mineral density has been mentioned in two studies; both of them were unable to demonstrate a negative effect^{6,36}. However, in juvenile patients the use of azathioprine with CD was identified as a risk factor³⁷. As it is not possible to retrospectively assess long-term disease activity in CD, the proxy parameters of disease activity used in this study were: disease duration, number of hospital admissions, number of resections and life prednisolone dosage. No single one of these parameters emerged as a risk factor. Recently it has been demonstrated that genetic factors, the presence of interleukin 6 allele, and the absence of the interleukin 1 receptor antagonist allele correlated with bone loss in a mixed group of 86 UC and CD patients³⁸. In the future, it might be demonstrated that the phenotypic expression of the disease correlates with the genotype, which would facilitate calculations of treatment /outcome correlations.

Surprisingly, the corrected serum calcium level was found to be a positive determinant of BMD especially in male patients at the level of the lumbar spine. A possible explanation for this phenomenon is that small fluctuations of the serum calcium and vitamin D level, which might not be compensated by an increased calcium absorption in some patients, influences the secretion of PTH and in the long-term affects BMD. The use of corticosteroids has a negative effect on the calcium and vitamin D absorption. Furthermore, the conversion of vitamin D into its active form is compromised. A high prevalence (36%) of vitamin D deficiency was found in this group of CD patients, but no patient had clinical signs of hypovitaminosis D. BMD, expressed in Z-scores, was not different between patients

with normal serum vitamin D levels and vitamin D deficient patients. The presence of vitamin D deficiency did not correlate significantly with BMD, although small mineralisation defects can be missed by DXA. However, addition of this parameter to the linear regression model led to a small improvement in the correlation between the sum of all risk factors and BMD. In a comparable study of 115 CD patients, Andreassen et al. demonstrated a negative correlation between the PTH level and BMD of the femoral neck, distal forearm and total body³⁹. The present study only confirmed a significant negative correlation between the T-score of the femoral neck and serum PTH level.

Almost seventy percent of this population-based cohort of patients with Crohn's disease had used corticosteroids during periods of disease activity, with a mean lifetime dose of 5 grams, but with a large inter-patient variation. Considering the incidence and amount of corticosteroids used in this population, the prevalence of osteoporosis seems relatively low, therefore factors protecting against bone loss might be existing. Possibly, the magnesium metabolism is of importance in this context as the serum magnesium level was found to be a negatively correlated with the Z-score of lumbar spine and femoral neck in female CD patients. This is the first study to bring up the potential role of magnesium as determinant for BMD in CD. Serum magnesium concentrations are no good indicator of body magnesium stores. Lower serum levels can be a consequence of malabsorption and higher levels can be caused by an increased bone resorption. Recently, a large cross-sectional study on biochemical markers of bone turnover in CD demonstrated an increased bone resorption but normal bone formation; this imbalance might explain higher serum magnesium levels as indicator for bone loss⁴⁰. A recent study on bone loss after cardiac transplantation, demonstrated that patients with magnesium deficiency had a lower bone resorption probably due to PTH resistance⁴¹. The long-term effects of a suboptimal magnesium supply inducing a marginal or moderate deficiency compared to an excessive magnesium supplementation had been investigated in a rat experiment⁴². The results indicated that the long-term suboptimal magnesium supply improved some of the indicators of bone health whereas the long-term supplementation was deleterious. Serum concentrations of 1,25-dihydroxyvitamin D, PTH and IGF-I and the length of the right humeri were not affected by the dietary treatment. An exact explanation of the mechanism was not given in both previous studies. In a population of patients with CD and ileal resections a low urinary magnesium excretion was found in one third of the patients⁴³. The prevalence of low serum magnesium levels in this population-based study sample was 19%.

BMD was found to be independent of disease localisation. Robinson et al. established that jejunal disease localization was a risk factor⁶. In our study the number of patients with only proximal small bowel localised disease was too small for separate analysis.

Although a linear regression model was established, the correlation with the BMD of different localisations was relatively small, and the predictive value therefore seems low.

From this study it can be concluded that patients with CD, who are particularly at risk for low BMD are: the male and post-menopausal female patients with low body weight and a history of prednisolone use or combined use of prednisolone

and azathioprine, possibly reflecting the cumulative disease burden. A surprising finding was the inverse correlation between serum magnesium levels and BMD, and the correlation with the corrected serum calcium level, findings that need further study. However, clinical risk factors alone are not strong enough predictors of BMD to abandon DXA measurements in patients with Crohn's disease.

References

1. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997;40: 228-233.
2. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987;28:410-415.
3. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994;107: 1031-1039.
4. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997;40:313-319.
5. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992;37:1396-1403.
6. Robinson RJ, al Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998;43:2500-2506.
7. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl* 2000;35:43-47.
8. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995;37:71-76.
9. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. *J Bone Miner Res* 1995;10:250-256.
10. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr.Gastroenterol Nutr* 1997;24:289-295.
11. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr. Gastroenterol Nutr* 1997;24:361-362.
12. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am J Gastroenterol* 1999;94:824-828.
13. Vogelsang H, Ferenci P, Woloszczuk W, et al. Bone disease in vitamin D-deficient patients with Crohn's disease. *Dig Dis Sci* 1989;34:1094-1099.
14. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. *Scand J Gastroenterol* 1996;31:367-371.
15. Robinson RJ, Iqbal SJ, al Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. *Aliment Pharmacol Ther* 1998; 12:21-25.
16. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am J Gastroenterol* 1998;93:1483-1490.
17. Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. *J Clin Endocrinol Metab* 2000;85:2122-2126.
18. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. *Am J Gastroenterol* 2000;95:699-704.
19. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. *Gastroenterology* 2000;119:1203-1208.
20. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000;46:176-181.

21. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med* 2000;133:795-799.
22. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997;112:1710-1713.
23. Russel MG, Dorant E, Volovics A, et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. *Dis Colon Rectum* 1998;41:33-40.
24. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989;170:2-6.
25. Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. *Rheumatol Int* 1997;17:45-48.
26. Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. *Osteoporos Int* 1992;2:135-140.
27. Mazess RB, Barden HS, Ettinger M, et al. Spine and femur density using dual-photon absorptiometry in US white women. *Bone Miner* 1987;2:211-219.
28. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? *BMJ* 1989;298:924-928.
29. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
30. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36:936-942.
31. Beal VA. The nutritional history in longitudinal research. *J Am Diet Assoc* 1967;51: 426-432.
32. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I- labeled tracer. *Clin Chem* 1993;39:529-533.
33. Roos BA, Lindall AW, Aron DC, et al. Detection and characterization of small midregion parathyroid hormone fragment(s) in normal and hyperparathyroid glands and sera by immunoextraction and region-specific radioimmunoassays. *J Clin Endocrinol Metab* 1981;53:709-721.
34. Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1997;9:931-933.
35. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. *Scand J Gastroenterol* 1999;34:696-702.
36. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. *J Intern Med* 1998;243:123-126.
37. Semeao EJ, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk factors for low bone mineral density in children and young adults with Crohn's disease. *J Pediatr* 1999;135:593-600.
38. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. *Gastroenterology* 2000;119:909-920.
39. Andreassen H, Rix M, Brot C, Eskildsen P. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. *Scand J Gastroenterol* 1998; 33:1087-1093.
40. Robinson RJ, Iqbal SJ, Abrams K, al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. *Aliment Pharmacol Ther* 1998;12:699-705.
41. Boncimino K, McMahon DJ, Adesso V, Bilezikian JP, Shane E. Magnesium deficiency and bone loss after cardiac transplantation. *J Bone Miner Res* 1999;14: 295-303.
42. Riond JL, Hartmann P, Steiner P, et al. Long-term excessive magnesium supplementation is deleterious whereas suboptimal supply is beneficial for bones in rats. *Magnes Res* 2000;13:249-264.
43. Hesson I, Hasselblad C, Fasth S, Hulten L. Magnesium deficiency after ileal resections for Crohn's disease. *Scand J Gastroenterol* 1983;18:643-649.

CHAPTER 5

Bone mineral density in patients with recently diagnosed inflammatory bowel disease

EJ Schoon, BM Blok, BJ Geerling, MG Russel,
RW Stockbrügger, R-JM Brummer

Gastroenterology 2000;199:1203-1208

Abstract

Background

A high prevalence of osteoporosis is reported in inflammatory bowel disease and its pathogenesis is not completely resolved. We investigated whether bone mineral density in patients with inflammatory bowel disease at diagnosis is lower than in population controls, and whether bone mineral density differs between patients with Crohn's disease and those with ulcerative colitis.

Methods

In 68 patients and 68 age- and gender-matched population controls, bone mineral density of total body, spine, and hip was assessed using dual-energy X-ray absorptiometry within 6 months after establishing the diagnosis. Determinants for low bone mineral density were assessed.

Results

There were no significant differences in bone mineral density (g/cm^3) between patients and controls, and no significant differences in bone mineral density between patients with either Crohn's disease or ulcerative colitis. Multivariate regression analysis showed that duration of complaints longer than 6 months before diagnosis ($p = 0.041$), age ($p = 0.019$), and body mass index lower than 20 kg/m^2 ($p = 0.006$) significantly correlated with low bone mineral density.

Conclusions

Bone mineral density in patients with recently diagnosed inflammatory bowel disease was not significantly decreased compared with population controls. Subsequent development of osteoporosis in patients with IBD seems to be a phenomenon related to the disease process and/or the treatment modalities of inflammatory bowel disease.

Introduction

A high prevalence of osteoporosis and osteopenia in inflammatory bowel disease (IBD), especially in Crohn's disease (CD), has been reported in several cross-sectional and population-based studies^{1,7}. Multiple risk factors such as the systemic use of corticosteroids, disease activity, malnutrition, vitamin D deficiency, smoking, and lack of physical activity are believed to be involved in the pathophysiology of IBD-associated osteoporosis^{8,15}. Osteoporosis may lead to low impact fractures, which are reported already in young children with Crohn's disease^{16,17}. Low bone mineral density (BMD) is more often observed in CD than in ulcerative colitis (UC)¹⁸. Ghosh et al.¹⁹ reported that patients with newly diagnosed CD had a significantly lower bone mass than those with newly diagnosed UC. In a large controlled study on long-term CD vs. UC, BMD in patients with CD was significantly reduced at all measured sites compared with patients with UC and healthy subjects¹⁸. Such findings imply that patients with CD should be screened for osteoporosis at diagnosis, and that systematic preventive treatment should be considered early in the course of the disease.

The aim of this case-control study was to assess whether (1) BMD is lower in patients with newly diagnosed IBD in comparison with matched population controls and (2) BMD differs between CD and UC patients at diagnosis. In addition, determinants of low BMD in IBD patients at diagnosis were assessed.

Patients and Methods

Subjects

All patients with newly diagnosed IBD ($n = 76$) during the study period from June 1995 to December 1997 at the Department of Gastroenterology of the University Hospital Maastricht, the Atrium Medical Center Brunssum, and at the Maasland Hospital Sittard (all located in the south of the province of Limburg in The Netherlands) were asked to participate in the study. Sixty-nine patients (91%) agreed. The patients were studied within 6 months of diagnosis that was based on findings from endoscopy with histology and/or radiology²⁰. One patient with indeterminate colitis was subsequently excluded. Of the 68 patients with IBD, 24 had CD (8 men and 16 women) and 44 had UC (24 men and 20 women) (Table 5.1). In the patients with CD, the disease was localized in the colon in 5 patients, small bowel in 6 patients, and both small bowel and colon in 13 patients. In the UC group, 12 patients had pan-colitis, 26 patients distal colitis, and 6 patients proctitis, respectively. The characteristics of CD and UC patients are shown in Table 5.2. Patient characteristics did not differ significantly between CD and UC. One CD patient and 2 UC patients were postmenopausal. Thirty-three women with IBD used oral contraceptives (15 CD, 18 UC).

Table 5.1 Age and sex of patients with IBD and control subjects

	CD patients n = 24	UC patients n = 44	all IBD patients n = 68	controls n = 68
age (y)	29.7 (10.4)	38.4 (14.4)	35.3 (13.7)	35.3 (13.7)
gender (F/M)	16 / 8	20 / 24	36 / 32	36 / 32

Age is expressed as mean (SD), gender as number of patients.

Table 5.2 Clinical characteristics of patients with CD and UC

	CD n = 24	UC n = 44
small bowel involvement (%)	17 (79)	---
resection (%)	4 (17)	---
smoking (%)	8 (33)	15
duration of complaints (months)	4.9 (7.3)	3.4 (7.7)
number of patients with complaints >6 months before diagnosis ^a	18	12
Crohn's disease activity index	94 ± 67	---
truelove & Witts index	---	9.6 ± 5.8
active disease (%)	3 (12.5)	4 (9)
prednisolone use (%)	8 (33)	11 (25)
life time prednisolone dose (mg)	495 (845)	301 (641)
duration of prednisolone use (days)	28.3 (47.2)	14.1 (28.4)

Results are presented as mean (standard deviation), as number, or as percentages if indicated (%).

Disease activity in CD was assessed using the Crohn's Disease Activity Index (CDAI) and in UC according to the Truelove and Witts index graded numerically from 6 to 19 as being in remission and, when exceeding 19, as having active disease^{21,22}. Patients with CD were considered to have active disease when CDAI was > 150. The total prednisolone dose administered until the date of the dual-energy x-ray absorptiometry (DXA) investigation was calculated from medical records. Sixty-eight volunteers were selected from the patient population database of a general health care center (3 general practitioners) located in the same study area. The health care system in The Netherlands is organized with general practitioners as primary health care providers. Nearly every inhabitant (> 95%), is registered in a family practice. The controls were matched for age and sex with the IBD patients (within 3 years of age). Three postmenopausal patients were matched with postmenopausal controls (1 CD control, 2 UC controls). In the control group, 30 female control subjects used oral contraceptives (14 CD controls, 16 UC controls).

The following exclusion criteria were applied for both IBD patients and controls: concomitant diseases predisposing to secondary osteoporosis (thyroid disease, renal disease, diabetes, liver disease or ankylosing spondylitis). Control subjects had no history of IBD or other chronic disease, were not bedridden for an extended period, or were not undergoing long-term medical therapy. Furthermore, patients and controls with a history of medication for the treatment of osteoporosis were not included.

Bone mineral Density

BMD was measured using DXA (Lunar DPX-L, Lunar software version DPX-L 1.3; Lunar Radiation Corp., Madison, WI) of lumbar spine (L_2-L_4), nondominant hip, and total body²³. The coefficients of variation of the lumbar spine and femoral neck were 0.77% and 1.09%, respectively. BMD was expressed in absolute values (g/cm^2), T-score (1 standard deviation (SD) compared with a young adult gender-matched reference population), and Z-score (1 SD compared with an age and sex-matched reference population). Reference data were based on populations from the United States, United Kingdom, and Northern Europe²⁴⁻²⁶. The variation of mean BMD values among geographical areas contributing to normal data was 1.3%.

The number of patients with osteopenia and osteoporosis was assessed according to the World Health Organization (WHO) classification defining osteopenia as a T-score between -1 and -2.5 and osteoporosis as T-score less than -2.5 ²⁷. Body composition (i.e., body fat percentage and fat-free mass) was assessed using DXA of the total body²⁸.

Parameters

The number of wrist, spine and other spontaneous or traumatic fractures in the past was assessed by questionnaire. The cumulative amount of cigarettes smoked during the lifetime was calculated in pack-years (1 pack-year is 1 packet of cigarettes smoked daily during 1 year) from the same questionnaire. Physical activity was assessed by a habitual physical activity index score according to Baecke et al.²⁹ which is an 18-points scale involving physical activity (sports and daily physical exercise) during childhood (< 12 years), young adulthood (12-18 years) and the previous 6 months, respectively. The body mass index (kg/m^2) was assessed. Daily intake of alcohol (g), calcium (mg), and magnesium (mg) were assessed by an experienced dietitian using dietary history³⁰. Serum 25-hydroxyvitamin D concentration was measured by a ^{125}I -radioactive immunoassay (RIA, Incstarr Corp., Stillwater, MN) with 2 different ranges of reference values (summer (June to December): 70-100 nmol/l, winter (January to May): 25-70 nmol/l)³¹.

Statistical analysis

Comparisons of parameters and risk factors between patients and controls were performed by using a parametric test (paired Student *t* test) if normal distribution was present; otherwise a nonparametric test (paired Wilcoxon signed-rank test) was used. Comparisons of parameters and risk factors between CD and UC patients were performed using a parametric test (independent *t* test); otherwise, a non-

parametric (Mann-Whitney U test or χ^2 test) was performed. The Z-score was used to compare the BMD of CD and UC patients to correct for the age difference between both groups.

Determinants of low bone mass in IBD patients and controls were assessed using a multiple linear regression analysis, after the assessment of potential determinants by an explorative univariate analysis. A backward elimination procedure was performed based on these data. A p-value of ≤ 0.05 was considered to be statistically significant. The Statistical Package for the Social Sciences (SPSS 8.0.1 for windows package 1998, SPSS Inc., Chicago, IL) was used for the analysis. The study protocol was approved by the Ethics Committee of the University Hospital Maastricht, and all subjects gave their informed consent before the start of the study.

Results

BMD (g/cm^2) at total body, lumbar spine, or femoral neck did not differ significantly between IBD patients and controls (Table 5.3 and Figure 5.1). Neither did subgroup analysis (CD vs. controls, UC vs controls, and gender-specific analysis) show any differences. Exclusion of the patients with proctitis ($n = 6$) in the UC group did not change any of the statistical outcomes.

Table 5.3 Mean BMD of total body, lumbar spine, and femoral neck in patients with IBD and control subjects.

BMD (g/cm^2)	UC		CD		all	
	patients	controls	patients	controls	patients	controls
number	44	44	24	24	68	68
total body	1.167 (0.144)	1.201 (0.117) ¹	1.163 (0.097)	1.164 (0.096) ¹	1.166 (0.108)	1.188 (0.110) ²
lumbar spine	1.227 (0.150)	1.217 (0.161) ²	1.217 (0.115)	1.240 (0.176) ³	1.223 (0.137)	1.226 (0.166) ⁴
femoral neck	1.007 (0.183)	1.014 (0.151) ¹	1.031 (0.191)	1.007 (0.178) ⁵	1.016 (0.184)	1.012 (0.160) ²

All values are expressed as mean (SD)
There were no significant differences between groups (paired Student's t test).
¹p = 0.700, ²p = 0.740, ³p = 0.807, ⁴p = 0.558, ⁵p = 0.662, ⁶p = 0.972, ⁷p = 0.115, ⁸p = 0.919, ⁹p = 0.858.

According to the WHO criteria, 18 patients with IBD and 10 controls had osteopenia (T-score ≤ -1) of either total body, lumbar spine, or femoral neck ($p = 0.09$). One of the patients was osteoporotic (T-score ≤ -2.5) vs. none of the controls (NS). There was no significant difference in number of fractures (all traumatic) between IBD patients and controls (48 and 46, respectively). Body mass index ($p = 0.005$), vitamin D-levels in winter ($p = 0.008$), magnesium intake (0.025) and alcohol intake ($p = 0.002$) were significantly lower in IBD

patients than in controls. Percentage body fat, fat free mass, calcium intake, smoking behavior, and physical activity did not differ between the total group of patients and controls (Table 5.4).

BMD did not significantly differ between CD and UC groups at total body, lumbar spine, and femoral neck. Figure 5.2 shows the Z-score of patients with and CD and UC separately, at the different sites of measurement.

Three patients with CD and 4 patients with UC had active disease at the time of bone density measurement. Duration of complaints before IBD diagnosis did not differ significantly between the CD and UC groups, neither did life prednisolone dosage (mg) and duration of prednisolone use before DXA (days)(Table 5.2).

Figure 5.1 BMD (g/cm²) at different sites of measurement in patients with IBD compared with control subjects. Lines indicate median values. No significant differences were found between IBD patients and controls. Paired differences of mean and 95% confidence intervals (Cis) of the difference: were calculated. BMD total body: mean 2.25×10^{-2} ; SD 0.11, 95% CI: -5.6×10^{-3} to -5.06×10^{-3} ; patients vs. controls. BMD at lumbar spine: mean, -4.4×10^{-3} ; SD 0.174; 95% CI: -5.4×10^{-3} to -4.47×10^{-3} ; patients vs. controls. BMD at femoral neck: mean 2.65 , SD 0.186, 95% CI, -4.9×10^{-2} to 5.46×10^{-2} ; patients vs. controls.

Table 5.4 Difference in potential risk factors of osteoporosis between IBD patients and controls.

	UC		CD		all		p ¹
	patients	controls	patients	controls	patients	controls	
number	44	44	24	24	68	68	
body mass index (kg/m ²)	23.1 (3.0) ²	24.8 (3.5) ²	22.2 (2.7)	22.7 (2.7)	22.8 (2.9)	24.0 (3.4)	0.005
percentage body fat	26.2 (10.1)	27.8 (8.1)	28.8 (8.5)	30.1 (8.7)	27.1 (9.6)	28.6 (8.3)	0.152
fat free mass (kg)	48.7 (10.2)	50.3 (10.7)	45.9 (9.2)	44.1 (8.9)	47.7 (9.9)	48.1 (10.4)	0.630
calcium intake	970 (327)	1247 (545)	1296 (790)	1119 (450)	1085 (555)	1202 (514)	0.228
magnesium intake (mg/day)	324 (100)	364 (124)	311 (117)	354 (116)	319 (106)	361 (121)	0.025
alcohol intake (g/day)	6.9 (11.3)	13.8 (18.3)	3.3 (5.4) ³	15.6 (21.5) ³	5.6 (9.8)	14.4 (19.4)	0.002
physical activity index	15.9 (2.2)	16.3 (1.9)	15.5 (2.0)	16.1 (2.3)	15.8 (2.1)	16.3 (2.1)	0.260
smoking (pack years)	8.4 (11.4)	5.4 (8.3)	4.9 (8.3)	9.1 (14.7)	7.2 (10.5)	6.7 (10.9)	0.798
vitamin D-summer (nmol/l)	57.5 (13.4)	68.7 (40.3)	72.1 (30.2)	61.4 (20.4)	63.0 (21.9)	66.0 (33.8) ⁵	0.843
vitamin D-winter (nmol/l)	38.7 (14.9) ⁴	52.3 (18.8) ⁴	42.5 (25.6)	67.8 (11.7)	39.9 (18.4)	57.4 (11.7) ⁶	0.008

Results are presented as mean (SD). Paired Student's t-test

¹ IBD vs., controls, ² p = 0.006, ³ p = 0.009, ⁴ p = 0.041, ⁵ n = 21, ⁶ n = 37

Figure 5.2 BMD (Z-score) at different sites of measurement in patients with CD compared with UC. Lines indicate median values. No significant differences were found between CD and UC patients.

Potential determinants of low bone mass emerging from the explorative univariate analysis in the IBD patients were postmenopausal status in women (only 3 patients), age, low body mass index ($< 20 \text{ kg/m}^2$), and duration of complaints (> 6 months) before diagnosis. In the multiple linear regression analysis, an independent influence was confirmed with statistical significance for duration of complaints ($p = 0.041$), age ($p = 0.019$) and body mass index $< 20 \text{ kg/m}^2$ ($p = 0.006$). Because of the small numbers, the effect of the menopausal status was not included in the multivariate regression analysis. The multivariate analysis model showed that in patients with IBD, cross-sectionally, an increase of age by 1 year resulted in a decrease of 0.27% of BMD, which is similar to the expected loss of 3–5% in 10 years for healthy men and premenopausal women. Multivariate regression analysis in the control population showed that low body mass index ($p < 0.001$) and increased age ($p < 0.001$) were independent risk factors of low BMD. Alcohol intake was not a significant risk factor in either IBD patients ($p = 0.784$) or the control population ($p = 0.489$).

Discussion

Because the pathogenesis of osteoporosis in IBD is still not clear, a careful analysis of the metabolic state of the bone in the initial phase of IBD may provide some important clues. Our study showed no significant difference in BMD between patients with recently diagnosed IBD and matched population controls. Furthermore, we found no significant differences in BMD between CD, UC, and

controls. BMD, corrected for age difference by using Z-scores, did not differ between CD and UC at the time of diagnosis. Although body mass index, alcohol consumption, magnesium intake, and the vitamin D-level in the winter were lower, this was not reflected in a significant difference in BMD in newly diagnosed IBD compared with population controls. Although many of the patients in this study had already been treated with a short course and relatively low dose of corticosteroids before the bone density measurements, we do not think that this influenced the outcome of the study because we found no difference in BMD between CD patients and controls. Also, it seems unreasonable that corticosteroids would improve BMD. In 1994, Ghosh et al.¹⁹ described that bone mass of patients with newly diagnosed CD was lower than in those with newly diagnosed UC despite the lack of differences in disease activity, body mass index, smoking, gender, physical activity, and biochemical parameters¹⁹. These data either suggest a genetic predisposition to osteoporosis in CD or mean that metabolic effects of the disease were already present at diagnosis. If confirmed, such a finding could have major consequences for the management of patients with newly diagnosed IBD, especially for patients with CD. However, several methodological comments can be made regarding the study by Ghosh et al.¹⁹: only a small patient group with a wide age range (14-83 years) was involved, including 2 prepubertal boys with CD and presumably low BMD. Patients with proctitis (6 of 15 compared with 6 of 44 in the present study) were overrepresented. Also, the menopausal status of the female patients was not mentioned. These factors might have influenced the outcome of the study. To overcome some of these methodological problems we preferred to perform a case-control study. To our knowledge, this study is the second reported so far, but the first controlled study on BMD in patients recently diagnosed with IBD.

In view of the high prevalence of osteoporosis in IBD, the knowledge of a risk factor profile may be beneficial for surveillance of the individual patient. Age, body mass index of $< 20 \text{ kg/m}^2$, and duration of complaints > 6 months before diagnosis are risk factors for low bone mass at the time of the IBD diagnosis. Therapeutic and secondary preventive measures could be taken, particularly in patients with these risk factors, to avoid deterioration of bone mass.

Body mass index per se is an important determinant of BMD in the general population. Our study confirmed that low body mass index at diagnosis is also a predictive factor for BMD in IBD. This might be of importance during the course of the disease, especially in CD, because, malabsorption and malnutrition are frequently found in patients with small bowel involvement or small bowel resection³².

Disease activity is a confounding factor in the pathophysiology of metabolic bone disease in IBD. During active disease, circulating pro-inflammatory cytokines have a direct effect on osteoblast and osteoclast function and thereby influence bone turnover^{6,33-37}. We identified as a risk factor duration of complaints longer than 6 months before diagnosis. Therefore, BMD should be measured at diagnosis in patients with long-term undiagnosed and untreated complaints of IBD type. Although the mean duration of complaints before diagnosis was not significantly longer in patients with CD than in those with UC, this did not result in a significant difference in BMD. At the time of BMD measurement, the disease activity,

especially of CD patients, was relatively mild. The selection of patients was not restricted to the very ill patients with CD because our aim was to explore, whether in general patients with recently diagnosed disease had lower BMD than controls. We found no difference in physical activity according to the Baecke²⁹ habitual physical activity questionnaire between patients and controls. Robinson et al.³⁸ recently reported that a simple schedule of regular physical activity is able to increase BMD in patients with CD. For maintenance of bone mass, patients with IBD should be advised to stay physically active if possible.

Although vitamin D, hormone replacement therapy and exercise are able to reduce the rate of bone loss in CD, the optimum prevention and therapy for osteoporosis in IBD has yet to be established³⁹.

In conclusion, a previous report on low BMD in patients with newly diagnosed IBD, particularly in CD, was not confirmed in our case-control study, and no significant differences in BMD were found between CD and UC patients at diagnosis after adjustment for age. These findings imply that disease-related factors in IBD seem to be mainly responsible for the development of low BMD. Thus, control of disease activity and active, diagnostic and therapeutic management, started early in the course of the disease, may be successful in preventing osteoporosis in IBD.

References

1. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995;108:417-22.
2. Robinson RJ, AlAzzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998;43:2500-6.
3. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997; 40:228-33.
4. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987; 28:410-5.
5. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du-Puy MT, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992; 37:1396-403.
6. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am J of Gastroenterol* 1998;93:1483-90.
7. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995;37:71-6.
8. Abitbol V. The mechanisms underlying osteopenia in chronic inflammatory bowel disease. *Semaine des Hopitaux* 1998; 74:1090-3.
9. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. *Scand J Gastroenterol* 1997; 32:1247-55.
10. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. *J Bone Miner Res* 1995;10:250-6.
11. Boot AM, Bouquet J, Krenning EP, de MK. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. *Gut* 1998; 42:188-94.
12. Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. *Aliment Pharmacol Ther* 1995; 9:237-50.
13. Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* 1982; 83:1252-8.
14. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. *J Intern Med* 1996;239:131-7.
15. Vogelsang H, Klamert M, Resch H, Ferenci P. Dietary vitamin D intake in patients with Crohn's disease. *Wien Klin Wochenschr* 1995; 107:578-81.
16. Cowan FJ, Parker DR, Jenkins HR. Osteopenia in Crohn's disease. *Arch Dis Child* 1995; 73:255-6.
17. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997;112:1710-3.
18. Jahnsen J, Falch JA, Aadland E, Mowinkel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997; 40:313-9.
19. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994; 107:1031-9.
20. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl.* 1989; 170:2-6.
21. Best WR, Beckett JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; 70:439-44.
22. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994; 330:1841-5.

23. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. *Am J Clin Nutr* 1990; 51:1106-12.
24. Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson HB, Baran D, Powell M, Notelovitz M. Spine and femur density using dual-photon absorptiometry in US white women. *Bone Miner* 1987;2: 211-9.
25. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? *BMJ* 1989;298: 924-8.
26. Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. *Osteoporos Int* 1992;2:135-40.
27. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
28. Laskey MA. Dual-energy X-ray absorptiometry and body composition. *Nutrition* 1996;12(1):45-51.
29. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36(5):936-42.
30. Beal VA. The nutritional history in longitudinal research. *J Am Diet Assoc* 1967;51:426-32.
31. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. *Clin Chem* 1993;39(3):529-33.
32. Geerling BJ, BadartSmook A, Stockbrugger RW, Brummer RM. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. *Am J Clin Nutr* 1998; 67:919-26.
33. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997; 24:289-95.
34. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997; 24:361-2.
35. Marcus R. Endogenous and nutritional factors affecting bone. *Bone* 1996; 18 (Suppl):115-35.
36. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. *Lymphokine Cytokine Res* 1991;10:15-21.
37. Wallach S, Avioli LV, Feinblatt JD, Carstens-JH J. Cytokines and bone metabolism. *Calcif Tissue Int* 1993; 53:293-6.
38. Robinson RJ, Krzywicki T, Almond L, AlAzzawi F, Abrams K, Iqbal SJ, Mayberry JF. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial. *Gastroenterology* 1998;115:36-41.
39. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. *Eur J Gastroenterol Hepatol* 1995; 7:609-14.

CHAPTER 6

Low serum and bone vitamin K status in patients with long-standing Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?

EJ Schoon, MCA Müller, C Vermeer,
LJ Schurgers, R-JM Brummer,
RW Stockbrügger

Gut 2001;48:473-477

Abstract

Background

A high prevalence of osteoporosis is reported in Crohn's disease. The pathogenesis is not completely understood but is probably multifactorial. Long-standing Crohn's disease is associated with a deficiency of fat-soluble vitamins, among them vitamin K. Vitamin K is a co-factor in the carboxylation of osteocalcin, a protein essential for calcium binding to bone. A high level of circulating undercarboxylated osteocalcin is a sensitive marker of vitamin K deficiency.

Aims

To determine serum and bone vitamin K status in patients with Crohn's disease and to elucidate its relationship with bone mineral density.

Methods

Bone mineral density was measured in 32 patients with long-standing Crohn's disease and small bowel involvement, currently in remission, and receiving less than 5 mg of prednisolone daily. Serum levels of vitamins D and K, triglycerides, and total immunoreactive osteocalcin as well as undercarboxylated osteocalcin ("free" osteocalcin) were determined. The hydroxyapatite binding capacity of osteocalcin was calculated. Data were compared with an age and gender matched control population.

Results

Serum vitamin K levels of the CD patients were significantly decreased compared with normative controls ($p < 0.01$). "Free" osteocalcin was higher and hydroxyapatite binding capacity of circulating osteocalcin was lower than in matched controls ($p < 0.05$ and $p < 0.001$, respectively), indicating a low bone vitamin K status in Crohn's disease. In patients, an inverse correlation was found between "free" osteocalcin and lumbar spine bone mineral density ($r = -0.375$, $p < 0.05$) and between "free" osteocalcin and the Z-score of the lumbar spine ($r = -0.381$, $p < 0.05$). Multiple linear regression analysis showed that "free" osteocalcin was an independent risk factor for low bone mineral density of the lumbar spine, whereas serum vitamin D was not.

Conclusions

The finding that a poor vitamin K status is associated with low BMD in long-standing Crohn's disease may have implications for the prevention and treatment of osteoporosis in this disorder.

Introduction

A high prevalence of osteopenia and osteoporosis is reported in Crohn's disease (CD)¹⁹. The pathogenesis of low bone mineral density (BMD) in CD is multifactorial. Important factors are disease activity, corticosteroid use, hypogonadism and nutritional depletion^{10,11}. The latter includes malabsorption of fat soluble vitamins, especially in patients with ileal involvement and has been proved for vitamin D^{12,13}. Bone is a living organ with a continuous process of remodelling, consisting of bone resorption by osteoclasts and bone formation by osteoblasts. Osteoblasts need vitamin K as a co-factor for the post-translational carboxylation of protein bound glutamate (Glu) residues into gamma-carboxyglutamate (Gla) (Figure 6.1). During bone formation the osteoblasts produce three Gla-proteins: osteocalcin (OC), matrix-Gla-protein (MGP), and protein S. OC and MGP have a regulatory role in the mineralization and remodelling of bone, whereas the function of protein S in bone metabolism remains unclear. Precursors of all three Gla-proteins contain a sequence that serves as a recognition signal for the vitamin K dependent carboxylase. Carboxylation renders the proteins capable of binding to calcium¹⁴⁻¹⁶.

Figure 6.1 Schematic representation of the vitamin K dependent carboxylation reaction. Reduced vitamin K acts as a co-factor in the carboxylation of glutamic acid residues (Glu) into gamma-carboxylation acid residues (Gla). These residues render the protein osteocalcin capable of calcium binding to bone.

Osteocalcin can have three Gla residues, but it is not known how many carboxyl groups are needed for adequate function. Circulating Gla-proteins provide information on vitamin K status of bone. Under conditions of subclinical vitamin K deficiency, OC remains under-carboxylated and is transferred into the circulation. In this chapter undercarboxylated osteocalcin is referred to as "free" osteocalcin (OC_{FREE}).

Several studies have reported evidence of a relation between vitamin K status and bone mineralization. Low serum concentration of vitamin K has been reported in patients with osteoporotic fractures¹⁴. Higher concentrations of undercarboxylated OC have been shown to be related to advanced age, low BMD and the risk of hip fracture¹⁴. Loss of bone mass was associated with poor vitamin K status in postmenopausal women¹⁵. Oral anticoagulant therapy was associated with an increased fracture risk¹⁷. Vitamin K supplementation decreases bone loss and calcium excretion¹⁴.

The aim of this study was to investigate the serum and bone vitamin K status in patients with long-standing CD and to elucidate the relation between vitamin K status and BMD in these patients. Furthermore the relationship of vitamin K status with the serum concentrations of vitamin D and of triglycerides was established.

Methods

Patients

Patients were randomly asked to participate in this study while attending the gastroenterology outpatient clinic of the University Hospital of Maastricht. Thirty-three patients with CD (13 males, 20 females) were included in the study in April and May 1997. Basic characteristics of the patient population are given in Table 6.1. Crohn's disease was diagnosed by clinical findings and a combination of radiology, endoscopy and histology for which the Lennard-Jones criteria were applied¹⁸. At the time of the study, all patients were in clinical remission. Disease activity was measured by the Crohn's disease activity index (CDAI)¹⁹. All patients had small bowel involvement, 13 patients also had inflammation of the colon. In 24 patients an ileal resection had been performed. All patients were using mesalazine (5-ASA). Four patients were taking prednisolone or a steroid equivalent; however for inclusion the prednisolone equivalent dose had to be less than 5 mg/day. Six patients were taking vitamin D supplements (400 IU /day) and four also used calcium supplements (500 mg/day). Six female patients were postmenopausal, none received hormone replacement therapy. Five other women were taking oral contraceptive medication. At the time of inclusion 14 patients were regular cigarette smokers. Body mass index (kg/m^2) was calculated. One female patient, who had been taking vitamin K supplements, was excluded during the course of the study. The study protocol was approved by the ethics committee of the University Hospital of Maastricht and all patients gave informed consent before the start of the study.

Table 6.1 Basic characteristics of the patients with Crohn's disease (n = 32) and age and gender matched healthy controls (n = 34).

	patients	controls
number	32	34
male/female	13 / 19	13 / 21
age (years)	42 ± 13	42 ± 14
body Mass Index (kg/m ²)	23 ± 4	---
Crohn's disease activity index	106 ± 78	---
steroid use (n, (mg/day))	3 (2.5)	---
	1 (5.0)	---
postmenopausal (n)	6	8
disease duration (years)	16 ± 6	---
resection (n, cm)	24, 65 ± 45	---

Parameters are given in numbers or in mean ± standard deviation. Controls were healthy age and gender matched population controls randomly selected from the community registry.

Biochemical measurement

Total osteocalcin was measured by using the Osteometer test kit (Biotech, Herlev / Denmark). Since carboxylated OC and undercarboxylated OC substantially differ in their affinity for insoluble calcium salts, these fractions can be quantified by measuring serum OC before and after extraction with a standard amount of hydroxyapatite. The fraction that does not bind to hydroxyapatite consists of undercarboxylated "free" osteocalcin (OC_{FREE}). To measure the OC_{FREE} fraction, 45 mg of hydroxyapatite were added to 300 µl of serum. The fraction of carboxylated OC (OC_{BOUND}) is calculated from the difference between the total immunoreactive OC (OC_{TOTAL}) and OC_{FREE}. OC_{BOUND} expressed as a percentage of total OC is known as the hydroxyapatite binding capacity (HBC) of osteocalcin¹⁶. The percentage HBC of the circulating OC was calculated by the formula: $HBC(\%) = ((OC_{TOTAL} - OC_{FREE}) / OC_{TOTAL}) \times 100$. The OC levels and HBC(%) were compared to those of an age and gender matched control group of 34 healthy men and women^{20,21}.

Vitamin K was assessed using a HPLC technique with post-column reduction and fluorescence detection as previously described²². The serum vitamin K levels of the patients were compared to those of a reference population of 384 healthy men and women. Serum 25-hydroxyvitamin D concentration was measured using a ¹²⁵I radioactive immunoassay (Incstarr Corporation-Stillwater, Minnesota, USA) in specimens obtained in April and May for which the winter reference value was applied (25-70 nmol/l)²³.

Bone Mineral Density

Bone mineral density (BMD) was measured using dual energy X-ray absorptiometry (DXA) (Lunar DPX-L, Lunar software version DPX-L 4.7; Lunar Radiation Corp., Madison, WI, USA) of lumbar spine (L₂-L₄), femoral neck and total body²⁴. BMD was expressed in absolute values (g/cm²), T-score (one standard deviation of the mean of a young adult gender matched reference population) and Z-score (one standard deviation of the mean of an age and sex matched reference population),

respectively. Reference data were based on populations from the US, United Kingdom and Northern Europe. There was a 1.3% SD of the average density values of populations contributing to the normative data in the various geographical areas. The prevalence of osteopenia and osteoporosis was assessed according to the WHO classification in which osteopenia is defined as T-score between -1 and -2.5 and osteoporosis as T-score < -2.5²⁵.

Statistical analysis

Results are shown as mean and standard deviation (SD). The (unpaired) independent t-test was used for the comparison of CD patients with the reference population regarding serum vitamin K concentration, OC_{FREE} and HBC(%). One way ANOVA was used to evaluate the vitamin K status in CD patients with either normal bone mineral density or osteopenia and osteoporosis. Non-parametric tests were used for the remaining statistical evaluations. Correlations between continuous variables were assessed using Pearson's correlation coefficient. Multiple linear regression analysis was performed to identify independent risk factors for bone mineral density and to correct for vitamin D deficiency as a potential confounder. The following independent variables were separately used in this analysis: absolute BMD, T-score and Z-score of femoral neck, lumbar spine and total body, respectively. Two-tailed tests for significance were used in all statistical analyses. A P value of < 0.05 was considered to be statistically significant. The Statistical Package for the Social Sciences (SPSS 7.5 for windows package 1996, SPSS inc., Chicago, Illinois/USA) was used for the analysis.

Results

Mean BMD, expressed as absolute values in g/cm³, of femoral neck, lumbar spine and total body were 0.89 (±0.13), 1.10 (±0.16) and 1.11 (±0.09). Mean T-score was -0.61 (±1.29) for the total body, -0.98 (±1.16) for the femoral neck and -0.66 (±1.13) for the lumbar spine, respectively. Mean Z-score was -0.49 (±1.07) for the total body, -0.45 (±1.25) for the femoral neck and -0.28 (±1.10) for the lumbar spine, respectively. The prevalence of osteopenia and osteoporosis in these patients according to the WHO definition is given in Table 6.2.

Table 6.2 Prevalence of osteoporosis and osteopenia in patients with long-standing Crohn's disease (n = 32), according to the WHO definition.			
	normal T-score > -1 n (%)	osteopenia T-score -1 to -2.5 n (%)	osteoporosis T-score < -2.5 n (%)
lumbar spine	19 (59)	7 (22)	6 (19)
femoral neck	14 (44)	16 (50)	2 (6)
total body	21 (66)	8 (25)	3 (9)

Serum vitamin K concentrations in patients with CD were significantly lower than in a reference population of 384 healthy men and women ($p < 0.01$) (Figure 6.2). Patients with CD had higher serum OC_{FREE} ($p < 0.05$) and lower HBC values ($p < 0.001$) as compared to the values obtained from the age and gender matched control group of 34 healthy men and women randomly selected from the community registry (Figure 6.3/ Figure 6.4). Serum vitamin K, OC_{FREE} and HBC did not significantly differ between male and female patients. Although mean OC_{FREE} was generally lower and mean serum vitamin K was higher in patients with normal BMD than in patients with a T-score < -1 (osteopenia plus osteoporosis), this difference was not statistically significant. In patients a negative correlation was found between lumbar spine BMD and OC_{FREE} ($r = -0.375$, $p < 0.05$) (Figure 6.5) and between lumbar spine Z-score and OC_{FREE} ($r = -0.381$, $p < 0.01$) (Figure 6.6).

Figure 6.2 Serum vitamin K concentrations in patients with long-standing Crohn's disease ($n = 32$) compared with healthy controls ($n = 34$). Median for patients with Crohn's disease is 0.402 (ng/ml); median of healthy controls is 0.610 (ng/ml)

Figure 6.3 Serum concentrations of "free" (undercarboxylated) osteocalcin in patients with long-standing Crohn's disease ($n = 32$) compared to age and sex-matched and healthy controls ($n = 34$). Lines indicate median values. Median of patients with Crohn's disease = 3.89 (ng/ml); median of healthy controls = 1.51 (ng/ml)

Mean serum level of vitamin D in patients was 28.4 (± 10.5) nmol/l; 11 patients (34%) were vitamin D deficient (serum 25-hydroxy vitamin D < 25 nmol/l). Of the patients taking a vitamin D supplement (400 IU/day for more than 2 months), 3 patients had still serum vitamin D levels < 25 nmol/l (13, 14 and 23 nmol/l, respectively). A significant correlation was found between the serum concentrations of vitamin D and K ($r = 0.681$, $p < 0.01$). No correlation was found between the concentrations of vitamin D and the vitamin K status of bone (either OC_{FREE} or $HBC(\%)$). Mean serum triglyceride level was 1.5 (± 1.1) mmol/l. A positive correlation was found between serum concentrations of vitamin D and triglycerides ($r = 0.707$, $p < 0.01$) and vitamin K and triglycerides ($r = 0.789$, $p < 0.01$), respectively.

Figure 6.4 Hydroxyapatite binding capacity (HBC)(%) in patients with long-standing Crohn's disease (n = 32) compared to age and sex matched healthy controls (n = 34). Lines indicate median values. Median of patients with Crohn's disease = 61.71 %; median of healthy controls = 76.84%.

Figure 6.5 Correlation between "free" (undercarboxylated) osteocalcin and bone mineral density (BMD) of the lumbar spine in patients with long-standing Crohn's disease (n = 32). Correlationcoefficient (Pearsons) $r = -0.375$, $p < 0.05$.

Figure 6.6 Correlation of "free" (undercarboxylated) osteocalcin and bone mineral density Z-score of the lumbar spine in patients with long-standing Crohn's disease (n = 32). Correlation coefficient (Pearsons) $r = -0.381$, $p < 0.01$.

In the patient group the variables sex, age, body mass index, serum vitamin K, OC_{FREE} , and vitamin D were included in a multiple linear regression. No correlations were found between serum vitamin K levels and BMD, T- and Z-scores at any measurement site. We found that OC_{FREE} correlated significantly with BMD of the lumbar spine ($p = 0.05$) and with the lumbar spine Z-score ($p = 0.035$) (Table 6.3). The correlation between OC_{FREE} and the T-score of the lumbar spine did not reach significance ($p = 0.091$). No correlations were found between either BMD, T- and Z-score of femoral neck and total body and OC_{FREE} . No correlations were found between serum vitamin D levels and BMD, T- and Z-scores at any measurement site.

Table 6.3 Results of the multiple linear regression analysis in patients with long-standing CD (n = 32), with absolute BMD and Z-score of the lumbar spine as dependent, and vitamin D and "free" (undercarboxylated) osteocalcin as independent variables.

	BMD lumbar spine			Z-score lumbar spine		
	β	95%CI	P	β	95%CI	P
vitamin D	6.8^{E-4}	-0.005-0.007	0.885	-1.2^{E-1}	-0.43-0.41	0.953
"free" osteocalcin	-8.5^{E-3}	-0.17-0.000	0.050	-6.8^{E-2}	-0.132-0.005	0.035

β , weight factor; 95% CI, 95% confidence interval for β

Discussion

The results of the study reveal low serum vitamin K and low bone vitamin K status (increased OC_{FREE} and lowered HBC (%)) in a group of patients with long-standing CD compared with normal controls. Serum OC_{FREE} status, but not the serum vitamin K concentration, correlated with BMD of the lumbar spine.

To exclude the effects of disease activity and corticosteroid use, we investigated a group of patients with inactive CD, all with small bowel involvement and/or a previous ileal resection. They were receiving no or very low doses of steroids. In some patients with ileal resection, Crohn's disease activity index scores (CDAI) were relatively high, in spite of clinical remission. The index obviously reflects high frequency of liquid stools in these patients due to ileal resection rather than current intestinal inflammation.

In patients with CD and with ileopathy, caused by either inflammation or previous resection, bile acid and fat malabsorption causes steatorrhea and malabsorption of fat-soluble vitamins. Serum vitamin K concentrations are influenced by the plasma triglyceride concentrations and reflect recent dietary intake in healthy subjects^{16,26}. While there are several publications on the role of vitamin D in metabolic bone disease in CD^{1,13,27-30} only a few data are available with regard to vitamin K status in CD. In a study, in which undercarboxylated prothrombin was used as a marker, vitamin K deficiency was indicated in 46% of CD patients with ileal involvement but not in patients with Crohn's colitis³¹. It has also been reported that OC_{FREE} , as used in the present study, is a much more sensitive marker for vitamin K status than prothrombin³².

The fact that vitamin K serves as a co-factor for the carboxylation of bone Gla-proteins and is of potential importance for bone formation is reflected by an significant independent and inverse correlation between OC_{FREE} and BMD of the lumbar spine (BMD and Z-score). The trabecular bone of the spine is metabolically more active than the cortical bone of the hip and might thus be more susceptible to vitamin K deficiency. This might explain the lack of correlation between OC_{FREE} and BMD of femoral neck and total body. Surprisingly, no correlation was found between HBC (%) and BMD at any site. These findings could indicate that the absolute amount of circulating undercarboxylated osteocalcin (OC_{FREE}) is more indicative of a low bone vitamin K status than the fraction of OC_{BOUND} expressed by HBC (%).

Bone mineral loss in CD is a multifactorial process and vitamin K deficiency is certainly only one factor in this process. In the present study there are indications that in patients with long-standing Crohn's disease vitamin K deficiency of bone has a greater influence on BMD than the serum 25-hydroxy vitamin D level. The body vitamin D stores are reflected by the serum concentration of 25-hydroxy vitamin D. In accordance with our expectations significant correlations between serum vitamin D and K concentrations and triglycerides were found. In the present study, however, patients who were vitamin D-deficient did not have significantly decreased BMD. Published data are equivocal in this respect: significant correlation between vitamin D and the BMD of the forearm was found in one of three large studies on vitamin D deficiency and BMD in patients with CD²⁷⁻²⁹. Vitamin D

deficiency may cause secondary hyperparathyroidism that predominantly affects cortical bone.

The questions remaining are whether or not bone that is vitamin K deficient is rendered sensitive to other pathogenetic factors of osteoporosis, such as the administration of corticosteroids, and whether vitamin K supplementation would improve bone mineralization in CD patients as has been demonstrated in other conditions. In prednisolone-treated rats, vitamin K supplementation inhibited bone loss³³. Treatment with vitamin K (menatetrenone) has been reported to increase BMD in disused bones in vitamin K and D deficient hemiplegic patients³⁴. In a study in cystic fibrosis patients, a significantly elevated level of OC_{FREE} was found in patients who were not supplemented with vitamin K (phyloquinone) versus supplemented patients³⁵. The questions addressed above require further study. It has recently been demonstrated that vitamin K treatment effectively prevents the occurrence of new vertebral fractures in patients with osteoporosis³⁶.

In summary, a low serum and bone vitamin K status was found in patients with long-standing CD, currently in remission. The poor vitamin K status correlated with low lumbar spine BMD. Circulating undercarboxylated osteocalcin in particular was found to be an independent risk factor of low BMD of the lumbar spine in these patients, whereas low serum vitamin D was not. Further studies are needed to assess the implications of low serum and bone vitamin K status and the value of vitamin K supplementation for the prevention of osteoporosis in CD.

References

1. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995;108:417-22.
2. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997;40:228-33.
3. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987;28:410-5.
4. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994;107:1031-9.
5. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997;40:313-9.
6. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992;37:1396-403.
7. Robinson RJ, AlAzzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998;43:2500-6.
8. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995;37:71-6.
9. Tromm A, Rickels K, Huppe D, et al. Osteopenia in chronic inflammatory bowel diseases. Results of a cross-sectional study using quantitative computerized tomography. *Leber Magen Darm* 1994;24:23-30.
10. Robinson RJ, Iqbal SJ, AlAzzawi F, et al. Sex hormone status and bone metabolism in men with Crohn's disease. *Aliment Pharmacol Ther* 1998;12:21-5.
11. Russell R. Nutrition and inflammatory bowel disease. *Current Opinion in Gastroenterology* 1992; 8:688-93.
12. Geerling BJ, BadartSmook A, Stockbrugger RW, et al. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. *Am J Clin Nutr* 1998;67:919-26.
13. Driscoll RH, Meredith SC, Sitrin M, et al. Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* 1982; 83:1252-8.
14. Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. *J Nutr* 1995;125:1812-21.
15. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. *Biochem J* 1990; 266:625-36.
16. Vermeer C, Jie KS, Knapen MH. Role of vitamin K in bone metabolism. *Annu Rev Nutr* 1995;15:1-22.
17. Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. *Arch Intern Med* 1999;159:1750-6.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl.* 1989;170:2-6.
19. Best WR, Becketl JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; 70:439-44.
20. Knapen MH, Nieuwenhuijzen Kruseman AC, Wouters RS, et al. Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. *Calcif Tissue Int* 1998;63:375-9.
21. Knapen MH, Eisenwiener HG, Vermeer C. Osteocalcin detection in aging serum and whole blood: stability of different osteocalcin fractions. *Clin Chim Acta* 1996;256:151-64.
22. Schurgers LJ, Geleijense J, Grobee D, et al. Nutritional intake of vitamins K1 (Phylloquinone) and K2 (Menaquinone) in the Netherlands. *Journal of Nutritional & Environmental Medicine* 1999;9:115-22.
23. Hollis BW, Kamerud JQ, Selvaag SR, et al. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. *Clin Chem* 1993;39:529-33.

24. Mazess RB, Barden HS, Bisek JP, et al. Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. *Am J Clin Nutr* 1990;51:1106-12.
25. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
26. Ferland G, Sadowski JA, O'Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. *J Clin Invest* 1993;91:1761-8.
27. Andreassen H, Rix M, Brot C, et al. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. *Scand J Gastroenterol* 1998;33:1087-93.
28. Hesse I, Mosekilde L, Melsen F, et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. *Scand J Gastroenterol* 1984;19:691-6.
29. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. *J Intern Med* 1996;239:131-7.
30. Vogelsang H, Ferenci P, Woloszczuk W, et al. Bone disease in vitamin D-deficient patients with Crohn's disease. *Dig Dis Sci* 1989;34:1094-9.
31. Krasinski SD, Russell RM, Furie BC, et al. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. *Am J Clin Nutr* 1985;41:639-43.
32. Rucker RB. Improved functional endpoints for use in vitamin K assessment: important implications for bone disease. *Am J Clin Nutr* 1997;65:883-4.
33. Hara K, Akiyama Y, Ohkawa I, et al. Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. *Bone* 1993;14:813-8.
34. Sato Y, Honda Y, Kuno H, et al. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. *Bone* 1998;23:291-6.
35. Beker LT, Ahrens RA, Fink RJ, et al. Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients. *J Pediatr Gastroenterol Nutr* 1997;24:512-7.
36. Shiraki M, Shiraki Y, Aoki C, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res* 2000;15:515-21.

CHAPTER 7

Abnormal bone turnover in long-standing Crohn's disease in remission

EJ Schoon, BG Geerling, IMA van Dooren,
LJ Schurgers, C Vermeer, R-JM Brummer,
RW Stockbrügger

Aliment Pharmacol Ther 2001;15:738-792

Abstract

Background

A high prevalence of osteoporosis is found in patients with Crohn's disease. The pathogenesis of this condition seems to be multifactorial and its pathophysiology is still not completely understood.

Aim and Methods

To elucidate the pathophysiology of osteopenia in quiescent Crohn's disease, bone turnover was studied in 26 patients (13 males and 13 females) with long-standing quiescent Crohn's disease and small bowel involvement. Bone mineral density was assessed by dual energy X-ray absorptiometry. Biochemical markers for bone formation (osteocalcin and bone specific alkaline phosphatase) and for bone resorption (deoxypyridinoline and collagen type I C-terminal crosslinks) were measured. Urinary calcium excretion was determined.

Results

Markers for bone formation were significantly lower in patients than in controls (osteocalcin: $p = 0.027$, bone-specific alkaline phosphatase: $p < 0.001$), but both bone resorption markers were not significantly different. Urine calcium excretion was significantly decreased in patients ($p = 0.002$) compared to controls. Bone mineral density of the lumbar spine was significantly and inversely correlated with bone-specific alkaline phosphatase and collagen type I C-terminal crosslinks.

Conclusions

Bone turnover in long-standing Crohn's disease in clinical remission is characterized by suppressed bone formation and normal bone resorption. Urine calcium excretion is decreased. Hence, interventions and therapy should be directed towards improvement of bone formation.

Introduction

Patients with Crohn's disease (CD) are at high risk of developing osteopenia and osteoporosis¹⁻⁵. The pathogenesis and pathophysiology of these conditions in CD are still not completely understood. A number of factors are considered to contribute to the reduced bone density. These include: steroid use, malnutrition, vitamin D and calcium deficiency, immobilisation, smoking, sex hormone deficiency, hyper-parathyroidism, and the inflammatory process itself⁶. It has been demonstrated that clinical risk factors are poor diagnostic predictors of actual bone mass⁷. In a large controlled study, low BMD was found in patients with CD, but not in those with UC⁸.

The pathophysiologic process can be clarified by studying bone turnover by means of biochemical markers that reflect bone turnover in the entire skeleton and have the advantage of being non-invasive, relatively inexpensive and of allowing repeated evaluation⁹. Biochemical markers of bone resorption are: serum osteocalcin, total and bone-specific alkaline phosphatase and procollagen I extension peptides. Markers of bone formation are: urinary hydroxyproline and hydroxylysine glycosides, urinary pyridoline and deoxypyridinoline and serum tartrate-resistant alkaline phosphatase and pyridinoline peptides. Generally, these markers correlate poorly with current bone mineral density (BMD)¹⁰⁻¹² and, therefore, are not appropriate to diagnose low bone mineral density. Published data are conflicting with regard to whether osteopenia in CD is due to increased bone resorption¹¹⁻¹³, suppressed bone formation¹⁴ or both^{10,15}. Some studies have failed to indicate significant changes in biochemical markers in patients compared to controls¹⁶⁻¹⁸.

In patients with recently diagnosed IBD, BMD was not different from that in controls, indicating that the subsequent development of osteoporosis must be related to the disease process and/or the treatment modalities of IBD¹⁹. The use of corticosteroids in patients with CD is considered to be an important risk factor for low BMD. In cross-sectional BMD studies in CD patients, the correlation between the cumulative corticosteroids dose and low BMD is not unanimous. One of the pathophysiologic mechanisms of the effect of corticosteroids on bone in CD is the suppression of bone formation^{13,14}. Most of the studies on bone turnover in IBD have been flawed by the inclusion of heterogeneous patient populations regarding the type of disease (CD and UC), the disease activity (active disease and disease in remission), the administration of corticosteroids and the menopausal status of female patients. In two studies, only CD patients were included, in one study including 20 male patients with long-standing quiescent CD, no difference in biochemical markers was demonstrated between patients and controls²⁰. Another large study, comprising a population of 117 CD patients showed increased bone resorption. However, patients using corticosteroids and postmenopausal female patients were included in this study²¹. To date, the effects of disease activity on bone turnover in Crohn's disease have only been studied *in vitro*²².

The aim of this study was to evaluate bone turnover using biochemical markers, in long-standing Crohn's disease in the absence of active disease, of significant corticosteroid use and of the influence of menopausal status in order to further elucidate the pathophysiology of this condition.

Methods

Subjects

Patients were asked to participate in this study while attending the Gastroenterology outpatient clinic of the University Hospital Maastricht. Inclusion criteria were: Crohn's disease, clinical remission, prednisolone dose ≤ 5 mg/day and duration of disease of 5 years or longer. Exclusion criteria were: postmenopausal status in female patients, past or current active treatment for osteoporosis (bisphosphonates, calcitonine, fluorides, hormone replacement therapy apart from oral contraceptives) and concomitant disease predisposing to secondary osteoporosis (e.g. ankylosing spondylitis, liver disease, renal insufficiency). Twenty-six patients with Crohn's disease (13 males, age range 18-68 years and 13 females, age range 22-46 years) with an overall mean age of 38 ± 12 years (SD) were included in the study. Basic characteristics of the patient population are given in Table 7.1. Controls were healthy, age and gender-matched persons (males: 20-70 years and pre-menopausal females: 20-50 years) selected from a community registry.

Crohn's disease was diagnosed by a combination of clinical symptoms and endoscopic, radiological and histological data for which the Lennard-Jones criteria were applied²³. At the time of the study, all patients were in clinical remission for at least 3 months before inclusion. Disease activity was measured using the Crohn's disease activity index (CDAI)²⁴. All patients had small bowel involvement and in 13 patients inflammation also involved the colon. Four patients were taking prednisolone (≤ 5 mg/day). Steroid doses were kept stable over at least 1 month before inclusion. All patients were using 5-amino salicylic acid (5-ASA) in a dosage of 2-3 g/day. Five female patients were taking oral contraceptive medication. Five patients used physiological doses of vitamin D (400 IE/day), and 3 of them were also taking a low-dose calcium supplementation (500 mg/day) which, at the time of the study, was not considered to be active treatment of osteoporosis. Thirteen patients were cigarette smokers; for all patients the number of pack-years was calculated. The patients' lifetime physical activity and their activities during the last 6 months were evaluated according to Baecke²⁵. The study protocol was approved by the Ethics Committee of the University Hospital of Maastricht, and all subjects gave their informed consent before the start of the study.

Table 7.1 Basic characteristics of 26 patients with long-standing quiescent Crohn's disease.

	patients
male /female	13 / 13
age (years)	38 $\pm$ 12
Crohn's disease activity index	110 $\pm$ 80 / 99 (0-302)
steroid use (mg/day)	2.5 (n = 3)
	2.0 (n = 1)
small bowel involvement	26
disease duration (years)	16 $\pm$ 8
resection (cm)	65 $\pm$ 45 (n = 19)
body mass index (kg/m ²)	22 $\pm$ 4
smokers/non-smokers	13 / 13

Data are presented as mean (standard deviation) or as number, except for CDAI, which is also noted as median (range).

Biochemical Assessment

Blood samples taken at baseline in the morning after an overnight fast were immediately centrifuged and stored at -70°C . The second morning urine portion was collected on the same day and stored at -70°C . Two biochemical markers for bone formation and two markers for bone resorption were determined. For the assessment of bone formation, serum osteocalcin (OC) and bone-specific alkaline phosphatase (BAP) were measured. For the assessment of bone resorption, collagen type I C-terminal crosslinks (CTX) and deoxypyridinoline (DPD) were determined in urine.

Serum OC was measured using the Osteometer test kit (Osteometer Bio Tech A/S, Copenhagen/ Denmark). BAP was measured using the IRMA test kit (Hybritech, Liege, Belgium)²⁶. The results were compared to those of a group of population controls consisting of 90 healthy men (age range 20-70 years) and women (age range 20-50 years).

CTX is a product of type I collagen that is degraded during remodelling of the skeleton and is excreted in the urine²⁷. CTX was measured using the Crosslabs TM ELISA technique (Osteometer Bio Tech A/S, Copenhagen/ Denmark)²⁸. DPD was measured using Pylilinks-D, a competitive enzyme immunoassay for measuring DPD in urine (Metra Biosystems Inc., Mountain View, California/ USA)²⁹. Results for both resorption parameters were calculated as the CTX/ creatinine and DPD/ creatinine ratio to correct for small differences in renal function. Data were compared to those of a group of 12 controls, 6 healthy males and 6 healthy females ranging in age from 18 to 28 years.

Calcium-excretion in urine was measured using atom absorption spectrometry and calculated as the calcium/creatinine ratio. The results were compared to the same control population as OC and BAP.

Serum 25-hydroxyvitamin D concentration was measured using a ¹²⁵I radioactive immunoassay (Incstar Corporation, Stillwater, Minnesota, USA) in specimens

obtained in April for which the winter reference value was applied (25-70 nmol/l)³⁰. Routine laboratory parameters were measured including serum creatinine and hematocrit, in order to calculate the CDAI.

Bone Mineral Density

Bone mineral density (BMD) was measured using dual energy X-ray absorptiometry (DXA) (Lunar DPX-L, Lunar software version DPX-L 4.7; Lunar Radiation Corp., Madison, WI, USA)³¹ of the lumbar spine (L₂-L₄), femoral neck and total body. BMD was expressed in absolute values (g/cm²), T-score (one standard deviation to the mean of a young adult gender-matched reference population) and Z-score (one standard deviation compared to the mean of an age and gender-matched reference population), respectively. Reference data were based on populations from the United States, United Kingdom and Northern Europe³²⁻³⁴. There was a 1.3% SD in the average density values among various geographic areas. The diagnosis of osteopenia and osteoporosis was based on T-scores according to the WHO criteria³⁵.

Statistics

Continuous data were presented as mean ($\pm$ SD) when normally distributed or as median (range) when not. If continuous data were normally distributed, a Student t-test was applied. In other cases, the non-parametric Mann-Whitney U test was used. Correlations between continuous variables were assessed using the Pearson's correlation test or Spearman's rank test, respectively. Two-tailed tests for significance were used in all the statistical analyses and $p \leq 0.05$ was considered statistically significant. The Statistical Package for the Social Sciences (SPSS) was used for the analysis (version 7.5, SPSS Inc.1998).

Results

Mean BMD of the lumbar spine, of the femoral neck, and of the total body, as well as the T- and Z-scores and the prevalence of osteopenia and osteoporosis are given in Table 7.2.

In the patients, BAP and OC, as biochemical markers of bone formation, were significantly decreased compared to the control population ($p < 0.001$ and $p = 0.027$, respectively), while CTX and DPD as bone resorption markers were not significantly different from those of controls. Urinary calcium excretion was significantly decreased ($p = 0.002$) compared to controls (Table 7.3, Figures 7.1-7.3).

Table 7.2 Mean bone mineral density, T- and Z-scores, and prevalence of osteoporosis and osteopenia (according to the WHO criteria³⁹) in 26 patients with long-standing Crohn's disease in remission.

	BMD (g/cm ³)	T-score	Z-score	osteopenia T-score -1 to -2.5 n (%)	osteoporosis T-score < -2.5 n (%)
lumbar spine	1.11 (± 0.14)	-0.71 (± 1.30)	-0.43 (± 1.20)	6 (23)	4 (15)
femoral neck	0.87 (± 0.12)	-1.03 (± 1.11)	-0.90 (± 0.98)	9 (31)	1 (4)
total body	1.11 (± 0.09)	-0.67 (± 1.23)	-0.38 (± 1.00)	7 (27)	2 (8)

Bone mineral density is given as mean (± standard deviation). The prevalence of osteopenia and osteoporosis is given in absolute numbers, and the proportion of the study population in percentage (%).

T-score = one standard deviation of the mean of a young adult gender-matched reference population.

Z-score = one standard deviation to the mean of an age and gender-matched control population

Table 7.3 Results of the biochemical markers of bone turnover in patients with Crohn's disease (n = 26) compared to controls.

	patients	controls	p-value(95%CI)
total osteocalcin (OC) (ng/ml)	14.2 (0.5-64.3)	17.3 (8.5-51.0)	0.027 0.023-0.030
bone-specific alkaline phosphatase (BAP) (U/l)	7.3 (1.8-37.9)	12.9 (1.3-81.5)	< 0.001 0.000-0.001
collagen type I C-terminal crosslinks (CTX) / creatinine (nmol/μmol)	135 (50-457)	130 (50-422)	0.360 0.350-0.369
deoxypyridinoline (DPD) / creatinine (nmol/μmol)	5.0 (1.5-18.4)	7.5 (2.5-14.0)	0.055 0.051-0.060
urinary calcium / creatinine (mmol/μmol)	0.13 (0.02-0.44)	0.21 (0.03-0.92)	0.002 0.001-0.003

Data are expressed as median (range). For comparison between patients and controls, the Mann-Whitney U-test was performed. 95% CI = 95% Confidence Interval.

Figure 7.1a Osteocalcin (OC) in 26 patients with long-standing quiescent Crohn's disease versus 90 healthy controls. Lines indicate median values. Mann-Whitney U-test.

Figure 7.1b Bone-specific alkaline phosphatase (BAP) in 26 patients with long-standing quiescent Crohn's disease versus 90 healthy controls. Lines indicate median values. Mann-Whitney U-test.

Figure 7.2a Collagen type I C-terminal crosslinks (CTX)/creatinine (nmol/μmol) urinary excretion in 26 patients with long-standing quiescent Crohn's disease versus 12 healthy controls. Lines indicate median values. Mann-Whitney U-test.

Figure 7.2b Deoxypyridinoline (DPD)/creatinine (nmol/μmol) urinary excretion in 26 patients with long-standing quiescent Crohn's disease versus 12 healthy controls. Lines indicate median values. Mann-Whitney U-test.

Figure 7.3 Calcium/creatinine urinary excretion in 26 patients with long-standing quiescent Crohn's disease versus 90 healthy controls. Lines indicate median values. Mann-Whitney U-test.

Figure 7.4 Correlation between the lumbar spine T-score and serum bone-specific alkaline phosphatase level (BAP) in 26 patients with long-standing quiescent Crohn's disease. Pearson's coefficient $r = 0.408$, $p = 0.035$.

A significant inverse correlation was found between the serum level of BAP and the lumbar spine BMD ($r = 0.386$, $p = 0.047$), the lumbar spine T-score ($r = 0.408$, $p = 0.035$) (Figure 7.4), but not between BAP and the lumbar spine Z-score ($r = 0.321$, $p = 0.103$). The CTX/creatinine ratio also inversely correlated with lumbar spine BMD ($r = 0.389$, $p = 0.030$), lumbar spine T-score ($r = 0.390$, $p = 0.049$) (Figure 7.5) and lumbar spine Z-score ($r = 0.400$, $p = 0.043$). A significant inverse correlation was found between the serum level of BAP and the total body T-score ($r = 0.421$, $p = 0.029$) (Figure 7.6). No significant correlations were found between the biochemical markers and femoral neck BMD scores.

Mean serum level of vitamin D was $28 (\pm 11)$ nmol/l, nine patients (35%) were considered vitamin D-deficient (serum 25-hydroxyvitamin D < 25 nmol/l), and only one patient had a serum vitamin D level below 10 nmol/l. Of the patients taking a vitamin D supplement (400 IU/day for more than 2 months), three patients still had serum vitamin D levels below 25 nmol/l (13, 14 and 23 nmol/l, respectively). No correlation was found between the extent of the small bowel resection (cm) and the vitamin D levels in those patients who did not take vitamin D supplements. Six patients had a CDAI above 150. In these patients, the C-reactive protein CRP, which is a sensitive indicator of disease activity in IBD, ranged from 2 to 10 mg/L. The clinical characteristics of these six patients are given in Table 7.4. Exclusion of these patients did not change the results; a significant difference was still found in bone formation (OC and BAP) but not in bone resorption (DPD and CTX).

BMI ($r = 0.631$, $p < 0.001$), percentage body fat ($r = 0.569$, $p = 0.002$) and serum vitamin D level ($r = 0.450$, $p = 0.018$) inversely correlated with CDAI.

Figure 7.5 Correlation between the lumbar spine T-score and collagen type I C-terminal crosslinks/creatinine ratio (expressed in nmol/ μ mol) in 26 patients with long-standing quiescent Crohn's disease. Pearson's coefficient $r = -0.390$, $p = 0.049$.

Figure 7.6 Correlation between the total body T-score and serum bone-specific alkaline phosphatase level (BAP) in 26 patients with long-standing quiescent Crohn's disease. Pearson's coefficient $r = 0.421$, $p = 0.029$.

Table 7.4 Clinical characteristics of six patients with Crohn's disease with a Crohn's disease activity index (CDAI) above 150.

	mean $\pm$ SD	median (range)
age	40 $\pm$ 9	36 (33-54)
disease duration (years)	20 $\pm$ 9	19 (10-32)
resection in centimeters (n = 5)	69 $\pm$ 61	40 (25-175)
CDAI	228 $\pm$ 45	217 (181-302)
number of liquid stools last 7 days	21 $\pm$ 14	19 (6-40)
C-reactive protein (mg/L)	6.3 $\pm$ 2.5	6.5 (2-10)
serum albumin level (g/L)	37 $\pm$ 4	38 (29-41)

SD = standard deviation

No significant correlations were found between biochemical markers of bone turnover and physical activity or BMI. No significant differences were found in markers of bone turnover between smokers and non-smokers.

Discussion

In this study biochemical markers of bone formation (BAP and OC) in patients with long-standing quiescent CD were significantly decreased compared to those in a control population, while bone resorption markers (CTX and DPD) were not

significantly different from those in controls. An inverse correlation was found between both BMD of the lumbar spine and BAP and BMD of the lumbar spine and CTX/creatinine ratio. Urinary calcium excretion was also significantly decreased compared to that in normal controls.

This unbalanced bone metabolism in patients with long-standing CD is pathologic and seems to be an ongoing process, even in the absence of clinical disease activity and significant corticosteroid use. Uncoupling of the bone degradation-formation cycle can be a risk factor for progression of bone loss and eventually lead to bone fractures. The inverse correlation between BMD of the lumbar spine and one marker for bone formation (BAP) as well as one marker for bone resorption (CTX/creatinine ratio) indicates that a higher bone turnover level is associated with a lower BMD. If the turnover is unbalanced bone loss occurs even during the "quiescent" phase of the disease process. Just how much the unbalanced bone turnover contributes to bone loss has to be proven in a follow-up study on these patients. The trabecular bone in the lumbar spine is metabolically more active than the cortical bone of the femoral neck and this may explain for the absence of correlation between biochemical markers and BMD of the femoral neck.

The use of corticosteroids and disease activity with high levels of circulating pro-inflammatory cytokines are supposed to play a pivotal role in the bone metabolism of patients with IBD. To exclude the confounding effects of active disease and corticosteroid use, we investigated a group of patients with inactive CD, all with small bowel involvement and/or a previous small bowel resection. They had no or very low stable doses of steroids. In six patients, CDAI scores were higher than 150, all patients were in clinical remission and had a low CRP.

The results of this study are in agreement with the results of a histomorphometric study performed in 19 patients with IBD and osteoporosis; reduced bone formation was found at cellular level with a negative remodelling balance³⁶. Although, in the present study, the biochemical markers for bone turnover BAP and CTX/creatinine were significant and inversely correlated with the bone BMD of the lumbar spine, these correlations were low. Recently, increased urinary N-telopeptide crosslinked type I collagen (NTx) excretion was found to be predictive of future spinal bone loss in IBD patients³⁵. The value of these markers as a diagnostic tool for osteoporosis for the individual patient with CD needs to be further investigated, given the evidence that the level of bone turnover is as strong a predictor of future fractures as is the level of BMD in conditions other than IBD³⁷⁻⁴⁰.

The different results of other studies on bone turnover in CD may be explained by a different bone formation or bone resorption, responsible for bone loss at different phases of the disease process¹⁸. The patients of the present study were homogeneous according to disease activity, disease duration, steroid use and menopausal status. In only one study a comparable population of 20 male CD patients with quiescent long-standing CD was studied²⁰. In this study, normal bone turnover was found. The differences in outcome with the present study can possibly be explained by demography and some clinical features (only male patients were involved; patients with more than five bowel movements per day were excluded, fewer patients had been resected (55% versus 73%); and the disease duration was markedly shorter, mean of 10 vs. 16 years, respectively). Biochemical markers used were different in both studies, except for osteocalcin. In

the same study, fractional calcium absorption was not different from that of controls.

In patients with CD and with ileopathy, due either to inflammation or to previous resection, bile acid and fat malabsorption is prevalent, causing steatorrhoea and malabsorption of fat-soluble vitamins. This is suggested in the present study by the inverse correlation between CDAI and BMI, body fat and serum vitamin D level, respectively. A low urinary calcium excretion can be a consequence of vitamin D deficiency, which was prevalent in this group of patients (35%). The mean age of the controls for the DPD and CTX measurements was lower than the mean age of the patients. If there had been a significant influence of increasing age, a higher bone resorption would have been expected; however, this was not the case.

It is not possible to determine, on the basis of DXA measurements, whether mineralisation defects also contribute to low bone mineral density. In the present patient group, clinical signs of osteomalacia as bone pain or muscle weakness were absent. Furthermore, the serum BAP level, which is a sensitive indicator of osteomalacia, was generally low. The patient with the highest BAP level had a normal serum 25-hydroxyvitamin D level.

The low bone formation, but normal bone resorption, found in this study indicates an unbalanced bone turnover, eventually leading to osteopenia and osteoporosis, which is already prevalent in about 40% of these patients. In CD, therapy should be directed to the prevention of bone loss and/or to the restoration of BMD in patients with low BMD values. Low bone formation points to a lower activity level of osteoblasts. Osteoblast growth and function, cellular life span and eventual apoptosis are influenced in a complex way by several hormones, circulating cytokines and growth factors^{41,42}. A pharmacological agent capable of stimulating bone formation through a direct effect on osteoblastic activity is sodium fluoride, which has been extensively investigated in postmenopausal women⁴³. Recently, von Tirpitz et al. presented the results of a study that demonstrated a positive effect of a slow release fluoride formulation versus placebo on BMD, also in CD⁴⁴. Therefore, this might be an option for patients with long-standing CD and osteopenia, although the quality of bone after fluoride use is still a subject of debate⁴⁵. It has been demonstrated in vitro that other agents, such as bisphosphonates and calcitonine, can prevent osteoblast and osteocyte apoptosis⁴⁶. Treatment with alendronate significantly improves lumbar spine BMD in patients with Crohn's disease compared to those taking placebo. Furthermore, biochemical markers of bone turnover decreased significantly in the alendronate group compared to those taking placebo⁴⁷.

In summary, the finding of a pathologic bone turnover in patients with long-standing Crohn's disease in remission, in absence of main risk factors for bone loss, i.e. corticosteroids and active disease, may be of importance for future preventive and therapeutic action. In these patients therapy should be directed towards the stimulation of bone formation and the prevention and treatment of vitamin D deficiency.

References

- 1 Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995;108:417-422.
- 2 Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987;28:410-415.
- 3 Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992;37:1396-1403.
- 4 Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. *Eur J Gastroenterol Hepatol* 1995;7:609-614.
- 5 Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). *Exp Clin Endocrinol* 1994; 102:44-49.
- 6 Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. *Scand J Gastroenterol* 1997;32:1247-1255.
- 7 Deal CL. Osteoporosis: prevention, diagnosis, and management. *Am J Med* 1997; 102:355-395.
- 8 Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997;40:313-319.
- 9 Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. *J Rheumatol* 1997;24:1215-1217.
- 10 Bischoff SC, Herrmann A, Goke M, Manns MP, von-zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. *Am J Gastroenterol* 1997; 92:1157-1163.
- 11 Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997; 40:228-233.
- 12 Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. *Gut* 1996;38:223-228.
- 13 Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 1998;4:268-275.
- 14 D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. *Aliment Pharmacol Ther* 1998;12:419-424.
- 15 Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. *Am J Gastroenterol* 2000;95:699-704.
- 16 Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. *J Intern Med* 2000; 247:63-70.
- 17 Dinca M, Fries W, Luisetto G, et al. Evolution of osteopenia in inflammatory bowel disease. *Am J Gastroenterol* 1999;94:1292-1297.
- 18 Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. *Osteoporos Int* 1995;5:156-160.
- 19 Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. *Gastroenterology* 2000;119:1203-1208.
- 20 Martin A, Fries W, Luisetto G, et al. Bone density and calcium metabolism in patients with long-standing quiescent Crohn's disease. *Eur J Gastroenterol Hepatol* 1994;6:611-616.
- 21 Robinson RJ, Iqbal SJ, Abrams K, Al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. *Aliment Pharmacol Ther* 1998;12:699-705.

- 22 Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997;24:289-295.
- 23 Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989;170:2-6.
- 24 Best WR, Beckett JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976;70:439-444.
- 25 Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36:936-942.
- 26 Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. *J Clin Endocrinol Metab* 1993;77:1046-1053.
- 27 Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. *Clin Chem* 1994;40:2022-2025.
- 28 Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. *J Clin Endocrinol Metab* 1995;80:864-868.
- 29 Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. *J Bone Miner Res* 1994;9:1643-1649.
- 30 Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. *Clin Chem* 1993;39:529-533.
- 31 Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. *Am J Clin Nutr* 1990;51:1106-1112.
- 32 Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson HB, Baran D et al. Spine and femur density using dual-photon absorptiometry in US white women. *Bone Miner* 1987;2:211-219.
- 33 Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? *BMJ* 1989;298:924-928.
- 34 Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. *Osteoporos Int* 1992;2:135-140.
- 35 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
- 36 Croucher PJ, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. *Osteoporos Int* 1993;3:236-241.
- 37 Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. *J Bone Miner Res* 1996; 11(10):1531-1538.
- 38 Melton LJ, III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. *J Bone Miner Res* 1997;12:1083-1091.
- 39 Riggs BL, Melton LJ, III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. *Bone* 1996;18:197S-201S.
- 40 Riggs BL. Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? *Bone* 2000;26:551-552.
- 41 Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. *J Bone Miner Res* 1998;13:793-802.
- 42 Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. *J Bone Miner Res* 1999;14:1061-1066.
- 43 Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. *Rheumatol Int* 1997;17:45-48.

- 44 von Tirpitz C, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease [In Process Citation]. *Eur J Gastroenterol Hepatol* 2000;12(1):19-24.
- 45 Lips P. Fluoride in osteoporosis: still an experimental and controversial treatment. *Ned Tijdschr Geneesk* 1998;142:1913-1915.
- 46 Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. *J Clin Invest* 1999;104:1363-1374.
- 47. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. *Gastroenterology* 2000;119:639-646.

CHAPTER 8

Osteoporosis and spontaneous vertebral fractures in Crohn's disease: size of the problem and risk factor analysis in a large European study population

RW Stockbrügger, EJ Schoon, S Bollani, PR Mils, E Israeli, L Landgraf, D Felsenberg, S Ljunghall, G Nygard, T Persson, H Graffner, G Bianchi Porro, A Ferguson¹, on behalf of the MATRIX Study Group

Submitted for publication

Abstract

Background

A high prevalence of osteoporosis has been noted in Crohn's disease (CD), but data about fractures are scarce.

Methods

Potential risk factors for low bone mineral density (BMD) and the prevalence of vertebral fractures were studied in 273 patients with ileocecal CD before randomization into a large European/Israeli intervention study. One-hundred and eighty-two steroid-free patients (STF) with currently active CD and 91 steroid-dependent patients (STD) with quiescent CD were investigated with DXA scan of the lumbar spine and standardized lateral X-ray of the thoracic and lumbar spine.

Results

Thirty-seven asymptomatic fractures were seen in 24/179 STF patients (13.4 %; 27 wedge, 10 concavity), and 19 fractures in 14/90 STD patients (15.6 %; 14 wedge, 5 concavity). The average T-score and Z-score of patients with fractures were not significantly different from those without fractures (-0.707 vs. -0.794 ($p = 0.07$), and -0.323 vs. -0.562 ($p = 0.30$), respectively). 54 % of patients with fractures had a normal T-score. BMD and Z-scores were negatively correlated to lifetime steroids, but not to previous bowel resection, or current disease activity. Fracture rate was not correlated with BMD ($p = 0.65$), Z-score ($p = 0.32$), or lifetime steroid dose ($p = 0.85$).

Conclusions

The lack of correlation between BMD, Z-score, or lifetime steroid dose on the one hand and the prevalence of fractures on the other necessitates new hypotheses for the pathogenesis of the latter.

Introduction

As late as in the early 1990s, inflammatory bowel disease (IBD) did not appear in the list of causes of secondary osteoporosis in authoritative reviews or textbooks. However, in recent years a multitude of articles have been published indicating that osteopenia and osteoporosis are frequent in IBD^{1,7}, more so in Crohn's disease (CD) than in ulcerative colitis (UC)^{8,9}. In the published literature the prevalence of osteopenia in IBD varies widely between 7% and 70%. So far, only a few studies have assessed the natural history over longer periods of time¹⁰⁻¹⁵. There are many discordant results regarding the risk factors and pathogenesis of osteoporosis in IBD, but most studies agree on the important negative effect of steroid treatment on BMD^{2,7-9,16-19}. The variation between study results can probably be explained by differences in the patient population, disease duration, cumulative disease activity, previous medical and surgical treatment, dietary status, and smoking habits. So far, there are no studies regarding the relationship of BMD and fractures in IBD.

The present study describes the degree of osteopenia and osteoporosis and the prevalence and localization of radiologically established vertebral fractures in a large and well-characterized multi-national group of patients with ileo-cecal CD, either with active disease presently in need of oral steroid medication, or with quiescent disease activity following protracted steroid medication. The bipolar study population reflects frequent management situations in Crohn's disease. The data published here represent the baseline of the international MATRIX study ("Effect of long-term treatment with Entocort (budesonide CIR) capsules and prednisolone on bone density, bone metabolism and osteoporosis in patients with Crohn's disease using dual energy X-ray absorptiometry"). In that study the therapeutic effect of both compounds will also be seen in relationship to vertebral fractures.

Patients and Methods

Study design and patients

The MATRIX study started in 1996, and is a multicenter European/Israeli study with a two-year inclusion period and a maximum two-year follow-up of the individual patient after the start of intervention. Between July 1996 and July 1999, 278 patients were recruited in 34 academic and non-academic centers in nine countries and 273 patients (with at least one intake of study medication) participated in the study. The inclusion and exclusion criteria are described in Table 8.1.

Table 8.1 Inclusion and exclusion criteria for MATRIX study

Inclusion criteria

Age between 20-70 years

Confirmed diagnosis of Crohn's disease (by combination of X-ray, endoscopy, histology, and scintigraphy)

Disease confined to the distal ileum, the ileo-cecal region and/or the ascending colon

For the steroid-free (STF) group: patients not having received steroids during 6 months before study entry and having an active disease (CDAI > 150)

For the steroid-dependent (STD) group: patients having received 7-20 mg/day of steroids for at least 4 out of 6 months immediately prior to inclusion in the study and having quiescent disease (CDAI ≤ 200)

Signed informed consent

Exclusion criteria

Pregnancy or breast-feeding

Hypersensitivity to budesonide or other glucocorticosteroids

Previous gastric surgery (except for closure of a perforation or selective vagotomy)

Ileostomy, colostomy or pouch

Small bowel resection exceeding 100 cm

Any resection distal to the mid-transverse colon

Disease proximal to the ileum

Active Crohn's disease in the rectum (verified by rectoscopy)

Complicated Crohn's disease (abscess, obstruction, perforation, active fistulas)

Dependence on either parenteral or enteral nutrition

Indication for immediate surgery

Active systemic infection

Clinically relevant renal, hepatic, cardiovascular or psychiatric disease

Uncontrolled diabetes mellitus

Active peptic disease

Rheumatoid arthritis

Ankylosing spondylitis

Primary sclerosing cholangitis

Hyperparathyroidism

History of gastrointestinal malignancy or high grade dysplasia within the last 5 years

Alcohol or drug abuse

Use of NSAIDs chronically (> 3 days consecutively)

Start of therapy with azathioprine, 6-mercaptopurine or methotrexate less than 3 months prior to visit 1

Treatment with cyclosporine within the month prior to visit 1

Start of therapy with cholestyramine during the 2 weeks prior to visit 1

Start of hormone replacement therapy less than 6 months prior to visit 1

Treatment with calcitonin and/or bisphosphonates within the last 6 months

Treatment with fluoride, androgens, anabolic steroids, active metabolites of vitamin D within the last 6 months

Treatment with oral ketoconazole within 7 days prior to visit 1

Exposure to live viruses or live bacteria within 3 months prior to visit 1

Demographic and clinical data.

The demographic and clinical data recorded for all patients included gender, age at time of investigation, age at diagnosis of CD, extent of CD (including localization and extent of previous operations), current medication for CD and for non-related diseases, cumulative steroid dose, current steroid dose in the STD group, current Crohn's Disease Activity Index (CDAI)²⁰, body mass index (BMI), and a physical activity index²¹. A smoking history (non-smokers, ex-smokers, and smokers) and a menstrual history (pre-and post-menopausal female, hormone replacement therapy) were also obtained. At the screening visit approximately 20 ml blood was collected and analyzed at each study center: b-hemoglobin, b-hematocrit, b-leukocyte concentration, b-platelets, s-alkaline phosphatase, s-albumine, and b-ESR. A number of markers of bone metabolism, including osteocalcin, pyridinoline cross links, and parathyroid hormone, were assessed in either blood or urine. The preliminary findings of this part of the study have been presented elsewhere²².

Radiography of the thoracic and lumbar spine.

An posterior- anterior radiograph of the thoracic and lumbar spine was taken at the patient's clinical center following a study-specific procedure manual applying the EVOS (European Vertebral Osteoporosis Study) recommendations^{23,24}. Radiographs were sent with a coded identification to two expert radiologists (L.L., D.F.) who assessed the findings unaware of relevant clinical or laboratory data. In the radiological assessments, vertebrae with an osteoporotic deformation and a height reduction of more than 20 % were considered fractured. In borderline cases morphometric evaluation (6-point-measurement) of the suspected vertebrae was performed using the algorithm of Felsenberg with a threshold of 80% (Figure 8.1)²³. Osteoporotic vertebral fractures were subdivided into wedge, concavity, biconcavity, and crush fractures. Vertebral fractures or deformities with an etiology other than osteoporosis (for example degenerative deformities or traumatic fractures) were not included in the assessment.

Bone Mineral Density

Bone mineral density (BMD) of the lumbar spine (posterior/anterior), the left femoral neck, and the total body was measured using dual X-ray absorptiometry (DXA) (Hologic QDR 1000 W, 1500, 2000, 2000 plus, 4000 (Hologic Inc., Bedford MA, USA); or Lunar DPX, DPX/L, or DPXplus (Lunar Inc., Madison WI, USA). All scans were performed according to the manufacturers' instructions. A study-specific Quality Assurance and Procedures manual was distributed by a central quality assurance program provider (Synarc/MDM Hologic, Maynard MA, USA). All DXA scans were stored on floppy discs and sent to Synarc/MDM Hologic for centralized review and data collection.

DXA results were expressed as BMD in absolute values (g/cm^2), as gender-controlled *T*-scores using the WHO criteria definition ("normal" less than 1 standard deviation (SD) below the mean for the reference population, "osteopenia" between 1 SD and 2.5 SD below the mean, and "osteoporosis" more than 2.5 SD below the mean²⁵, and as age- and gender-controlled Z-scores. Mean BMD from at least three

evaluable vertebrae (four when available) from L1 to L4 was used. For the purpose of this study only the lumbar spine results are referred to, in order to enable correlation with lumbar X-ray findings.

Figure 8.1 Vertebra with fracture of inferior endplate (6-point measurement)

Statistical analysis

BMD was calculated by dividing the total bone mineral content by total area. Fractured vertebrae as seen on the X-ray were excluded (one vertebra for each of 15 patients). For the sake of comparability with Hologic data, Lunar data were transformed using the formula: new BMD value = (0.906 x Lunar value) minus 0.025. T-scores and Z-scores were calculated from BMD values using formulae supplied by Synarc/ MDM Hologic.

Means were compared with Student's t-test, and chi-square test was used for the distribution of T-scores. Correlations were assessed using Spearman rank correlations. Analyses involving several independent variables to explain one dependent variable were done as analysis of covariance and multiple regression with backward selection of variables.

Results

Demographic and clinical baseline data

As defined by the study entry criteria, the subgroups of steroid-free (STF) and steroid dependent (STD) patients were significantly different in their clinical presentation (Table 8.2). The STF group had a higher disease activity, a shorter duration of disease, a shorter time since the last exacerbation, and – most importantly – a lower life-time dose of corticosteroid (100 out of the 182 STF patients had never had any corticosteroid treatment for their bowel disease). The groups were similar regarding data such as gender distribution, smoking habits and hormone replacement therapy in female patients. Age was significantly lower in the STF group, and therefore Z-scores were applied in the evaluation when necessary. Five patients aged 17-19 years were erroneously included as was one patient with 4 fractures. They are all included in the analyses of this paper.

Table 8.2 Demographic and clinical characteristics of 273 treated patients

	STF (n = 182)	STD (n = 91)	p-value
men / Women	86 / 96	48 / 43	NS
mean age (range)	35.6 (17-67)	39.0 (20-69)	0.034
CDAI (SD)	327 (69)	132 (57)	
mean disease duration, yr	5.7	8.2	0.0096
time since last exacerbation, mo	5.0	8.8	0.0069
bowel resection	34%	29%	NS
life-time prednisolone, mg (SD)	1600 (3300)	13100 (14600)	< 0.001
postmenopausal women	17	13	NS
hormone replacement therapy	8	3	NS
active smokers	90 (49%)	43 (47%)	NS
non-smokers	66 (37%)	31 (34%)	NS
ex-smokers	26 (14%)	17 (19%)	NS
physical activity index	14.3	13.5	0.043
body mass index, kg/m ²	22.2	23.8	0.0023

STD = steroid-dependent patients; STF = steroid-free patients

Bone Mineral Density

BMD, T-scores, and Z-scores are shown in Table 8.3. In absolute values, BMD was about five per cent higher in the STF group than in the STD group, this difference being highly statistically significant. The subgroup difference was also apparent in the distribution of patients with normal BMD, osteopenia and osteoporosis: nearly two thirds of the STF patients had a normal BMD, compared with less than half of

the STD patients. Applying a chi-square test, the difference in distribution of T-scores was significant ($p = 0.0079$). The age-corrected Z-score was also significantly higher in the STF group than in the STD group ($p = 0.0032$).

Table 8.3 Bone mineral density in 179 steroid-free (STF) and 90 steroid-dependent (STD) patients with Crohn's disease.			
	STF (n = 179)	STD (n = 90)	p-value
BMD values (mean (SD))	(0.16)	0.95 (0.17)	0.0018
T-score (mean (SD))	-0.61 (1.25)	-1.13 (1.25)	0.0014
Z-score (mean (SD))	-0.37 (1.23)	-0.86 (1.29)	0.0032
T-score values	n (%)	n (%)	
T-score > -1	110 (61)	38 (42)	0.0079
T-score -1 to -2.5	56 (31)	39 (43)	
T-score ≤ -2.5	13 (7)	13 (15)	

Thoracic and lumbar fractures of the spine

A total of 56 fractures were discovered in 38 of 269 (14.1%) evaluable patients (Table 8.4a) without a significant difference regarding prevalence and type between the groups (STF: 27 wedge, 10 concavity; STD: 14 wedge, 5 concavity). Forty-one of the fractures were wedge fractures (Figure 8.1) and fifteen were concavity fractures (Figure 8.2). Biconcavity or crush-fractures were not found in the baseline radiographs. Twelve (of 98) STF patients previously never treated with steroids had vertebral fractures. These twelve steroid naive patients with fractures were not significantly different from the remaining STF patients with respect to any demographic, clinical, or laboratory data including BMD/T-score.

Table 8.4a Prevalence of vertebral fractures (fx) in 179 steroid-free (STF) and 90 steroid dependent (STD) patients with Crohn's disease.			
	STF (n = 179)		p-value
	number of fx (%)	STD (n = 90) number of fx (%)	
never steroids			
	12 / 98 (12.2)	14 (15.6)	NS
previous steroids	12 / 81 (14.8)		

In men the fracture rate tended to be generally higher than in women (Table 8.4b), and was similar in all age groups; in women, a significant increase in fracture rate was observed with increasing age ($p = 0.0037$; linear regression analysis) with a sharp rise in the postmenopausal period (Figure 8.3). Regarding localization of fractures, prevalence peaks were found in the middle thoracic spine and thoracic-lumbar junction for wedge fractures, and in the thoracic-lumbar junction and lumbar spine for concavity fractures (Figure 8.4).

Figure 8.2 Two vertebrae with wedge fracture

Table 8.4b Total number of patients with fractures (fx) and number of patients with fractures (fx) divided by sex and age groups.

	total	age 17-30	31-40	41-50	51-60	61-69
patients	269	110	63	46	34	16
patients with fx	38 (14%)	12 (11%)	8 (13%)	7 (15%)	6 (18%)	5 (31%)
women	135	49	36	27	16	7
women with fx	17 (13%)	3 (6%)	4 (11%)	4 (15%)	3 (19%)	3 (43%)
men	134	61	27	19	18	9
men with fx	21 (16%)	9 (15%)	4 (15%)	3 (16%)	3 (17%)	2 (22%)

Note: Four patients (all women) had no evaluable x-rays

Figure 8.3 Prevalence of vertebral fractures in 269 patients with Crohn's disease by sex and age group.

Correlations between demographic and clinical data, BMD, and spinal fractures

In the study population as a whole, the BMD, T-score, and Z-score were negatively correlated to lifetime steroid dose ($p < 0.001$, $p < 0.001$, $p = 0.0012$, respectively), but not to previous bowel resections or current disease activity. Men had significantly lower T-scores (-1.03 vs. -0.54 ; $p = 0.0013$) and Z-scores (-0.91 vs. -0.18 , $p < 0.001$) than women.

The fracture rate was not significantly influenced by smoking, bowel resections or current disease activity. Only in women was there a positive association with age: women above the age of 50 years had significantly more fractures than women below that age ($p = 0.049$); however, the fracture rate of women above 50 years was not significantly higher than that of men above 50 years of age.

Fracture rate was not correlated with BMD ($p = 0.68$), T-score ($p = 0.80$), or Z-score ($p = 0.32$) in the patient group as a whole, not even in the subgroup of postmenopausal women ($p = 0.74$ for T-score and $p = 0.98$ for Z-score). The mean lumbar T-score of the 38 patients with fractures was -0.707 ± 1.393 and that of the remaining 231 patients without fractures -0.794 ± 1.262 ($p = 0.70$); corresponding figures for Z-scores were -0.323 ± 1.375 vs. -0.562 ± 1.277 ($p = 0.30$). Fifty-four per cent of the patients with fractures had a normal T-score.

In multiple regression analysis, none of the following factors was found to independently determine the prevalence of vertebral fractures: gender; age; age at disease onset; previous resection; life-time steroid dose; current CDAI; STF or STD group.

Figure 8.4 Prevalence of vertebral fractures in 269 patients with Crohn's disease by type and localization.

Discussion

In this study of 273 patients with either currently steroid-free and active or currently steroid-treated and inactive Crohn's disease, the prevalence of osteopenia and osteoporosis has been investigated simultaneously with a radiological assessment of spinal fractures. Overall, a reduced BMD (expressed as T-score < -1) was seen in about 46% and vertebral fractures in about 14% of the patients. BMD was significantly lower in the STD group than in the STF group, and consequently a negative correlation between lifetime steroid dose and BMD emerged. Surprisingly, the fracture rate was similar in both subgroups and was not correlated to the BMD of the lumbar spine.

The entry of patients into this study attempted to match as closely as possible the everyday clinical use of steroids in CD, namely either patients who are considered for steroid treatment because of recent exacerbation (STF patients) or protracted treatment of steroids (> 3 months) in patients who are currently unable to stop prednisolone. Both patients groups were refractory to treatment with mesalamine and/or azathioprine only but not under consideration for surgery (STD patients). The multi-center participation in the study allowed a representative population of CD patients to be obtained. At the same time, strict definition of inclusion criteria, uniform collection of demographic and clinical data, and standardized morphological investigations allowed valid comparisons between such data and the prevalence of low BMD and fractures to be made. For the assessment of possible risk factors for osteopenia/osteoporosis and fractures, it was an advantage that a number of confounding clinical conditions were excluded at study entrance. The two subgroups had distinct differences: the STF patients were slightly younger, had a shorter history of CD and a lower life-time dose of steroids, although now in

need of steroid treatment because of a moderate to high disease activity. In this group of patients with active disease at the time of inclusion, the proportion of patients with osteopenia (30%) was comparable to the prevalence of most cross-sectional studies^{1-3,16,17,26}. The combined prevalence of osteopenia and osteoporosis in the STD subgroup (58%), however, exceeded the reported prevalence of most comparable studies^{1-4,6,7,13,17}.

Lifetime steroid dose emerged as the strongest and possibly sole causative factor for decreased BMD in the total study group with the exemption of male sex. Other factors reported in the literature as contributors to osteopenia and osteoporosis in CD and/or ulcerative colitis (UC) were not identified in this large survey: age²⁷ (in this study corrected for with Z-scores), smoking habits²⁸, previous bowel resection²⁹, or current disease activity^{17,30}. Clearly, disease activity is suppressed in the STD subgroup due to steroid treatment, but not even in the STF subgroup a correlation was found between disease activity and BMD. One has to realize that the correlation between disease activity and BMD at any point may not be conclusive. Only a prospective cumulative registration of the CDAI over a longer period could possibly disclose whether increased systemic inflammatory activity, involving proinflammatory cytokines, is a determinant of osteoporosis^{31,34}.

To our knowledge, this is the first study using both BMD measurement by DXA and systematic radiological assessment of vertebral fractures in a large group of CD patients. Overall rates of spinal fracture around 14% from appear high in this generally young patient population. The prevalence of vertebral fractures increases up to 43% in female patients above 60 years, however, this group was small (7 patients). The present study suffers from a drawback: it cannot compare fracture rate with an age- and gender- matched population from a comparable geographic area. The best comparison for the present study stems from the European Vertebral Osteoporosis Study (EVOS) in which community-based subjects above the age of 50 years were investigated, showing a crude prevalence of low BMD deformities in men and in women of about 10% in the age of 50 to 65 years³⁵. The same radiological method recommended by EVOS was applied in the present study. Fractures were subdivided into wedge fractures and concavity fractures, the former being significantly more frequent than the latter. In a previous study only symptomatic patients had X-rays of the spine⁹. In another small cross-sectional study a fracture rate of 7% was reported, but data of patients with ulcerative colitis and Crohn's disease were not differentiated¹. Recently, a large well-controlled clinical-epidemiological study, based on hospital records, has shown that the relative risk of CD patients developing symptomatic vertebral fractures is increased overall by about 50% compared to the background population³⁶. Another study reported an increased risk of low energy fractures in CD compared to controls (15.7% versus 1.4%, respectively), which was calculated on the basis of a self-administered postal questionnaire and compared to the data of population-based controls³⁷.

The present study describes a similar prevalence of vertebral fractures in male and in female CD patients. The questionnaire study by Vestergaard et al.³⁷ reported a higher frequency in women (relative risk 2.5), but no increased risk in male patients with CD. The reason for this gender difference is unclear³⁸: it could hypothetically be caused by environmental factors, such as higher physical activity of men during

work and leisure activities. In the post-menopausal period, women overtake men with regard to fractures, even if figures are too small to draw any far-reaching conclusions. It is likely that in women in this period of life the effect of disease-induced bone damage combined with hormonally induced alterations could be responsible for the disproportionately high fracture rate³⁹.

In this large group of CD patients no correlation could be found between degree of osteopenia and vertebral fractures. This correlation has been proven in postmenopausal women⁴⁰⁻⁴³, and such a correlation has appeared to be evident, but in CD that has rarely been investigated. A potential explanation for the lack of correlation in the present study is that CD patients are more susceptible to fractures in certain biological phases such as infancy, adolescence, post-menopause, or old age. The report of Semeao et al.⁴⁴ regarding six children could be interpreted in this way, as could our findings in post-menopausal women. However, in the male patients with fractures no correlation with either disease onset or senescence could be demonstrated. Another possibility is that subclinical fractures occur during phases of active disease - whether treated with high doses of steroids or not, and whether with transient osteopenia or not - and that the bone matrix thereafter recovers, obscuring the relationship with the fracture¹⁵. As a third hypothesis we suggest that there might be more relationships than vertebral fractures and osteopenia alone. The fractures could be occurring on the basis of completely different events changing the matrix structure in the trabecular bone of these patients. The suggested micro-architectural changes in the trabecular bone may weaken the strength of the vertebra. Loss of BMD in CD is partially reversible²⁹ but not necessarily the structural changes of the trabecular bone, i.e., cortical thinning and disruption of trabecular lattice⁴⁵. Ultimately, vertebral fractures may represent a further extra-intestinal manifestation of IBD, comparable to primary sclerosing cholangitis (PSC) or pyoderma gangraenosum, which occur nearly exclusively in patients with IBD but behave surprisingly independently of the natural or treated course of the bowel disorder.

This phenomenon needs further investigation, and it may be necessary to obtain bone biopsies in various phases of CD activity and treatment to improve our understanding of the vertebral fractures so frequently found.

The interventional study (MATRIX) that followed this baseline investigation will reveal whether budesonide in modified-release capsules is as able to suppress activity in CD and to maintain a prednisolone-induced quiescent disease state without causing further deterioration the bone matrix or leading to additional fractures.

In summary, this study demonstrated a high prevalence of osteopenia and osteoporosis in patients with CD, more in the steroid-dependent than in the steroid-free patients. Lifetime steroid dose was the factor most strongly correlated to a reduced BMD, which may be a causative relationship and/or an expression of a high cumulative disease activity. The high frequency of vertebral fractures and the lack of correlation with osteopenia necessitate further investigation.

References

1. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995;108:417-422.
2. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997;40:228-233.
3. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987;28:410-415.
4. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy MT, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992;37:1396-1403.
5. Robinson RJ, al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998;43:2500-2506.
6. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl* 2000;35:43-47.
7. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995;37:71-76.
8. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994;107:1031-1039.
9. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997;40:313-319.
10. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ, Compston JE. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. *Scand J Gastroenterol* 1992;27:1055-1060.
11. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. *Am J Gastroenterol* 2000;95:699-704.
12. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. *Gut* 1988;29:1332-1336.
13. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. *Bone Miner* 1993;23:95-104.
14. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, Amor B, Couturier D. Bone loss in patients with inflammatory bowel disease: a prospective study. *Osteoporos Int* 1995;5:156-160.
15. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. *Scand J Gastroenterol* 1999;34:696-702.
16. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. *J Bone Miner Res* 1995;10:250-256.
17. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. *Am J Gastroenterol* 1997;92:1157-1163.
18. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. *J Intern Med* 1998;243:123-126.
19. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am J Gastroenterol* 1998;93:1483-1490.
20. Best WR, Beckett JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976;70:439-444.

21. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36:936-942.
22. Bollani S, Schoon EJ, Mills P, Goldin E, Ljunghall S, Vatn M, Persson T, Stockbrugger RW, G.Bianchi Porro. Bone matrix metabolism in ileo-cecal Crohn's disease. Does disease activity matter ? *Gastroenterology* 2001;120:A 626.
23. Felsenberg D, Wieland E, Gowin W, Armbrrecht G, Bolze X, Khorassani A, Weingarten U. Morphometric analysis of roentgen images of the spine for diagnosis of osteoporosis-induced fracture. *Med Klin* 1998;93 Suppl 2:26-30.
24. Kiel D. Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. *J Bone Miner Res* 1995;10:518-523.
25. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
26. Tromm A, Rickels K, Huppe D, Wiebe V, May B. Osteopenia in chronic inflammatory bowel diseases. Results of a cross-sectional study using quantitative computerized tomography. *Leber Magen Darm* 1994;24:23-30.
27. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am J Gastroenterol* 1999;94:824-828.
28. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. *Scand J Gastroenterol* 1996;31:367-371.
29. Compston JE, Ayers AB, Horton LW, Tighe JR, Creamer B. Osteomalacia after small-intestinal resection. *Lancet* 1978;1:9-12.
30. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997;24:289-295.
31. Fiocchi C. Production of inflammatory cytokines in the intestinal lamina propria. *Immunol Res* 1991;10:239-246.
32. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997;24:361-362.
33. MacDonald BR, Gowen M. Cytokines and bone. *Br J Rheumatol* 1992;31:149-155.
34. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. *N Engl J Med* 1988;318:818-828.
35. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Masaryk P, Pols HA, Poor G, Reid DM, Scheidt-Nave C, Weber K, Varlow J, Kanis JA, O'Neill TW, Silman AJ. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. *J Bone Miner Res* 1997;12:1883-1894.
36. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med* 2000;133:795-799.
37. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000;46:176-181.
38. Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? *Osteoporos Int* 2000;11:153-157.
39. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. *N Engl J Med* 1998;339:733-738.
40. Hui SL, Slemenda CW, Johnston CC, Jr. Baseline measurement of bone mass predicts fracture in white women. *Ann Intern Med* 1989;111:355-361.
41. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-1259.
42. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. *Ann Intern Med* 1991;114:919-923.

43. Takahashi M, Kushida K, Naitou K. The degree of osteoporosis in patients with vertebral fracture and patients with hip fracture: relationship to incidence of vertebral fracture. *J Bone Miner Metab* 1999;17:187-194.
44. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997;112:1710-1713.
45. Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P. Bone structure in patients with low bone mineral density with or without vertebral fractures. *J Bone Miner Res* 2000;15:1368-1375.

CHAPTER 9

General discussion

Introduction

Osteoporosis has become a well-known complication in IBD, and a subject of increasing interest and awareness to clinicians. Osteoporosis is defined as a decreased bone mass, but also indicates changes of architectural structure leading to an increased fragility of bone¹. When, in patients with Crohn's disease, the many potentially contributing factors to low bone mineral density are taken into consideration the term metabolic bone disease seems more appropriate in this context. Osteomalacia is a part of the metabolic bone disease in IBD, but it has only a moderate contribution, even when it is studied by histomorphometric analysis in selected subgroups at risk²⁻⁴.

Prevalence of osteoporosis in IBD

A high prevalence of osteoporosis and osteopenia was found in the population-based study on BMD in CD described in this thesis⁵. BMD was significantly lower in the hip compared to the lumbar spine, which had also previously been demonstrated in other studies⁶⁻⁸. In elderly persons the relatively higher BMD-values of the lumbar spine could have been influenced by artefacts, e.g. of degenerative abnormalities or fractures. This is unlikely in this predominantly young patient population. However, X-rays of the lumbar spine were not regularly taken in order to exclude such abnormalities. The lower BMD in the femoral neck compared to the lumbar spine and the slightly higher risk for decreased BMD in male patients with Crohn's disease indicate the presence of a different pathophysiologic mechanism for low BMD to that of senile osteoporosis and purely corticosteroid-induced osteoporosis. The risk of osteoporosis increases in female patients after menopause as expected from the knowledge of the normal population. In our study, an age of onset of CD below 18 years of age was found to be a significant risk factor for low BMD⁵. Therefore, patients who develop the disease at young age have a lower chance of reaching an adequate peak bone mass and should be monitored⁹⁻¹¹.

Risk factors for osteoporosis in IBD

Patients with IBD have disease and treatment related risk factors for osteoporosis in addition to the risk factors that are present in the general population. In the two largest cross-sectional studies on risk factors of osteoporosis in CD patients, published so far, low body weight, male sex as well as current use and cumulative dose of steroids were reported as independent determinants of low BMD in one¹², and high age, male sex and low body weight in the other study¹³, respectively. Low body weight, which is the most important clinical risk factor identified so far, contributed to about 20% of the correlation with BMD. The relatively lower BMD in male patients is not very well explained so far, when extrapolating from the protective effects of oral contraceptives in young female patients and the low testosterone levels found in male CD patients independent of current corticosteroid use¹⁴.

Many other contributing factors have been mentioned, such as smoking, malabsorption, vitamin D deficiency and decreased physical activity, but their contribution is likely to be moderate. Smoking is difficult to study in a mixed population of CD and UC¹⁵, as smoking improves the disease activity in UC but worsens it in CD¹⁶.

In general, chronic use of corticosteroids is the most important cause of secondary osteoporosis¹⁷. However, the effect of corticosteroids on BMD in IBD is a subject of debate. Possible arguments in this controversy are given in Table 9.1. It is evident that BMD values assessed at one point in time reflect multiple past and present influences. In follow-up studies, the prospective bone loss of patients with well-controlled IBD, both CD and UC, is only moderate^{18,19}.

Table 9.1 Possible explanations of the controversies regarding the effects of corticosteroids on BMD in IBD.

- The multifactorial nature of the bone loss
- The difficulties of accurate retrospective calculations of steroid doses used
- The individual susceptibility of the patients to the damaging effects of corticosteroids
- The heterogeneity of the populations studied
- A reversible component during remission
- Sample size
- Confounding effects of disease activity

The study on determinants of BMD in CD described in this thesis demonstrated that the sum of all significant risk factors contributes only to a maximum of 50% to the correlation with BMD. Thus, clinical risk factors do not appear to be good predictors of bone mineral density. Therefore, in IBD the threshold for measuring of BMD by means of DXA should be low, and the result should be judged in its clinical context.

If it is not possible to test all CD patients for logistic or economic reasons, it is advisable to test the subgroups with a relatively higher risk (e.g. juvenile and post-menopausal patients).

Almost seventy percent of the population-based cohort of patients with Crohn's disease presented in this thesis had used corticosteroids during periods of disease activity. Considering the incidence and amount of corticosteroids used in this population, the prevalence of osteoporosis seems relatively low. This could be caused by protective effects, e.g. genetic or metabolic factors. An example of genetic variability influencing BMD in IBD has been described by Schulte et al.²⁰. These authors demonstrated that the presence of interleukin 6 allele, and the absence of interleukin 1 receptor antagonist allele correlated with bone loss in a mixed group of 86 UC and CD patients. Another genetic factor influencing bone metabolism could be the vitamin D receptor gene polymorphism, a gene which represents a strong positional candidate susceptibility gene for IBD²¹. It is the cellular receptor for 1,25(OH)₂ vitamin D³ (calcitriol) which has a wide range of

different regulatory effects on the immune system. Other genes influencing the type and course of IBD, are now being vigorously studied^{22,23}. In the future, it might be demonstrated that the phenotypic expression of the disease correlates with the genotype, which would facilitate predictions of outcome and may offer the possibility of choosing the appropriate treatment for the disease and facilitate anticipation of possible complications, e.g. osteoporosis.

Recently diagnosed patients with IBD

In this thesis we demonstrated in a case-control study that BMD in recently diagnosed patients with IBD was not different from controls²⁴. Furthermore, we found no significant differences in BMD between CD and UC. Our findings conflicted with the data from a previously reported study²⁵, but could be explained by methodological differences. Duration of IBD type complaints greater than six months prior to diagnosis was a negative determinant for low BMD in our study. The latter confirms the negative effects of untreated disease on BMD. We concluded that subsequent development of low BMD should be related to the disease activity and/or the treatment of IBD. In another controlled study comparing CD with UC and controls, BMD of CD patients was significantly lower than in both UC and controls²⁶. Median disease duration in CD was 10 years and in UC 7 years. In rheumatoid arthritis, in which there is another type of "inflammation associated" bone loss, this loss occurs more rapidly early in the course of the disease and correlates well with measures of inflammation and function²⁷. Thus, control of the disease activity and active diagnostic and therapeutic management, started early in the course of the disease, may be successful in preventing osteoporosis in IBD.

The role of vitamin K

The nature and significance of the relationship between vitamin K status and bone health has been debated for some years. Previously, Vitamin K deficiency was found in 18 of 58 patients (31%) with chronic gastrointestinal disease and/or resection²⁸. All patients with vitamin K deficiency had either Crohn's disease involving the ileum or ulcerative colitis treated with sulfasalazine or antibiotics.

In a study by Szulc et al., the serum levels of undercarboxylated osteocalcin correlated with hip bone mineral density in elderly women²⁹. We demonstrated that the vitamin K levels of serum and bone in CD patients were significantly decreased compared with normal controls. Undercarboxylated osteocalcin was found to be an independent risk factor for low bone mineral density of the lumbar spine whereas serum vitamin D was not³⁰. The finding that a poor vitamin K status is associated with low bone mineral density in longstanding Crohn's disease may have implications for the prevention and treatment of osteoporosis in this disorder. The fact that vitamin K inhibited bone loss in prednisolone treated rats is challenging³¹. The findings which are presented in this thesis have been discussed in two articles and require further confirmation as well as assessment of clinical consequences^{32,33}.

Bone turnover: biochemical assessment

A key to the solution of the pathophysiology of inflammation associated bone disease might be found at the cellular level of bone turnover. Bone is a living tissue in which there is a constant cycle of degradation (resorption) performed by osteoclasts and of bone formation by osteoblasts, replacing old bone with new bone. This bone turnover should be in balance; otherwise, decreased formation, increased resorption or both lead to net bone loss. Osteoblasts and osteoclasts originate from stem cells in the bone marrow and proliferate under a complex influence of growth factors, cytokines, and hormones³⁴. It has been demonstrated that cytokines directly affect bone formation and resorption as they influence the osteoblast and osteoclast function. Particularly pro-inflammatory cytokines like TNF, IL-1, and IL-6 are thought to have a pivotal role in this process^{35,36}.

The same cytokines are important in the inflammatory process in IBD³⁷. In an experimental study, serum of pediatric patients with active CD was injected into rats³⁸. Compared to controls, this serum decreased bone mass, while serum from UC patients had no such effect. These data suggest that pro-inflammatory cytokines influence bone formation and bone resorption, resulting in bone loss. The abundance of circulating cytokines in Crohn's disease plays an important role in the inflammation associated bone loss³⁹.

Recent studies have shown that pro-inflammatory cytokines stimulate the expression of osteoprotegerin ligand, a transmembrane protein of the tumor necrosis factor ligand superfamily, which is also expressed on activated T cells. Osteoprotegerin ligand stimulates osteoclast formation and activation³⁷. The T-cell activation in Crohn's disease may also be involved in the pathways of inflammation induced bone resorption.

We studied bone turnover in patients with longstanding Crohn's disease in remission, currently using no or only very low doses of prednisolone⁴⁰. Low bone formation was found, which was significantly different from controls. The results were also different from studies on bone turnover in active CD, which demonstrate an increased bone resorption⁴¹⁻⁴³. The diverse outcomes of these studies may indicate, that bone turnover is different in different phases of Crohn's disease and may depend on disease activity, corticosteroid use and menopausal status.

Vertebral fractures in Crohn's disease

In osteoporosis, the whole diagnostic therapeutic and/or preventive interest should be aimed at the prevention of fractures, which is the critical clinical endpoint⁴⁴.

Especially in Crohn's disease (CD), reports of vertebral fractures in children⁴⁵, or a child presenting with vertebral fractures as first clinical manifestation of CD⁴⁶, underline the severity of this complication. Two major epidemiological studies which used questionnaires/ or record studies found a higher relative risk of fractures which was higher than in the background population^{47,48}.

This thesis describes the result of the first study that correlates DXA scores of the lumbar spine with the presence of vertebral fractures. The results of the study indicate a high percentage of vertebral fractures in male as well as in female patients with CD. In this large group of CD patients no correlation could be found between degree of osteopenia and vertebral fractures. A potential explanation for

the lack of correlation in the present study is that CD patients are more susceptible to fractures in certain biological phases of their life. Another possibility is that subclinical fractures occur during phases of active disease, a phenomenon occurring in patients after liver transplantation⁴⁹. A third hypothesis is that the fractures may occur because of completely different events that change the matrix structure in the trabecular bone of these patients. In that way, vertebral fractures may represent a further extra-intestinal manifestation of Crohn's disease.

These hypotheses are supported by an experimental study, in which local inflammation provoked by subcutaneous talc powder injections, induced a marked trabecular bone loss in rats within 7 days⁵⁰. The pathological findings included local granulomatosis and distally, a decreased number of trabecular osteoblasts. Neither the appearance and function of osteoblasts in the vicinity of the cortical bone, nor the number of osteoclasts in the metaphysis were found to be altered. The loss of trabecular bone in granulomatosis was caused by a suppression of bone elongation and a failure of osteoblasts to form normal secondary spongiosa. This study indicates that systemic inflammation can have local effects on a particular type of bone.

For clinicians, the consequence of these findings is that they have to be aware of the potential presence of fractures, e.g. low back pain in young patients with CD. The strategy for prevention of osteoporotic complications may be changed to the short periods of the disease course where the patients are at risk of developing a fracture.

Future perspectives

More evidence is needed on the prevention and treatment of metabolic bone disease in IBD, especially in Crohn's disease in which this co-morbidity is more apparent than in UC. Nevertheless, bone loss in ulcerative colitis should be treated according to the protocols of corticosteroid-induced bone loss. Data are also lacking on optimal prevention in active Crohn's disease. For example, in ileo-cecal Crohn's disease do locally acting steroids such as budsonide (in controlled ileal release formulation), protect bone from further loss in comparison with prednisolone? Studies are now ongoing. Secondly what is the potential role of drugs such as bisphosphonates and SERM's (selective estrogen receptor modifiers) amongst others, and in which formulation? Thirdly what is the effect of using new biological agents (e.g. anti-TNF α antibodies) in the treatment IBD related bone disease? These questions raised should be studied further in randomized controlled trials of adequate sample size, and hopefully the results will shed some further light on nebulous areas concerning the treatment of patients with IBD.

References

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994;843:1-129.
2. Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. *Osteoporos Int* 1993;3:236-241.
3. Driscoll RH, Jr., Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* 1982;83:1252-1258.
4. Hesso I, Mosekilde L, Melsen F, Fasth S, Hulten L, Lund B, Lund B, Sorensen OH. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. *Scand J Gastroenterol* 1984;19:691-696.
5. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl* 2000;35:43-47.
6. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997;40:228-233.
7. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am J Gastroenterol* 1998;93:1483-1490.
8. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 1998;4:268-275.
9. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. *Gut* 1998;42:188-194.
10. Issenman RM. Bone mineral metabolism in pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 1999;5:192-199.
11. Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn's disease. *Inflamm Bowel Dis* 1999;5:161-166.
12. Robinson RJ, al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998;43:2500-2506.
13. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am J Gastroenterol* 1999;94:824-828.
14. Robinson RJ, Iqbal SJ, al Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. *Aliment Pharmacol Ther* 1998;12:21-25.
15. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. *Scand J Gastroenterol* 1996;31:367-371.
16. Russel MG, Volovics A, Schoon EJ, van Wijlick EH, Logan RF, Shivananda S, Stockbrugger RW. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. *Inflamm Bowel Dis* 1998;4:182-186.
17. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. *J Intern Med* 1998;244:271-292.
18. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. *Scand J Gastroenterol* 1999;34:696-702.
19. Olivieri FM, Piodi LP, Taioli E, Lisciandrano D, Ranzi T, Vezzoli M, Cermesoni L, Bianchi P. Bone mineral density and body composition in ulcerative colitis: a six-year follow-up. *Osteoporos Int* 2001;12:343-348.

20. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. *Gastroenterology* 2000;119:909-920.
21. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. *Gut* 2000;47:211-214.
22. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001;411:599-603.
23. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001;411:603-606.
24. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. *Gastroenterology* 2000;119:1203-1208.
25. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994;107:1031-1039.
26. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997;40:313-319.
27. Green MJ, Deodhar AA. Bone changes in early rheumatoid arthritis. *Baillieres Best Pract Res Clin Rheumatol* 2001;15:105-123.
28. Krasinski SD, Russell RM, Furie BC, Kruger SF, Jacques PF, Furie B. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. *Am J Clin Nutr* 1985;41:639-643.
29. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. *J Bone Miner Res* 1994;9:1591-1595.
30. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? *Gut* 2001;48:473-477.
31. Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. *Bone* 1993;14:813-818.
32. Compston JE. Boning up on vitamin K. *Gut* 2001;48:448.
33. Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? *Lancet* 2001;357:1995-1996.
34. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. *N Engl J Med* 1995;332:305-311.
35. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. *Lymphokine Cytokine Res* 1991;10:15-21.
36. Wallach S, Avioli LV, Feinblatt JD, Carstens JH, Jr. Cytokines and bone metabolism. *Calcif Tissue Int* 1993;53:293-296.
37. Hommes DW, van Dullemen H, Radema SA, Tytgat GN, van Deventer SJ. The role of cytokines in the pathogenesis of inflammatory intestinal diseases. *Ned Tijdschr Geneesk* 1994;138:2427-2432.
38. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997;24:289-295.
39. Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997;24:361-362.
40. Schoon EJ, Geerling BG, Van Dooren IM, Schurgers LJ, Vermeer C, Brummer RJ, Stockbrugger RW. Abnormal bone turnover in long-standing Crohn's disease in remission. *Aliment Pharmacol Ther* 2001;15:783-792.
41. Bollani S, Schoon EJ, Mills P, Goldin E, Ljunghall S, Vatn M, Persson T, Stockbrugger RW, G.Bianchi Porro. Bone matrix metabolism in ileo-cecal Crohn's disease. Does disease activity matter ? *Gastroenterology* 2001;120:A 626.

42. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. *Am J Gastroenterol* 2000;95:699-704.
43. Robinson RJ, Iqbal SJ, Abrams K, al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. *Aliment Pharmacol Ther* 1998;12:699-705.
44. Cranney A, Welch V, Tugwell P, Wells G, Adachi JD, McGowan J, Shea B. Responsiveness of endpoints in osteoporosis clinical trials--an update. *J Rheumatol* 1999;26:222-228.
45. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997;112:1710-1713.
46. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE. Osteoporosis: an unusual presentation of childhood Crohn's disease. *J Clin Endocrinol Metab* 2000;85:2122-2126.
47. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. *Ann Intern Med* 2000;133:795-799.
48. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000;46:176-181.
49. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. *Eur J Gastroenterol Hepatol* 2000;12:931-935.
50. Krempien B, Vukicevic S, Vogel M, Stavljenic A, Buchele R. Cellular basis of inflammation-induced osteopenia in growing rats. *J Bone Miner Res* 1988;3:573-582.

CHAPTER 10

Summary

Summary

This thesis describes the epidemiology, pathophysiologic aspects, and clinical aspects of metabolic bone disease in inflammatory bowel disease (IBD), especially in Crohn's disease. In all the studies bone mineral density (BMD) was measured by dual-X-ray absorptiometry (DXA) of the femoral neck, lumbar spine, and total body.

Chapter 2 reviews the current knowledge on the relation between IBD and metabolic bone disease.

In **chapter 3** the results are presented regarding the prevalence of osteopenia and osteoporosis and of symptomatic fractures in Crohn's disease of a well-defined population based cohort from the IBD South-Limburg study area. One-hundred-nineteen eligible patients were investigated. Osteopenia of lumbar spine and/or femoral neck was found in 45% of patients. Osteoporosis was found in another 13 % of patients. Mean BMD (T-score) of femoral neck was significantly lower than of the lumbar spine. Male CD patients and patients aged under 18 at diagnosis are at higher risk of having a low bone mineral density at the lumbar spine and total body. The prevalence of osteoporosis in postmenopausal CD patients (29%) was significantly higher than in premenopausal patients (3%) (Odds ratio: 12). Twenty-nine of 119 (24%) of patients had a history of symptomatic fractures. We concluded that osteopenia and osteoporosis are frequent in CD and should have the full attention of the treating physician.

In **chapter 4**, clinical determinants of bone mineral density are discussed in a population-based cohort of patients with Crohn's disease. Many potential risk factors for low bone mineral density were taken into consideration and were analysed. Linear regression analysis indicated both body weight and female gender as significant positive determinants of BMD, and age as well as a combined use of prednisolone and azathioprine as negative determinants. In females alone, positive determinants of BMD were: body weight and the use of azathioprine. Postmenopausal status, use of prednisolone, serum magnesium level, and the combined use of prednisolone and azathioprine, respectively, were negative determinants. In males, serum calcium level and body weight were significant positive determinants, whereas age was a negative determinant of BMD.

From this study we concluded that patients with CD, who are particularly at risk for low BMD are: the male and post-menopausal female patients, with low body weight and a history of combined use of prednisolone and azathioprine, normal or increased serum magnesium levels and a low serum calcium level. However, from the low correlation between the sum of all the risk factors and the BMD measurement in the linear regression model we concluded that clinical risk factors alone are not strong enough predictors of BMD and do not replace DXA measurements in patients with Crohn's disease.

A study investigating whether bone mineral density in patients with IBD is already low at diagnosis is described in **chapter 5**. Bone mineral density measurement of recently diagnosed patients with Crohn's disease and ulcerative colitis was measured and compared to age- and gender-matched population controls. No significant differences in bone mineral density (g/cm^2) between patients and controls were found. Also, there were no significant differences found in bone mineral density between patients with either Crohn's disease or ulcerative colitis. Multiple linear regression analysis revealed that duration of complaints longer than six months before diagnosis, age, and body mass index lower than 20 kg/m^2 significantly correlated with low bone mineral density.

From this study we concluded that bone mineral density in recently diagnosed patients with inflammatory bowel disease was not significantly decreased compared to population controls. Subsequent development of osteoporosis in IBD patients seems to be a phenomenon related to the disease process and/or the treatment modalities.

In **chapter 6**, vitamin K status in serum and bone of patients with long-standing Crohn's disease in remission is assessed. Long-standing Crohn's disease is associated with deficiency of fat-soluble vitamins, amongst them vitamin K. Vitamin K is a co-factor in the carboxylation of osteocalcin, a protein essential for calcium binding to bone. A high level of circulating undercarboxylated osteocalcin is a sensitive marker of vitamin K deficiency. Bone mineral density was measured in 32 patients with long-standing Crohn's disease and small-bowel involvement, currently in remission and using less than 5 mg prednisolone daily. Serum levels of vitamins D and K, of triglycerides, and of total immunoreactive osteocalcin as well as undercarboxylated osteocalcin ("free" osteocalcin) were determined. The hydroxyapatite binding capacity of osteocalcin was calculated. Data were compared to an age- and gender-matched control population.

Serum vitamin K levels of the CD patients were significantly decreased compared to normative controls. "Free" osteocalcin was higher and hydroxyapatite-binding capacity of circulating osteocalcin was lower than in matched controls, indicating a low bone vitamin K status in Crohn's disease. In patients, an inverse correlation was found between "free" osteocalcin and lumbar spine bone mineral density and between "free" osteocalcin and the Z-score of the lumbar spine. Multiple linear regression analysis showed that "free" osteocalcin was an independent risk factor for low bone mineral density of the lumbar spine, whereas serum vitamin D was not.

From this study we concluded that the finding of a poor vitamin K status, associated with low BMD in long-standing Crohn's disease, could have implications for the prevention and treatment of osteoporosis in this disorder.

In **chapter 7**, the pathophysiologic process of bone turnover using biochemical markers is described in a homogeneous group of patients with Crohn's disease. Bone turnover was studied in 26 patients with long-standing quiescent Crohn's disease and small bowel involvement. Biochemical markers for bone formation (osteocalcin and bone specific alkaline phosphatase) and for bone resorption

(deoxypyridinoline -and collagen type I C-terminal crosslinks) were measured. Urinary calcium excretion was determined.

Markers for bone formation were significantly lower in patients than in controls (osteocalcin, bone-specific alkaline phosphatase), but both bone resorption markers were not significantly different. Urine calcium excretion was significantly decreased in patients compared to controls. Bone mineral density of the lumbar spine was significantly and inversely correlated with bone-specific alkaline phosphatase and collagen type I C-terminal crosslinks.

From this study we concluded that bone turnover in long-standing Crohn's disease in clinical remission was characterised by suppressed bone formation and normal bone resorption. Furthermore, urine calcium excretion was decreased. Hence, interventions and therapy should be directed towards improvement of bone formation.

In **chapter 8** the baseline data of an European multi-centre intervention study were described. Potential risk factors for low bone mineral density (BMD) and the prevalence of vertebral fractures were studied in 273 patients with ileo-cecal Crohn's disease. Steroid-free patients (STF) with currently active CD and steroid-dependent patients (STD) with quiescent CD were investigated with DXA scan of the lumbar spine and standardized lateral X-ray of the thoracic and lumbar spine.

Thirty-seven asymptomatic vertebral fractures were seen in 24 out of 182 STF patients (13.4%), and 19 fractures in 14 out of 91 STD patients (15.6%). The average T-score and Z-score of patients with fractures were not significantly different from those without fractures. Fifty-four percent of patients with fractures had a normal T-score. BMD and Z-scores were negatively correlated to lifetime steroids, but not to previous bowel resection, current disease activity, or prevalence of vertebral fractures. Fracture rate was not correlated with BMD, Z-score, or lifetime steroid dose.

From this study we concluded that the lack of correlation between BMD, Z-score, or lifetime steroid dose on the one hand and the prevalence of fractures on the other necessitates new hypotheses for the pathogenesis of the latter. The inflammatory process might cause architectural changes in the trabecular bone leading to bone fragility, or vertebral fractures might be another extra-intestinal manifestation of Crohn's disease.

In **chapter 9**, the results of above mentioned studies were discussed in the context of current literature. An opinion is given on potential future developments.

CHAPTER 11

Samenvatting

Samenvatting

Dit proefschrift beschrijft de epidemiologie, pathofysiologische aspecten, als wel klinische aspecten van osteoporose en/of metabole botziekten die optreden bij chronische inflammatoire darmziekten (IBD), met name bij de ziekte van Crohn. In alle onderzoeken die in dit proefschrift beschreven worden, is de botdichtheid van de lumbale wervelkolom, femurhals en het totale lichaam gemeten met behulp van dual-energy X-ray absorptiometry (DXA).

In **hoofdstuk 2** wordt een overzicht gegeven van de literatuur en wordt de huidige kennis omtrent het verband tussen IBD en metabole botziekten beschreven.

In **hoofdstuk 3** wordt de prevalentie getoond van osteopenie en osteoporose evenals de prevalentie van symptomatische fractures bij een goed gedefinieerde en op populatiegegevens gebaseerde groep patiënten met de ziekte van Crohn. De patiënten zijn geselecteerd uit de registratie van IBD patiënten (IBD Zuid-Limburg). In totaal werden er 119 patiënten met een gemiddelde leeftijd van 42 jaar onderzocht. Osteopenie van de lumbale wervelkolom en/of van de femurhals werd bij 45% van de patiënten gevonden. Osteoporose werd bij 13% van de patiënten vastgesteld. De gemiddelde botdichtheid van de femurhals was significant lager dan die van de lumbale wervelkolom. Mannelijke patiënten en patiënten waarbij de ziekte van Crohn voor het achttiende levensjaar werd vastgesteld hadden een hoger risico op een verlaagde botdichtheid van de lumbale wervelkolom en het totale lichaam. De prevalentie van osteoporose in post-menopauzale vrouwen met de ziekte van Crohn (29%) was significant hoger dan die in pre-menopauzale patiënten (3%, relatief risico 12). Negenentwintig van de 119 (24%) patiënten hadden symptomatische fractures in de voorgeschiedenis. Concluderend wordt gesteld dat osteopenie en osteoporose frequent voorkomen bij de ziekte van Crohn en dat preventie en behandeling van deze complicatie de aandacht van de behandelend arts behoeven.

In **hoofdstuk 4** worden de klinische determinanten van de botmineraaldichtheid beschreven in een populatie gebaseerd cohort van patiënten met de ziekte van Crohn. Er worden veel verschillende potentiële risicofactoren voor het krijgen van een lage botmassa onderzocht, zoals algemene- en voor de ziekte specifieke risicofactoren. Lineaire regressie analyse toonde aan dat zowel lichaamsgewicht als het vrouwelijke geslacht significante positieve determinanten van botmineraaldichtheid zijn en dat leeftijd zowel als het gecombineerd gebruik van corticosteroïden en azathioprine als negatieve determinanten zijn gevonden. Bij vrouwelijke Crohn patiënten waren lichaamsgewicht en het gebruik van azathioprine positieve determinanten. De postmenopauzale status en het gebruik van prednisolon, het gecombineerde gebruik van prednisolon en azathioprine en de serum magnesiumspiegel waren negatieve determinanten. Bij mannen waren

de serum calciumspiegel en het lichaamsgewicht significante positieve determinanten en de leeftijd een negatieve determinant van de botmineraaldichtheid. Uit dit onderzoek worden de volgende conclusies getrokken. Patiënten met de ziekte van Crohn die met name een verhoogd risico hebben op de aanwezigheid van een lage botmineraaldichtheid zijn: mannelijke en postmenopauzale vrouwelijke patiënten die een laag lichaamsgewicht en een voorgeschiedenis met een gecombineerd gebruik van zowel prednisolon als azathioprine, normale of hoge serum magnesium-spiegels en een lage serum calciumspiegel hebben. De lage correlatie die wordt gevonden tussen de som van alle risicofactoren en de gemeten botmineraaldichtheid in het lineaire regressiemodel laat zien dat de klinische risicofactoren een onvoldoende voorspellende waarde hebben om de DXA-meting te vervangen bij patiënten met de ziekte van Crohn.

In **hoofdstuk 5** is een onderzoek beschreven waarbij wordt onderzocht of de botmineraaldichtheid bij patiënten met IBD reeds verlaagd is bij het stellen van de diagnose. De botmineraaldichtheid van patiënten die recent zijn gediagnostiseerd met de ziekte van Crohn of colitis ulcerosa worden vergeleken met op leeftijd en geslacht uitgekozen controle personen uit dezelfde populatie (case-control).

Er werden geen significante verschillen tussen patiënten en gezonde controle personen gevonden. Ook werden er geen verschillen gevonden in botmineraaldichtheid tussen patiënten met de ziekte van Crohn en colitis ulcerosa indien het leeftijdsverschil tussen beide groepen werd gecorrigeerd door gebruik te maken van de Z-score. Multipole lineaire regressie analyse toonde aan dat de aanwezigheid van bij IBD passende buikklachten, die langer dan 6 maanden voor het stellen van de diagnose aanwezig waren, de leeftijd en een body mass index ($BMI = \text{gewicht} / \text{lengte}^2$) lager dan 20 kg/m^2 , significante determinanten waren voor een lage botmineraaldichtheid.

Uit dit onderzoek concludeerden we dat de botmineraaldichtheid van patiënten waarbij recentelijk de diagnose IBD gesteld werd, niet lager was dan van op leeftijd en geslacht gecontroleerde controle personen. Het ontstaan van osteoporose bij IBD patiënten moet daarom een verschijnsel zijn, dat gerelateerd is aan het ziekteproces en/of de behandeling van de ziekte.

In **hoofdstuk 6** wordt de vitamine K status van het serum en het bot beschreven bij een groep patiënten met langbestaande ziekte van Crohn in remissie. Langbestaande ziekte van Crohn is geassocieerd met een deficiëntie van vet oplosbare vitamines, waarvan vitamine K er één is. Vitamine K is een co-factor die noodzakelijk is voor de carboxylering van osteocalcine, een eiwit dat essentieel is bij de binding van calcium in het bot. Een hoge spiegel van ondergecarboxyleerd osteocalcine is een zeer gevoelige maat voor vitamine K deficiëntie. De botmineraaldichtheid werd gemeten bij 32 patiënten. Bij alle patiënten was de dunne-darm in het ziekteproces betrokken en de meeste patiënten hadden één of meerdere dunne-darmresecties ondergaan. Alle patiënten waren in remissie en gebruikten minder dan 5 mg prednisolon per dag. Serum spiegels van vitamine D, K en van triglyceriden, het totaal immunoreactieve osteocalcine en het ondergecarboxyleerd osteocalcine ("vrije osteocalcine") werden gemeten. Ook

werd de capaciteit om hydroxyapatiet te binden berekend. De gevonden waarden werden vergeleken met een naar leeftijd en geslacht gematchte controle groep. Serum vitamine K spiegels van de patiënten met de ziekte van Crohn waren significant lager dan die van de gezonde controles. Het "vrije" osteocalcine was hoger en de hydroxyapatiet bindingscapaciteit van het circulerende osteocalcine was lager dan in gematchte controles, hetgeen een lage vitamine K status bij de patiënten met de ziekte van Crohn indiceert. Bij patiënten werd een inverse correlatie gevonden tussen de serumspiegels van het "vrije" osteocalcine en de botmineraaldichtheid van de lumbale wervelkolom en tussen het "vrije" osteocalcine en de Z-score van de lumbale wervelkolom. Multiële lineaire regressie analyse toonde aan dat het "vrije" osteocalcine een onafhankelijke risicofactor is voor een lage botmineraaldichtheid van de lumbale wervelkolom. Voor de serum vitamine D-spiegel werd dit niet gevonden. Uit de gegevens van dit onderzoek concludeerden we dat een vitamine K deficiëntie in serum en bot en de associatie met de botmineraaldichtheid van de lumbale wervelkolom implicaties zouden kunnen hebben voor de preventie en de behandeling van osteoporose bij de ziekte van Crohn.

In **hoofdstuk 7** wordt het pathofysiologische proces van de botombouw beschreven van een homogene groep van patiënten met de ziekte van Crohn. Er werd gebruik gemaakt van meerdere biochemische merkstoffen.

Botombouw werd onderzocht bij 26 patiënten met een langdurig bestaande ziekte van Crohn en een ziekte lokalisatie in de dunne darm. De volgende biochemische merkstoffen van botombouw werden hierbij bepaald: voor botaanmaak (= formatie) osteocalcine en bot specifieke alkalische fosfatase en voor botafbraak (= resorptie) deoxypyridinoline en collageen type I C-terminale crosslinks. Tevens werd de calcium-excretie in de urine bepaald.

Merkstoffen voor botaanmaak waren significant lager bij patiënten met de ziekte van Crohn vergeleken met controlepersonen. Merkstoffen voor botresorptie waren echter niet verschillend ten opzichte van controlepersonen. De calcium excretie was significant lager bij patiënten vergeleken met de controlepersonen. De botmineraal-dichtheid van de lumbale wervelkolom was bij patiënten omgekeerd en significant gecorreleerd met het bot specifieke alkalische fosfatase en collageen type I C-terminale crosslinks.

Uit dit onderzoek werden de volgende conclusies getrokken: botombouw bij langdurige bestaande ziekte van Crohn in remissie kenmerkt zich door een verminderde botaanmaak en een normale botafbraak. De calcium-uitscheiding bij deze patiënten was verlaagd. Interventies en therapieën moeten erop gericht zijn om de botaanmaak te verbeteren.

In **hoofdstuk 8** worden de demografische gegevens, bij de aanvang vastgesteld, van een groot Europees multi-center interventie onderzoek beschreven.

Botmineraaldichtheid, potentiële risicofactoren voor het hebben van een lage botdichtheid en de aanwezigheid van wervelfracturen werden bestudeerd in een groep van 273 patiënten met ileo-coecaal gelokaliseerde ziekte van Crohn.

Patiënten die geen steroïden gebruikten met een actieve ziekte en steroïden-afhankelijke patiënten in een rustige fase van de ziekte van Crohn werden

onderzocht met behulp van een DXA en een gestandaardiseerde röntgenfoto van de thoracale en lumbale wervelkolom.

Er werden zevenendertig asymptomatische wervelfracturen gevonden bij 24 van de 179 patiënten zonder steroïden (13.4%) en 19 fracturen bij 14 van de 90 steroïden afhankelijke patiënten (15.6%). De gemiddelde T- en Z-score van patiënten met fracturen was niet significant verschillend ten opzichte van diegenen zonder fracturen. Vierenvijftig procent van de patiënten met wervelfracturen had een normale T-score. Botmineraaldichtheid en Z-score waren negatief gecorreleerd met de cumulatieve doses steroïden die een patiënt tijdens zijn leven gebruikt heeft. Er was geen correlatie tussen de botmineraaldichtheid en vroegere darmresectie, actuele ziekteactiviteit, of de prevalentie van wervelfracturen.

Fracturen waren niet gecorreleerd met botmineraaldichtheid, Z-score of de cumulatieve dosering steroïden.

Uit dit onderzoek concludeerden wij dat het ontbreken van de correlatie tussen botmineraaldichtheid, Z-score en de cumulatieve dosering steroïden die een patiënt tijdens zijn leven gebruikt heeft en de hoge prevalentie van fracturen, de noodzaak aantoont om nieuwe hypothesen op te stellen voor de pathogenese van de fracturen. Ofwel het ontstekingsproces zelf veroorzaakt mogelijk microarchitecturale veranderingen in het bot hetgeen leidt tot een verminderde botsterkte, of wervelfracturen zijn een extra-intestinale complicatie van de ziekte van Crohn.

In **hoofdstuk 9** worden de resultaten van bovenbeschreven onderzoeken besproken in de context van de huidige literatuur. Tenslotte wordt tevens een opinie gegeven over mogelijk toekomstige ontwikkelingen.

CHAPTER 12

Metabole botziekten bij chronische inflammatoire darmziekten

EJ Schoon, RW Stockbrügger

*Nederlands Tijdschrift voor Osteoporose en
andere botziekten 2000;4:75-81*

Samenvatting

Osteoporose is een bekende complicatie bij patiënten met een chronisch inflammatoire darmziekte (Inflammatory Bowel Disease, IBD). De gerapporteerde prevalentie is afhankelijk van de selectie van patiënten, van de meetmethoden en van de definities van verlaagde botmassa die gebruikt zijn in het betreffende onderzoek. De pathogenese van botverlies bij IBD is waarschijnlijk multifactorieel en wordt veroorzaakt door malnutritie, malabsorptie met vitamine D-en calcium deficiëntie, hypogonadisme, roken, ziekteactiviteit en het gebruik van corticosteroïden.

In een aantal onderzoeken is de botmineraaldichtheid (BMD) bij patiënten met de ziekte van Crohn (ZvC) gelijk aan die van patiënten met colitis ulcerosa (CU), maar anderen vinden een lage botdichtheid alleen bij de ZvC. Bij de ZvC zijn er meer risicofactoren aanwezig voor de pathogenese van osteopenie dan bij CU, waar het in het algemeen het gebruik van corticosteroïden als belangrijkste factor wordt beschouwd. Met behulp van biochemische merkstoffen wordt een verstoorde botopbouw beschreven door een verminderde botaanmaak, verhoogde afbraak, of beide, afhankelijk van de selectie van de patiënten. Recentelijk is de eerste serie beschreven van wervelfracturen bij kinderen met de ZvC. De drempel tot het meten van de botdichtheid zou bij patiënten met IBD laag moeten zijn. Er zijn slechts enkele onderzoeken over preventie en behandeling van osteoporose bij IBD beschikbaar.

De prevalentie van osteoporose bij IBD

De associatie tussen osteoporose en chronisch inflammatoire darmziekten (Inflammatory Bowel Disease, IBD) werd voor het eerst beschreven in 1964¹. Osteoporose werd in die tijd gediagnosticeerd met relatief onnauwkeurige methoden zoals radiologische tekenen van verminderde botdichtheid en de aanwezigheid van fractures. Osteopenie en groeiretardatie bij adolescenten met IBD werd beschreven door Genant in 1976².

Sinds 1987 zijn er verschillende onderzoeken gepubliceerd over de prevalentie van osteoporose en osteopenie bij IBD³⁻¹⁰. Met name sinds de introductie van dual energy X-ray absorptiometry (DEXA) is het aantal onderzoeken toegenomen. De gerapporteerde prevalentie van verminderde botmassa varieert zeer sterk van 4.4 tot 77%, en is hoger bij de ZvC dan bij CU. Er is geen algemeen gebruikte definitie van osteoporose uitgedrukt in Z-score (één standaard deviatie ten opzichte van een leeftijd en geslacht gemaakte controle groep) en daardoor kan het vergelijken van de bestaande gegevens over de prevalentie van osteoporose bij IBD nogal verwarrend zijn. Ondanks het gebrek aan uniformiteit van de aanwezige onderzoeken lijkt het duidelijk dat er een hoge prevalentie is van osteoporose en osteopenie bij IBD. Opvallend genoeg hebben mannen een hoger risico op botverlies dan vrouwen en is de botmassa van de heup in het algemeen lager dan die van de lumbale wervelkolom. Zoals in de gezonde populatie neemt ook bij IBD de kans op osteoporose significant toe na de menopauze.

De prevalentie van fractures Bij IBD is vastgesteld in vijf onderzoeken. In een studie van Compston hadden 6 van de 23 patiënten met osteoporose (26%) (in dit geval gedefinieerd als een Z-score < -2) radiologisch aanwijzingen van een of meer vertebrale compressie fractures⁵. In twee andere onderzoeken werden 5 en 7% van de patiënten wervelfractures gevonden^{3,7}. Jahnsen vond 3.3% symptomatische fractures bij de ZvC en 1.6% bij CU¹¹. Recentelijk werd een onderzoek gepubliceerd waarbij de prevalentie van symptomatische fractures bij patiënten met IBD en controles werd onderzocht met behulp van een enquête. Het aantal fractures bij vrouwen met de ZvC was verhoogd ten opzichte van controles (relatief risico 2.5), maar er werd geen verschil gevonden bij mannen met de ZvC noch tussen CU patiënten en controles¹².

De pathofysiologie van botverlies bij IBD

Bot is een levend orgaan waarin er een constante cyclus van botafbraak door osteoclasten en botaanmaak door osteoblasten aanwezig is. Een verminderde botaanmaak, een verhoogde afbraak, of beide kan botverlies veroorzaken. Deze onbalans kan leiden tot osteopenie en osteoporose. Voor het stellen van de diagnose osteomalacie is een botbiopsie noodzakelijk waarbij omgemineraliseerde botmatrix of osteoid wordt gevonden.

Histomorfometrie

De histomorfometrische veranderingen zoals die in het bot van 19 osteoporotische patiënten met IBD werden gevonden, toonden een verminderde botaanmaak. Tevens waren er aanwijzingen voor een mild mineralisatiedefect, die echter niet voldeden aan de criteria die gelden voor osteomalacie¹³. Bij 36 ongeselecteerde patiënten met de ZvC en dunne-darm resecties, werd een verlaagde trabeculaire botmassa gevonden. Er waren slechts aanwijzingen voor osteomalacie bij 2 patiënten in dit onderzoek¹⁴. Een onderzoek met patiënten na een dunne darmresectie (voornamelijk patiënten met de ZvC) toonde bij 9 van de 25 veranderingen in het bot passend bij osteomalacie. Bij 9 patiënten, geselecteerd als hoog risicopatiënt voor een metabole botziekte, was er osteomalacie bij 6 en bijkomende osteopenie bij 4 patiënten¹⁵.

Biochemische merkstoffen

Osteoblast and osteoclast functies kunnen worden gemeten door middel van biochemische merkstoffen¹⁶. Deze biochemische merkstoffen geven informatie over de botombouw die plaatsvindt in het gehele skelet. Ze zijn echter niet geschikt om de actuele botmassa te voorspellen¹⁷. Met behulp van deze merkstoffen, vinden sommige onderzoeken een verhoogde botafbraak^{4,18,19}, verminderde botaanmaak²⁰, of beide^{21,22}. In een aantal onderzoeken wordt geen verschil gevonden met controles²³⁻²⁶. De verschillen in de uitkomst van deze onderzoeken kan voor een deel worden verklaard door verschillen in patiënten selectie, ziekteactiviteit, gebruik van corticosteroiden en het includeren van post-menopauzale vrouwen^{3,4,18,21,25}. In een vergelijkend onderzoek naar de effecten van prednisolon en budesonide CIR ("controlled ileal release") bij actieve ZvC op osteoblastfunctie, gemeten met serum osteocalcine, werd een suppressie van het osteocalcine gezien door 40 mg prednisolon. Bij een equivalente dosering van 9 mg budesonide CIR trad dit fenomeen niet op²⁰. Er werd geen verschil gevonden in botafbraak gemeten met behulp van urine pyridinoline en deoxypyridinoline. Rectaal toegediende prednisolon (2 maal daags 20 mg) veroorzaakte een suppressie van de botaanmaak bij patiënten met een distale CU²⁷. Een longitudinaal onderzoek over 2 jaar bij 36 patiënten toonde dat het N-telopeptide cross-linked type-I collageen een voorspellende waarde heeft ten aanzien van het botverlies van de lumbale wervelkolom²². Een ander longitudinaal onderzoek vond geen voorspellende waarde van biochemische merkstoffen op het botverlies in 80 IBD patiënten²⁸.

Risicofactoren voor osteoporose bij IBD

Risicofactoren die bijdragen aan het ontstaan van een lage botmassa bij IBD zijn in het algemeen niet verschillend van risicofactoren bij andere aandoeningen die leiden tot secundaire osteoporose. Er zijn echter een aantal specifieke risicofactoren, die gerelateerd zijn aan de onderliggende ziekte en de behandeling daarvan. De belangrijkste risicofactoren zijn schematisch weergegeven in Figuur 12.1.

Figure 12.1 Schematisch overzicht van risicofactoren die een rol spelen bij de pathogenese van osteoporose bij IBD.

Corticosteroiden

Behandeling met corticosteroiden is in het algemeen de belangrijkste oorzaak van secundaire osteoporose. Corticosteroiden zijn effectief in de behandeling van actieve IBD, maar er zijn bij deze ziekten ook nadelige effecten op het bot. Corticosteroiden veroorzaken een negatieve calcium balans door verminderde resorptie van calcium uit de darm, verminderde vitamine D resorptie, verhogen de renale calcium excretie en veroorzaken suppressie van de geslachtshormoonproductie^{29,30}. Tevens hebben ze een suppresserend effect op de botaanmaak en veroorzaken ze een toename van de botafbraak.

In een aantal onderzoeken wordt een negatief effect van corticosteroiden op de botdichtheid van IBD patiënten gerapporteerd^{3,5,7,10,11}, analoog aan het effect van corticosteroiden bij andere chronische ziekten³¹. Bij de meerderheid van deze onderzoeken wordt deze hypothese ondersteund, maar zijn er ook tegenstrijdige gegevens. Bjarnasson vond in een populatie gebaseerd onderzoek geen correlatie tussen de BMD en het corticosteroid gebruik⁴. Een mogelijke verklaring voor deze bevinding is het uitsluiten van groepen met een hoog risico: patiënten die recentelijk (6 weken voor de DXA) nog 10 mg per dag of meer gebruikten, patiënten met een cumulatieve dosering van meer dan 25 gram en postmenopauzale vrouwen. In een populatie gebaseerd onderzoek van Silvennoinen werd een lage prevalentie van osteoporose gevonden⁹. De onderzoekers vonden wel een significante correlatie met de cumulatieve hoeveelheid corticosteroiden. In een gecontroleerd onderzoek van de BMD bij 60 patiënten met de ZvC, 60 met CU en 60 gezonde controle personen was de BMD significant lager bij patiënten met

de ZvC dan bij CU en controles. De cumulatieve hoeveelheid corticosteroïden bij patiënten met de ZvC was in dit onderzoek significant hoger¹¹. Resecties, lokalisatie en duur van de ziekte hadden geen significante invloed op de BMD. In een multivariate analyse werden body mass index en het gebruik van steroïden als belangrijkste determinanten gevonden van BMD bij de ZvC. In een longitudinaal 2 jaar durend onderzoek bij kinderen met CD werd geen verschil gevonden in BMD/body mass (index) ratio tussen patiënten met het gebruik van lage dosis prednison om de dag, in vergelijking met patiënten zonder steroïden³².

Ziekteactiviteit

Verondersteld wordt dat ziekteactiviteit zelf een belangrijke rol speelt bij de ontwikkeling van metabole botziekten bij IBD, met name bij de ZvC. Reeds bij het stellen van de diagnose bij patiënten die nooit met corticosteroïden zijn behandeld kan een significant verlaagde botmassa gevonden worden in vergelijking met patiënten met CU⁶. Het is aangetoond dat cytokinen een direct effect kunnen uitoefenen op botaanmaak en botaafbraak doordat zij de osteoblast- en osteoclastfuncties kunnen beïnvloeden. Met name pro-inflammatoire cytokinen zoals TNF, IL-1 en IL-6 worden verondersteld hier een centrale rol in te vervullen^{33,34}. Deze cytokinen spelen een ook belangrijke rol in het ontstekingsproces bij IBD³⁵. In een proefdierexperiment, waarbij ratten geïnjecteerd werden met serum van jeugdige patiënten met de ZvC, bleek dat er een sterk verminderd droog botgewicht en verminderde hoeveelheid calcium werd gevonden in vergelijking met de botten van ratten geïnjecteerd met serum van controles of CU patiënten³⁶. De exacte factoren die van belang zijn voor dit fenomeen worden verder onderzocht³⁷.

Roken

Slechts één onderzoek heeft het effect van roken op de botmassa bij IBD beschreven³⁸. Er werd een significant negatief effect van roken gevonden, met name bij vrouwelijke patiënten. Bij mannen werd geen effect van roken op de botmassa gevonden, dit was echter niet verwonderlijk omdat vrijwel alle mannen in dit onderzoek rookten.

Hypogonadisme

Hoewel het bekend is dat corticosteroïden de productie van geslachtshormoon onderdrukken, werden bij mannelijke patiënten met de ZvC lage testosteronspiegels gevonden als onafhankelijke risicofactor voor een lage botmassa. In dit onderzoek werd er een significante correlatie gevonden tussen de serum testosteron en osteocalcine spiegels. Deze correlatie was onafhankelijk van de leeftijd en het actuele gebruik van corticosteroïden³⁹. Bij vrouwelijke patiënten kan een secundaire amenorroe optreden bij het gebruik van hoge doses steroïden. Als de oestrogeen protectie na de menopauze stopt, neemt de botresorptie en daarmee de snelheid van het botverlies toe, met name in de eerste jaren.

Lichaamsgewicht

Een laag lichaamsgewicht is een risicofactor voor osteoporose in het algemeen. Bij de ZvC kan dit met name optreden door malnutritie, anorexie en door malabsorptie als gevolg van ziekteactiviteit in de dunne-darm en/of na resecties van dunne-darm met het extreme geval van een "short-bowel"syndroom. Meerdere onderzoeken bij IBD hebben aangetoond dat patiënten met een laag lichaamsgewicht of lage body mass index (kg/m^2) een grotere kans hebben op een lage botmassa^{40,41}.

Vitamine D deficiëntie

Er is een hoge prevalentie van vitamine D deficiëntie bij patiënten met de ZvC. De oorzaken zijn dunne-darmziekte, diarree, vetarm dieet, resecties en het gebruik van medicatie zoals cholestyramine. Dit kan leiden tot een verminderde calcium absorptie en veroorzaakt een negatieve calcium balans. Vitamine D status wordt gemeten door middel van de serumspiegel van het 25-hydroxy vitamine D, hetgeen de vitamine D status in het lichaam weergeeft. Ofschoon 25-OH vitamine D spiegels laag waren bij 56% van de ZvC patiënten in een populatie gecontroleerd onderzoek, was de actieve metabooliet, het 1,25-hydroxy vitamine D niet verschillend van controles^{41,42}. Uit dit onderzoek bleek de vitamine D status onafhankelijk van voedingstatus, ziektelocalisatie en voorafgaande resecties. Door vitamine D deficiëntie kan osteomalacie ontstaan. Als gevolg van hypocalcaemie kunnen, in ernstige gevallen, botpijnen, botdeformaties bij kinderen, fractures, spierzwakte en tetanie optreden. Er zijn typische radiologische veranderingen van het bot beschreven. Bij biochemische afwijkingen zoals een verhoogd parathyroid hormoon, een verhoogd (botspecifiek) alkalische fosfatase en hele lage 25-hydroxy vitamine D spiegels ($<10 \text{ nmol/l}$) zou er sprake kunnen zijn van osteomalacie en kan een botbiopsie worden overwogen. DEXA kan niet differentiëren tussen osteoporose en osteomalacie. Klinische symptomen van osteomalacie zijn echter zeer zeldzaam bij IBD¹⁵. In een onderzoek waarbij de relatie tussen vitamine D, PTH en BMD bij IBD werd onderzocht, toonden IBD patiënten lagere vitamine D spiegels dan gezonde controle personen. Vitamine D intake en PTH spiegels waren niet verschillend⁴³. Zowel serum vitamine D als vitamine D-inname en PTH waren niet geassocieerd met BMD.

Ziekte duur

In longitudinale onderzoeken bij IBD patiënten werd een verschillende mate van jaarlijks botverlies gezien. Motley beschreef de mate van BMD verlies in een jaar van de ruggenwervels met behulp van kwantitatieve computer tomografie (QCT) in 70 IBD patiënten⁴⁴. Hij vond een gemiddeld verlies van 3% per jaar. BMD van de radius werd vervolgd bij 39 IBD patiënten, met een gemiddelde follow-up van ongeveer 8 jaar⁴⁵. Het gemiddelde botverlies bedroeg minder dan 1% per jaar bij zowel mannen als vrouwen. In een kleiner onderzoek met 23 IBD patiënten met 1 jaar follow-up werd met behulp van DXA geen verschil gevonden, ondanks corticosteroid gebruik in 20 van deze patiënten⁶. Roux bestudeerde prospectief 35 patiënten met IBD met behulp van DXA gedurende een gemiddelde follow-up

periode van 19 maanden en werd een gemiddeld jaarlijks verlies van 6.2% and -0.9% gevonden, respectievelijk bij patiënten met en zonder het gebruik van steroïden, hetgeen significant verschillend was. Na colectomie bij patiënten met CU trad conform de verwachting geen botverlies meer op. Een ander longitudinaal onderzoek bij 109 ZvC patiënten en een gemiddelde follow-up van 5.5 jaar, liet slechts botverlies zien in de femurhals, die niet gerelateerd was aan corticosteroid gebruik, de duur van de ziekte, of de lengte van het gereserceerde dunne-darm segment⁴⁶. Schulte beschrijft een laag gemiddeld verlies van BMD (maximaal -1.1% ter hoogte van de Wards triangle) in een follow-up van gemiddeld 18 maanden, maar met een groot verschil tussen patiënten onderling²⁸.

Jeugdige patiënten

Jeugdige patiënten met de ZvC hebben een hoger risico op het ontwikkelen van osteoporose dan patiënten met CU⁴⁷. Behandeling met corticosteroiden en voedingsstatus zijn belangrijke determinanten van BMD bij deze patiënten⁴⁸. Behandeling van de onderliggende ziekte kan resulteren in een aanmerkelijke verbetering in botmineralisatie. Echter veel adolescente IBD patiënten bereiken een lagere piekbotmassa dan gezonde personen. In de normale populatie wordt de piekbotmassa bereikt op een leeftijd tussen 20 en 30 jaar. IBD patiënten met het begin van de ziekte op jeugdige leeftijd kunnen, indien er botverlies op gaat treden op latere leeftijd, eerder de fractuurdrempel bereiken.

Recentelijk is de eerste serie beschreven van vijf pediatrie patiënten met de ZvC en compressiefracturen van de ruggenwervels als complicatie van osteoporose⁴⁹. Ook zijn wervelfracturen als presenterend symptoom beschreven bij een kind met de ZvC⁵⁰.

Extra-intestinale ziekte

Vrouwelijke patiënten met de ZvC gelokaliseerd in het terminale ileum en bijkomende ontsteking van de sacro-iliacale gewrichten hadden een significant lagere botmassa dan patiënten met alleen ileitis terminalis ondanks dat deze laatste controlegroep een langere gemiddelde ziekteduur had⁵¹. Bij mannen is dit niet onderzocht.

Bijkomende leverziekten, zoals met IBD-geassocieerde primair scleroserende cholangitis (PSC), moeten als een sterke risicofactor voor osteoporose beschouwd worden.

Preventie en behandeling van osteoporose bij IBD

Behandelingen die het totale botverlies van jaren herstellen zijn niet beschikbaar. Om deze reden zouden er -indien mogelijk- preventieve maatregelen getroffen moeten worden. In het algemeen moet het dieet voldoende calcium en vitamine D bevatten, wordt geadviseerd het roken en excessief gebruik van alcohol te staken en voldoende lichaamsbeweging te nemen. De dagelijkse hoeveelheid elementair calcium die de voeding moet bevatten is ongeveer 1200 mg voor adolescenten en volwassenen en 1500 mg voor post-menopauzale vrouwen.

Er is slechts een zestal onderzoeken over de preventie en behandeling van osteoporose bij IBD beschreven. Botverlies werd in een groep van 75 patiënten met de zvc voorkomen door substitutie met vitamine D (1000 IE) gedurende een jaar. Bij met placebo behandelde controle patiënten trad een significant botverlies op van mediaan 7%⁵². Een niet gecontroleerd onderzoek toonde dat oestrogeen substitutie effectief is in het voorkomen van botverlies bij post-menopauzale IBD patiënten⁵³. Een prospectief gerandomiseerd onderzoek met calcium en lage dosis vitamine D versus placebo in corticosteroid behandelde IBD patiënten kon geen verschil aantonen na een jaar behandeling⁵⁴. Recentelijk werd er, ondanks het kleine aantal patiënten in het onderzoek, een significant verschil gevonden in BMD verandering tussen de patiënten met een chronisch actieve ZvC behandeld met ("slow release") fluoride versus placebo⁵⁵. Alle patiënten in dit onderzoek kregen als basistherapie calcium (1000 mg/ dag) en vitamine D (1000 IE/dag). Bij patiënten met de ZvC die gedurende een jaar lichaamsbeweging met lage intensiteit beoefenden en therapietrouw waren, was er een 3-4% toename in BMD ten opzichte van de uitgangswaarde⁵⁶. Bovengenoemde interventies zijn samengevat in Tabel 12.1.

Tabel 12.1 Interventies met geneesmiddelen en lichaamsbeweging ter preventie en behandeling van osteoporose bij chronische inflammatoire darmziekten (IBD).

auteur	geneesmiddel	aantal patiënten	studieopzet	periode (jaren)	resultaten
Vogelsang ⁵³	vitamine D 1000 IE	75 CD	open, gerandomiseerd	1	+
Clements ⁵⁴	oestrogeen	25 UC, 22 CD	open	2	+
Bernstein ⁵⁵	calcium 1000 mg, vitamine D 250 IE	14 UC, 10 CD	gerandomiseerd, placebo gecontroleerd	1	=
Tirptitz ⁵⁶	fluoride	33 CD	gerandomiseerd	1	+
Haderslev ⁵⁷	alendronaat	32 CD	gerandomiseerd, placebo gecontroleerd	1	+
overige					
Robinson ⁵⁸	lichaamsbeweging	117 CD	gerandomiseerd, placebo gecontroleerd	1	+

Gebruikmakend van de nu bekende beperkte gegevens zou iedere patiënt dieet advies moeten krijgen ten aanzien van calcium en vitamine D inname: deze zouden gesuppleerd moeten worden in het geval van vitamine D deficiëntie, het gebruik van corticosteroïden, na uitgebreide resectie van de dunne-darm of bij het chronisch gebruik van cholestyramine.

Er zijn nog geen onderzoeken gepubliceerd over behandeling met bisfosfonaten bij IBD, behoudens een onderzoek waar alendronaat werd gegeven ter preventie van osteoporose bij met corticosteroïden behandelde patiënten en een diversiteit aan onderliggende ziekten⁵⁷. Vijf procent van deze populatie betrof patiënten met

IBD. Na 48 weken therapie was er in de met 5 en 10 mg alendronaat behandelde patiënten groepen een significante toename in BMD. De onderliggende ziekte had geen effect op de respons in de subgroepanalyse, echter deze gegevens worden in het artikel niet verstrekt. De eerste onderzoeken met oraal en intraveneus toegediende bisfosfonaten bij patiënten met de ziekte van Crohn zijn recentelijk als abstract verschenen en de resultaten lijken goed.

Op basis van deze gegevens en op basis van eerder onderzoek bij post-menopauzale en corticosteroïden geïnduceerde osteoporose, zouden bisfosfonaten kunnen worden overwogen bij ieder IBD patiënt die langdurig met corticosteroïden moet worden behandeld met name degenen die bij de start van de therapie reeds een lage botmassa hebben, fracturen in de voorgeschiedenis, post-menopauzaal zijn, of bij wie de botmassa snel daalt bij opeenvolgende DEXA metingen, of een hoge botturnover met behulp van biochemische merkstoffen geïdentificeerd wordt. Preventieve behandeling bij iedere patiënt is op dit moment echter controversieel omdat er een verschillende individuele gevoeligheid is voor corticosteroïden bij patiënten met IBD. Echter osteoporose (T-score ≤ -2.5) van de heup of de lumbale wervelkolom of een laagenergetische fractuur zijn indicaties voor actieve behandeling. Bij osteopenie (T-score tussen -1 tot -2.5) zouden tenminste preventieve maatregelen genomen moeten worden. Het resultaat van de interventie moet worden vervolgd met BMD metingen in intervallen van 2-3 jaar. Tegelijkertijd is het van primair belang om de onderliggende ziekte optimaal te behandelen en indien nodig corticosteroïden te geven zo laag en zo kort mogelijk. Bij patiënten die van corticosteroïden afhankelijk zijn moet worden overwogen om steroïden-sparende en geneesmiddelen om recidieven te voorkomen, zoals azathioprine, aan de behandeling toe te voegen.

Bespreking

Bij IBD is er ondanks de verschillende meetmethoden een definitie van osteoporose voldoende bewijs voor een hoge prevalentie en hoge morbiditeit van metabole botziekten zoals osteoporose en osteopenie en in mindere mate osteomalacie. Hierbij moet het gegeven worden betrokken dat de gemiddelde leeftijd van de patiënten in de onderzochte populaties ongeveer 40 jaar is. Er zijn weinig beschikbare gegevens over symptomatische en asymptomatische fracturen en er zijn nog er geen lange termijn onderzoeken naar het optreden daarvan beschikbaar. Bij post-menopauzale vrouwen is er een goede correlatie tussen BMD en het optreden van fracturen, en deze gegevens kunnen misschien geëxtrapoleerd worden naar IBD patiënten⁵⁸.

Als methode van screenen voor een lage BMD, werd de relatie tussen de huidploidikte van de hand en gesuggereerd bij patiënten met de ZvC⁵⁹. De gemiddelde huidploidikte van de hand was significant lager bij patiënten met osteoporose in vergelijking met controle ZvC patiënten met een normale botmassa, echter de associatie was niet sterk genoeg om deze methode voor selectie van patiënten aan te bevelen.

Breedband ultrageluid metingen van de calcaneus bij een grote groep ZvC patiënten en leeftijd- en geslacht- gematchte gezonde controles toonde minder verzwakking van het ultrageluid in de patiëntengroep. Er was een significante associatie tussen de ultrageluid metingen en de BMD van de heup en wervelkolom, maar ook deze correlatie leek onvoldoende⁶⁰. Een ander onderzoek met ultrageluid toonde met name een goed correlatie met de DEXA metingen van de lumbale wervelkolom, hoewel de botdichtheid onderschat werd bij vrouwelijke patiënten met de ZvC⁶¹. Het belang van ultrageluid als methode van screenen bij IBD in de dagelijkse praktijk en de voorspellende waarde ten aanzien van het optreden van fracturen moet nog nader worden bepaald.

Tegenstrijdige uitkomsten van de effecten van corticosteroïden op het bot kunnen verklaard worden door de vele verschillende factoren die bijdragen aan het botverlies, de heterogene populaties die zijn onderzocht, de individuele gevoeligheid voor de nadelige effecten van corticosteroïden, de relatief onnauwkeurige retrospectieve berekening van cumulatief gegeven medicatie en tevens de ziekteactiviteit als confounder. Patiënten met IBD worden vaak initieel behandeld met hoge doses corticosteroïden die daarna zo snel mogelijk worden afgebouwd, met als doel een remissie te bereiken. Bij het gebruik van corticosteroïden treedt het meeste botverlies op in de eerste drie maanden van de behandeling en is er mogelijk een reversibele component na het stoppen van de therapie. Controle van de ziekteactiviteit met daarvoor geschikte middelen zou een verbetering van de botmineralisatie kunnen bewerkstelligen.

Er is behoefte aan meer kennis over de belangrijkste risicofactoren en hun interacties. Deze gegevens kunnen verkregen worden door grote, bij voorkeur op populatie gebaseerde onderzoeken. In deze context is van belang om te weten of lokaal werkende steroïden zoals budesonide een minder negatief effect hebben op bot dan prednisolon. Dit laatste word op dit moment onderzocht in een groot gerandomiseerd Europees onderzoek.

Omdat een lage botdichtheid bij ZvC reeds bij het stellen van de diagnose bij kan worden gevonden, er een hogere prevalentie en er een ander risicoprofiel is dan bij CU, moeten deze ziekten als een aparte entiteit worden beschouwd in het onderzoek, preventie en behandeling van osteoporose bij IBD.

Omdat patiënten met IBD een verhoogd risico hebben op osteoporose, zou de BMD moeten worden vervolgd om patiënten te identificeren die behandeling behoeven, om interventies te monitoren die bedoeld zijn om botverlies te voorkomen dan wel osteoporose te behandelen. Echter het hebben van één of meerdere doorgemaakte fracturen is een sterke risicofactor voor een toekomstige fractuur en moet beschouwd worden als een indicatie voor behandeling onafhankelijk van BMD. In het geval dat de mogelijkheid niet aanwezig is om botdichtheid te meten zou de patiënt voor behandeling geselecteerd moeten worden op basis van sterke risicofactoren zoals behandeling met corticosteroïden, hypogonadisme en malnutritie⁶².

Alle patiënten met de ZvC moeten dieetadvies krijgen ten aanzien van calcium en vitamine D inname. Vitamine D deficiëntie moet worden gecorrigeerd, zonodig preventief worden gesuppleerd. Een eventueel tekort aan geslachtshormoon moet worden gesuppleerd. Lichaambeweging moet worden gestimuleerd.

Literatuur

- 1 Edwards F, Truelove S. The course and prognosis of ulcerative colitis. *Gut* 1964; 5:1-22.
- 2 Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. *Invest Radiol* 1976; 11:541-549.
- 3 Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M et al. Metabolic bone assessment in patients with inflammatory bowel disease. *Gastroenterology* 1995; 108:417-422.
- 4 Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997; 40:228-233.
- 5 Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA et al. Osteoporosis in patients with inflammatory bowel disease. *Gut* 1987; 28:410-415.
- 6 Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. *Gastroenterology* 1994; 107:1031-1039.
- 7 Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du-Puy MT et al. Low bone mineral density in patients with inflammatory bowel disease. *Dig Dis Sci* 1992; 37:1396-1403.
- 8 Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. *Am. J. Gastroenterol* 1998; 93:1483-1490.
- 9 Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. *Gut* 1995; 37:71-76.
- 10 Tromm A, Rickels K, Huppe D, Wiebe V, May B. Osteopenie bei chronisch entzündlichen Darmerkrankungen. Ergebnisse einer Querschnittsuntersuchung mittels quantitativer Computertomographie. *Leber Magen Darm* 1994; 24: 23-30.
- 11 Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. *Gut* 1997; 40: 313-319.
- 12 Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. *Gut* 2000; 46:176-181.
- 13 Croucher PJ, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. *Osteoporos Int* 1993; 3:236-241.
- 14 Hesselov I, Mosekilde L, Melsen F, Fasth S, Hulthen L, Lund B et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. *Scand J Gastroenterol* 1984; 19: 691-696.
- 15 Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* 1982; 83: 1252-1258.
- 16 Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. *J. Rheumatol* 1997; 24:1215-1217.
- 17 Marcus R. Biochemical assessment of bone resorption and formation. *Bone* 1996; 18:155-165.
- 18 Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. *Gut* 1996; 38: 223-228.
- 19 Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases* 1998; 4: 268-275.
- 20 D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. *Aliment Pharmacol Ther* 1998; 12:419-424.
- 21 Bischoff SC, Herrmann A, Goke M, Manns MP, von-zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. *Am J Gastroenterol* 1997; 92:1157-1163.

- 22 Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. *Am J Gastroenterol* 2000; 95:699-704.
- 23 Abitbol V. The mechanisms underlying osteopenia in chronic inflammatory bowel disease. *Semaine des Hopitaux* 1998; 74:1090-1093.
- 24 Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L et al. Evolution of osteopenia in inflammatory bowel disease. *Am J Gastroenterol* 1999; 94:1292-1297.
- 25 Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M et al. Bone loss in patients with inflammatory bowel disease: a prospective study. *Osteoporos Int*. 1995; 5:156-160.
- 26 Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. *J. Intern. Med.* 2000; 247:63-70.
- 27 Robinson RJ, Iqbal SJ, Whitaker RP, Abrams K, Mayberry JF. Rectal steroids suppress bone formation in patients with colitis. *Aliment Pharmacol Ther* 1997; 11:201-204.
- 28 Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. *Scand J Gastroenterol* 1999; 34: 696-702.
- 29 Canalis E. Clinical review: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. *J Clin Endocrinol Metab* 1996; 81:3441-3447.
- 30 Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. *J Intern Med* 1995; 237:439-447.
- 31 Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. *N Engl J Med* 1983; 309:265-268.
- 32 Issenman RM, Atkinson SA, Radoja C, Fraher L. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr* 1993; 17:401-406.
- 33 Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. *Lymphokine Cytokine Res* 1991; 10:15-21.
- 34 Wallach S, Avioli LV, Feinblatt JD, Carstens-JH J. Cytokines and bone metabolism. *Calcif Tissue Int* 1993; 53:293-296.
- 35 Hommes DW, van Dulleman H, Radema SA, Tytgat GN, van Deventer SJ. SDe rol van cytokinen in de pathogenese van inflammatoire darmziekten. *Ned Tijdschr Geneesk* 1994; 138:2427-2432.
- 36 Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. *J Pediatr Gastroenterol Nutr* 1997; 24:289-295.
- 37 Issenman RM. Bones in Crohn's: cytokines, a missing link? *J Pediatr Gastroenterol Nutr* 1997; 24:361-362.
- 38 Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. *Scand J Gastroenterol* 1996; 31:367-371.
- 39 Robinson RJ, Iqbal SJ, AlAzzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. *Aliment Pharmacol Ther* 1998; 12:21-25.
- 40 Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. *Am J Gastroenterol* 1999; 94: 824-828.
- 41 Robinson RJ, AlAzzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. *Dig Dis Sci* 1998; 43:2500-2506.
- 42 Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S et al. Bone disease in vitamin D-deficient patients with Crohn's disease. *Dig Dis Sci* 1989; 34:1094-1099.
- 43 Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. *J Intern Med* 1996; 239:131-137.
- 44 Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. *Gut* 1988; 29:1332-1336.

- 45 Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. *Scand J Gastroenterol* 1992; 27:1055-1060.
- 46 Staun M, Tjellessen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. *Scand J Gastroenterol* 1997; 32:226-232.
- 47 Boot AM, Bouquet J, Krenning EP, de MK. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. *Gut* 1998; 42:188-194.
- 48 Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. *Gastroenterology* 1998; 114:902-911.
- 49 Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. *Gastroenterology* 1997; 112:1710-1713.
- 50 Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. *J Clin Endocrinol Metab* 2000; 85:2122-2126.
- 51 Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. *Rheumatol Int* 1997; 17:45-48.
- 52 Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. *Eur J Gastroenterol Hepatol* 1995; 7:609-614.
- 53 Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. *Gut* 1993; 34:1543-1546.
- 54 Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. *Aliment Pharmacol Ther* 1996; 10:777-786.
- 55 von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. *Eur J Gastroenterol Hepatol* 2000; 12:19-24.
- 56 Robinson RJ, Krzywicki T, Almond L, AlAzzawi F, Abrams K, Iqbal SJ et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial. *Gastroenterology* 1998; 115:36-41.
- 57 Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. *N Engl J Med* 1998; 339:292-299.
- 58 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996; 312:1254-1259.
- 59 Robinson RJ, al-Azzawi F, Iqbal SJ, Abrams K, Mayberry JF. The relation of hand skin-fold thickness to bone mineral density in patients with Crohn's disease. *Eur J Gastroenterol Hepatol* 1997; 9:945-949.
- 60 Robinson RJ, Carr I, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Screening for osteoporosis in Crohn's disease. A detailed evaluation of calcaneal ultrasound. *Eur J Gastroenterol Hepatol* 1998; 10: 137-140.
- 61 Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A. Calcaneal ultrasound bone densitometry in inflammatory bowel disease--a comparison with double x-ray densitometry of the lumbar spine. *Am J Gastroenterol* 1998; 93:2339-2344.
- 62 Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 1997; 9:931-933.

Dankwoord

Dankwoord

Het maken van een proefschrift, is een werk waar zeer veel mensen bij betrokken zijn. Niet iedereen die een steentje heeft bijgedragen aan het tot stand komen van dit proefschrift kan ik dan ook in dit dankwoord vermelden, maar ik zal trachten de belangrijkste hiervan te noemen.

Allereerst wil ik mijn respect uitspreken voor de patiënten die meedoen aan onderzoek waar voor henzelf de voordelen niet altijd even duidelijk zijn.

Reinhold Stockbrügger. Mede door jouw stimulerende krachten en het vertrouwen dat je mij schonk, je analytische denkwijze en werklust is dit proefschrift ontstaan. Alle manuscripten werden minitieuw van opbouwende kritiek voorzien. Hierbij werd het gebruik diverse communicatiemiddelen niet geschuwd. Ik ben je tevens erkentelijk voor de gastroenterologie opleiding en de vaste plaats die ik in de staf kreeg. Eén van de hoogtepunten vind ik het diner in Ferrara en ik ben dankbaar voor die gastvrijheid. Ik vind dat jij de enige Europeaan bent in het verenigde Europa die het predikaat Europeaan verdient.

Maurice Russel. Jouw pionierswerk op het gebied van de epidemiologie van IBD in Limburg en de daarbijbehorende registratie en opgedane kennis over de ziekte van Crohn en colitis ulcerosa in het algemeen, zijn van groot belang geweest voor dit onderzoek. Ondanks dat het "botten"-onderzoek een van de zijstraten is, bleef je enthousiast over de ideeën en stelde je wekelijks op de hoogte van de stand van zaken. Als vrienden hebben we vele gemeenschappelijke interesses en indien we wat meer tijd hadden om samen te fietsen door het Limburgse heuvelland (of elders) dan hadden we tenminste... een betere conditie gehad. Jouw organisatie talent belooft een goede toekomst.

Robert-Jan Brummer wil ik graag bedanken voor het begeleiden en becommentariëren van de "metabole" stukken.

Beoordelingscommissie. Prof.dr. E.M. Wouters, Prof.dr. P.B. Soeters en Prof.dr. S.J. van der Linden dank ik voor hun werk en hun bereidwilligheid om plaats te nemen in de beoordelingscommissie. I would like to thank professor Hanauer and professor Bianchi Porro for their willingness to participate in this thesis. It is an honor for me to have you in the board

Professor H.F.P. Hillen, beste Harry, ik heb 12 jaar zeer plezierig met je samengewerkt.

Bertine Geerling zag het voordeel om het voedingsonderzoek "in brede zin" te verrichten en verzamelde een schat aan gegevens, waarvoor ik veel dank verschuldigd ben. Mijn promotie werd reeds in je bekende kordate stijl tijdens je verdediging aangekondigd.

Rene Wouters liet voor mij een fantastisch onderwerp om te promoveren achter in Maastricht en bleef van een afstand interesse tonen in de vorderingen.

Bruce Wolfenbuttel wil ik bedanken voor de adviezen met name in de beginfase van het onderzoek en ook zeker het advies om eens contact op te nemen met Cees Vermeer.

Cees Vermeer bedank ik voor zijn expertise en de mogelijkheden om samen te werken met de afdeling biochemie van de Universiteit Maastricht. Leon Schurgers voor de buitengewoon plezierige samenwerking en de interesse voor het patiëntgebonden onderzoek. Met onze gemeenschappelijke theorieën zaten we zeker in de frontlinie van het bottenonderzoek en verder..... Succes met de laatste loodjes van jouw proefschrift.

Afdeling Nucleaire geneeskunde. Ing-ham Liem zag tijdens een voor hem zeer drukke periode nog kans om te helpen om vele DEXA's te re-analyseren met behulp van de nieuwste software. De DEXA laboranten en met name Lia van Iersel wil ik bedanken voor de betrokkenheid bij dit onderzoek.

Piet Geusens voor het delen van het enthousiasme voor botten en het daaraan gerelateerde onderzoek.

Petra Koken en Reini Bretveld voor de onmisbare hulp bij de statistische analyses.

Het Maastrichtse onderwijssysteem biedt studenten al vroeg de mogelijkheid om in het onderzoek te participeren, hieraan heb ik veel plezier beleefd. Vrijwel alle onze project-aanvragen werden in eerste instantie door de stagecommissie van de faculteit afgewezen. De studenten raakten hierdoor gelukkig nog meer gemotiveerd. Annick van Nunen maakte de eerste database, verrichtte veel werk aan hoofdstuk 3 en 4 en is nu ook zelf bijna gepromoveerd. Barbara Blok heeft de Parke-Davis studentenprijs gewonnen op de Nederlandse vereniging voor Gastroenterologie voor haar werk aan hoofdstuk 5. Marcella Müller won de tweede prijs in het internationale Maastrichtse wetenschappelijk symposium voor studenten met haar werk aan hoofdstuk 6. Verder wil ik graag Ivo van Dooren bedanken voor het werk aan hoofdstuk 7. Froukje Verstraeten dank ik voor het werk aan de follow-up data.

René van Oerle. Door het verfraaien van de grafieken gingen meerdere editors direct overstag.

Pamela Falger en Barbara Ryan. Dank voor de sympathieke correctie van de Engelse taal.

Collega's gastroenterologen. Wim Hameeteman, Peter Houben, Boudewijn Loffeld, Rob Adang, Ton Vrij en Ger Koek wil ik bedanken voor de uitermate plezierige samenwerking en de collegialiteit. Voor Annemarie Wensing, Frank Wolters en Marc de Bièvre verwacht ik een goede toekomst

IBD researchstaf. Martine van der Kruijs, Ingrid van der Eijk en Daisy Jonkers wil ik bedanken voor de goede spirit in het IBD-team.

Tiny Wouters heeft een hoofdrol gespeeld in de laatste fase van het proefschrift. Jouw inzet hiervoor is dan ook niet te beschrijven; zelfs in het weekend werd

zonodig doorgewerkt. De planning werd zorgvuldig bewaakt. Tiny, we zullen het op z'n Limburgs eens goed gaan vieren!

Paranimfen Bas Oldenburg en Cees Mosch voor hun vriendschap en de bereidheid deze taak op zich te nemen. Beste Bas, de gelijkenis tussen onze medische carrières moet op zuiver toeval berusten! Cees kwam ik op dag 1 van de studie Geneeskunde tegen op het faculteitsbureau aan de Catharijnesingel in Utrecht. We hebben toen dezelfde middag "onze eerste patiënt" bezocht. Deze patiënt had toevallig de ziekte van Crohn.

Pieter Blaauw, mijn schoonvader, voor het minutieus doornemen van het gehele proefschrift en de goede adviezen.

Mijn ouders wil ik bedanken voor alle liefde, het vertrouwen en de mogelijkheden om mij verder te kunnen ontwikkelen.

Lieve Gabriëlle, het is voor elkaar. Dit boek is uit. Ik hoop dat er ons nog vele hoofdstukken gegeven zijn. Jouw rol achter de schermen is groots. Folkert en Veerle, danzij jullie leer ik iedere avond naast liedjes, versjes en "Mestreechs" ook over dinosauriërs, apen en krokodillen. Karlijn, jouw vrolijkheid is ontroerend. Ik ben trots op jullie!

Curriculum Vitae

Curriculum Vitae

De auteur van dit proefschrift werd geboren in 1960 in Dordrecht. In 1989 behaalde hij zijn VWO diploma aan het Titus Brandsma College in Dordrecht. Door uitlatingen voor de studie geneeskunde studeerde hij eerst twee jaar scheikunde aan de rijksuniversiteit van Utrecht. In 1981 begon hij met de studie geneeskunde te Utrecht. In 1988 werd het artsexamen afgelegd. Na een korte periode als agnio op de afdeling interne geneeskunde in het academisch ziekenhuis te Maastricht en in het Catharina ziekenhuis te Eindhoven, startte hij in 1990 in Eindhoven met de specialisatie interne geneeskunde (opleider dr. H.F.P. Hillen). In 1993 werd deze opleiding in het academisch ziekenhuis te Maastricht vervolgd (opleiders: prof.dr. J.A. Flendrig¹, prof.dr. A. Nieuwenhuizen Kruseman en prof.dr. H.F.P. Hillen). De registratie tot internist volgde op 1 januari 1996 waarna direct aangevangen werd met de opleiding tot gastroenteroloog in het academisch ziekenhuis te Maastricht (opleider: prof.dr. R.W. Stockbrügger) en registratie volgde op 1 januari 1999. Tijdens de opleiding gastroenterologie werd gestart met de voorbereidingen van het wetenschappelijk onderzoek beschreven in dit proefschrift. In 1998 werd hij aangesteld als stafid bij de werkgroep maag/darm- en leverziekten van het academisch ziekenhuis te Maastricht (hoofd: prof.dr. R.W. Stockbrügger). Vanaf oktober 2001 zal de loopbaan vervolgd worden als maag/darm- en leverarts in het Catharina ziekenhuis te Eindhoven.

In 1992 is hij gehuwd met Gabriëlle Blaauw. Samen hebben ze drie kinderen: Folkert (1995), Veerle (1996) en Karlijn (1999).